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Abstract 
 
HOP (Heat shock protein 70/ Heat shock protein 90 organising protein) is a co-
chaperone essential for client protein transfer from HSP70 to HSP90 within the HSP90 
chaperone machine and has been found to be up-regulated in various cancers. However, 
minimal in vitro information can be found on the regulation of HOP expression. The 
aim of this study was to analyse the HOP gene structure across known orthologues, 
identify and characterise the HOP promoter, and identify the regulatory mechanisms 
influencing the expression of HOP in cancer. We hypothesized that the expression of 
HOP in cancer cells is likely regulated by oncogenic signalling pathways linked to cis-
elements within the HOP promoter. An initial study of the evolution of the HOP gene 
speciation was performed across identified orthologues using Mega5.2. The 
evolutionary pathway of the HOP gene was traced from the unicellular organisms to 
fish, to amphibian and then to land mammal. The synteny across the orthologues was 
identified and the co-expression profile of HOP analysed. We identified the putative 
promoter region for HOP in silico and in vitro. Luciferase reporter assays were utilized 
to demonstrate promoter activity of the upstream region in vitro. Bioinformatic analysis 
of the active promoter region identified a large CpG island and a range of putative cis-
elements. Many of the cis-elements interact with transcription factors which are 
activated by oncogenic pathways. We therefore tested the regulation of HOP levels by 
rat sarcoma viral oncogene homologue (RAS). Cancer cell lines were transfected with 
mutated RAS to observe the effect of constitutively active RAS expression on the 
production of HOP using qRT-PCR and Western Blot analyses. Additionally, inhibitors 
of the RAS signalling pathway were utilised to confirm the regulatory effect of mutated 
RAS on HOP expression. In cancer cell lines containing mutated RAS (Hs578T), HOP 
was up-regulated via a mechanism involving the MAPK signalling pathway and the 
ETS-1 and C/EBPβ cis-elements within the HOP promoter. These findings suggest for 
the first time that Hop expression in cancer may be regulated by RAS activation of the 
HOP promoter. Additionally, this study allowed us to determine the murine system to 
be the most suited genetic model organism with which to study the function of human 
HOP.   
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Chapter 1 
 
Literature Review 
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1.1 Molecular Chaperones 
In order for the cell to function properly, cellular proteostasis needs to be maintained. 
For this, the integrity of the cellular protein machinery needs to be meticulously 
maintained. Problems such as protein denaturation, misfolding and aggregation 
constantly challenge the cell under physiological conditions, and even more so upon 
environments with extended levels of stress (Buchner, 1996; Beissinger & Buchner, 
1998; Jolly, 2000; Tiroli-Cepeda & Ramos, 2011; Escusa-Toret et al., 2013). Examples 
of such stresses are heat, oxidative stress, heavy metals and toxic substances (Heikkila 
et al., 1982; Courgeon et al., 1984; Yura et al., 1984; Michel & Starka, 1986). A family 
of proteins known as molecular chaperones have the responsibility within the cell to 
facilitate the correct folding of proteins (known as clients) under both normal and 
stressful conditions (Buchner, 1996; Beissinger & Buchner, 1998; Jolly, 2000; Tiroli-
Cepeda & Ramos, 2011; Escusa-Toret et al., 2013). To prevent the aggregation 
potential of many of these folding proteins, the chaperones are required at 
stoichiometric ratios to decrease the comparative concentrations of non-native proteins 
(Kiefhaber et al., 1991). Without these chaperone proteins, the damaging effects of 
stresses in the cell can be lethal. Extended cell stress can result in defects within the 
cytoskeleton, prevent the correct localisation of organelles, disrupt intracellular 
transport processes, deregulation of RNA splicing and mRNA functioning, and 
enhanced cell membrane permeability. When these changes do not lead to cell death, it 
leads to a stagnation of both cell growth and proliferation (Lindquist, 1980; Welch & 
Suhan, 1985; Nover et al., 1989; Vogel et al., 1995; Kampinga & Craig, 2010; Richter 
et al., 2010). Furthermore, due to the dynamic functions of chaperones many of them 
require the assistance of accessory proteins known as co-chaperones; which partake in 
the functioning of chaperones (Caplan, 2003; Calderwood, 2013). 
 
1.2 Heat Shock Proteins 
A major subgroup of the molecular chaperone family are selected members of the heat 
shock proteins (HSP). In response to a variety of extra- and intra-cellular stresses or 
trauma, cells induce the synthesis of a series of HSPs. HSPs have adapted to protect the 
cells from the damage caused by abrupt environmental changes (Nicolet & Craig, 1989; 
Richter et al., 2010). HSPs have the role of folding immature or denatured proteins, 
while others act as proteases, thereby preventing protein aggregation and retaining 
proteins in native conformations. This is accomplished by the binding of HSPs to the 
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hydrophobic surfaces of the partially folded client proteins (Wegele et al., 2004; Song 
& Masison, 2005). Within the HSP family are two subfamilies of chaperones: Heat 
shock protein 90 (HSP90) and Heat shock protein 70 (HSP70). HSP90 and HSP70 are 
ubiquitous, essential and highly conserved proteins (Song & Masison, 2005). HSP90 
and HSP70 are found to exist together in a heterocomplex with HSP40 and other 
accessory proteins, which together act as a protein folding and stabilisation machine 
(Czar et al., 1994). HSP70 is required for de novo and stress related folding of clients, 
where the clients may be unfolded or misfolded proteins. HSP90 on the other hand is 
required for conformational regulation of clients and the clients are transferred to 
HSP90 already partially folded. Some of these clients are labile and require stabilisation 
by HSP90 until they are required within the cell (Buchner, 1996; Beissinger & 
Buchner, 1998; Jolly, 2000; Tiroli-Cepeda & Ramos, 2011; Escusa-Toret et al., 2013).  
 
1.2.1 – Heat Shock Protein 70 
The human HSP70 group of proteins is comprised of 17 genes and 13 isoforms, some 
of which are constitutively expressed under normal physiological conditions (known as 
the heat shock cognate proteins, examples being HSPA5/HSP70-5/GRP78, 
HSPA8/HSP70-8/HSC70, HSPA9/HSP70-9/GRP75). Others are inducible stress 
related proteins (examples being HSPA1A/HSP70-1, DNAJB1/HSP40, HSPB1/ 
HSP27) (Tavaria et al., 1996; Brocchieri et al., 2008; Kampinga et al., 2009). Certain 
HSP70 isoforms (such as HSPA8/HSC70) have housekeeping functions that aid in 
protecting proteins during specific cellular processes, such as protein transportation 
across membranes, proofreading protein structure and preventing the degradation of 
partially folded proteins during translation (Mayer & Bukau, 2005; Song & Masison, 
2005). Whereas upon cellular stress, the expression of certain alternative HSP70 
isoforms are induced (such as HSPA1A/HSP72) so as to prevent the aggregation of 
unfolding proteins and when necessary to refold aggregated proteins (Mayer & Bukau, 
2005). Various regulatory proteins are known to be controlled by transient associations 
with HSP70 (such as steroid hormone receptors, kinases [e.g. CyclinB1] and 
transcription factors [e.g. c-Myc]) (Mayer & Bukau, 2005). Common traits to these 
interactions are an initial interaction with HSP70 during the co- or post-translational 
folding of the newly synthesised client proteins, a sensitivity of these interactions to the 
phosphorylation of the client proteins or the presence of specific ligands, and the 
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requirement of HSP90 in the complexes (Bukau et al., 2000; Hartl & Hayer-Hartl, 
2002; Wegele et al., 2004; Mayer & Bukau, 2005). 
 
HSP70 is comprised of two major functional domains, an N-terminal nucleotide 
binding domain containing the ATP binding domain, and a C-terminal client binding 
domain that can bind to the hydrophobic residues of partially unfolded proteins 
(Liberek et al., 1991; Brocchieri et al., 2008). These domains are joined by a third 
domain known as the linker domain that is important for the mechanism of HSP70 
mediated folding. The HSP40 family are co-chaperones that aid the binding of HSP70 
to the non-native client proteins (Laufen et al., 1999). The HSP40s capture unfolded 
substrates via their substrate binding domains and thereby prevent the aggregation of 
the unfolded proteins while delivering these proteins to HSP70. HSP40s interact with 
HSP70s via exposed residues on the J-domain of HSP40s (Jiang et al., 2007). Upon 
delivering the client protein to HSP70, HSP40 stimulates the ATPase activity of HSP70 
via the J-domain, which converts HSP70 into the ATP bound state that has a higher 
affinity for client proteins (Mayer & Bukau, 2005; Jiang et al., 2007; Kampinga & 
Craig, 2010). Nucleotide exchange factors (NEF) cause the dissociation of ADP (a 
result of the hydrolysed ATP) from HSP70. The dissociation of ADP allows for the 
rapid binding of ATP to HSP70 and the subsequent dissociation of the client protein. 
The client protein is released when refolded or, in the case of a subset of proteins, 
transferred to HSP90 as partially folded proteins (Wegele et al., 2004; Mayer & Bukau, 
2005; Kampinga & Craig, 2010). 
 
1.2.2 – Heat Shock Protein 90 
HSP90 isoforms are found in high concentrations within the cytoplasm (HSP90α/β), 
nucleus (HSP90α/β), the mitochondria (Tumor necrosis factor receptor-associated 
protein 1, TRAP1) and the endoplasmic reticulum (glucose related protein 4, GRP94), 
(Richter et al., 2010). Two cytosolic isoforms of the protein exist, HSP90α which is the 
inducible form and HSP90β which is the constitutive form (Csermely et al., 1998; Li et 
al., 2012). HSP90β is an essential gene in the mouse, while HSP90α is not (Voss et al., 
2000; Grad et al., 2010). HSP90 is also found on the cell surface and is secreted into 
the extracellular space for certain cell types (Eustace et al., 2004; Sidera & Patsavoudi, 
2008; Li et al., 2012). The client proteins of HSP90, of which there are over 300, are 
involved in almost all cellular processes, from signal transduction, cell cycle 
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progression and transcriptional regulation. However, they are predominantly comprised 
of those involved in signalling pathways such as steroid receptors, kinases and 
transcription factors (TF) (Echeverría et al., 2011; Li et al., 2012). Little is known 
about how HSP90 recognizes these clients, however, a study by Taipale et al. (2012) 
revealed that HSP90 kinase client recognition is determined by thermodynamic 
parameters and not sequence motifs. They identified that an additional accessory 
protein, known as CDC37, is required to recognise kinase families and there upon 
HSP90 bound kinase clients within that family which were intrinsically unstable. 
 
HSP90 functions as a homodimer; each monomer is comprised of an N-terminal 
domain which contains an ATP-binding pocket and motifs encoding co-chaperone 
interaction regions. As with HSP70, the N-terminal domain of HSP90 is connected to 
the middle domain (M-domain) by a charged linker. The M-domain contains the 
binding sites for various clients and co-chaperones. The C-terminal domain of HSP90 
contains a dimerization motif (Makhnevych & Houry, 2012). The N terminal 
dimerization of HSP90 and client binding is regulated by ATP binding and hydrolysis, 
while the C terminal dimerization of HSP90 is constitutive. The release of ADP drives 
conformational changes in the protein thereby navigating it through high and low 
affinities for the impartially folded client proteins (Prodromou et al., 1997). However, 
the ATPase cycle is dependent on the involvement of co-chaperones that affect the 
conformational dynamics of the HSP90 complex and thus the rate at which the ATPase 
activity occurs (Trepel et al., 2010). 
 
Various co-chaperones interact with cytosolic HSP90 isoforms, modulating different 
aspects of the functioning of the HSP90 chaperone machine. Co-chaperones regulate 
HSP90 through three means: by determining the rate of ATP hydrolysis, determining 
the conformational flexibility of HSP90 or by binding specific client proteins to deliver 
them to HSP90. Additionally, co-chaperones aid HSP90 functioning by stimulating the 
ubiquitination or dephosphorylation of client proteins (Panaretou et al., 2002; Meyer et 
al., 2004; Roe et al., 2004; McLaughlin et al., 2006; Forafonov et al., 2008; Zhang et 
al., 2008a; Makhnevych & Houry, 2012). HSP90 co-chaperones fall into two groups, 
tetratricopeptide repeat (TPR) (e.g. HOP, PP5, Unc45, FKBP52/51, CYP40) and non-
TPR containing co-chaperones (e.g. p23, AHA1, and CDC37). p23, cell division cycle 
37 (CDC37) and the activator of the HSP90 ATPase protein (AHA1) regulate the 
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ATPase cycle of HSP90. p23 partially inhibits the ATPase activity of HSP90 by 
securing HSP90 in an ATP-dependant, stabilized conformation. This conformation of 
HSP90 has a higher affinity for client proteins, thus p23 enables HSP90 to bind to 
client proteins (McLaughlin et al., 2006). The C-terminal of CDC37 interacts with the 
N-terminal of HSP90 and thereby inhibits the ATPase activity of the chaperone by 
fixing the chaperone in an open conformation. Simultaneously, the N-terminal of 
CDC37 interacts with protein kinases. By inhibiting the ATPase activity of HSP90 it 
allows specifically for the binding of kinase client proteins to HSP90 (Roe et al., 2004; 
Calderwood, 2013). HOP also inhibits ATPase activity of HSP90 and is important for 
communication between HSP70 and HSP90, however its function will be addressed in 
greater detail at a later point. AHA1, on the other hand stimulates the ATPase activity 
of HSP90. The binding of the N-terminal of AHA1 to the middle domain of HSP90 
results in a conformational shift of the middle domain of HSP90. This shift that enables 
the N-terminal domain of HSP90 to interact with ATP, thereby accelerating the 
progression of the ATPase cycle (Meyer et al., 2004; Li et al., 2012). The co-chaperone 
CHIP is a ubiquitin E3 ligase that binds to HSP90 (and HSP70) in order to degrade 
damaged or misfolded client proteins (Xu et al., 2002; Calderwood, 2013). Thus CHIP 
acts as a protein quality control co-chaperone.  
 
1.3 The Heat Shock Response 
One major client of HSP90 is the heat shock factor 1 (HSF1), which is a regulator of 
the heat shock response (HSR). In the absence of cell stress, HSF1 is maintained in an 
inactive monomeric form through interaction with HSP90 and HSP70 in the cytoplasm 
(Fig.1) (Zou et al., 1998; Richter et al., 2010). During cellular stress, damaged proteins 
compete with HSF1 for HSP90/HSP70 binding. This causes the dissociation of HSF1 
from HSP90, which consequently allows the transcription factor (TF) to homotrimerise, 
undergo activation by hyperphosphorylation and translocate to the nucleus (Fig.1) 
(Sarge et al., 1993; Richter et al., 2010). Two phosphorylation sites within HSF1 are of 
particular importance for the transactivation function of HSF1, Ser230 and Ser326 
(Holmberg & Hietakangas, 2001; Guettouche et al., 2005; Akerfelt et al., 2010). The 
trimeric HSF1 then binds to the promoters of various HSPs to induce the up-regulation 
of their expression in response to the cellular stress (Zou et al., 1998; Guo et al., 2001; 
Mizrak et al., 2006). The cis-elements in the target gene promoters for HSF are known 
as heat shock elements (HSE) (Fig.1). Binding of HSF to an HSE leads to a change in 
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chromatin organization within HSP promoters, and an interaction with various 
components of the chromatin remodelling machinery and the basal transcriptional 
machinery (Morimoto, 1998). HSF1 activity is modulated by a negative feedback 
mechanism when the cell returns to a normal state of functioning and proteostasis. The 
excess of unemployed HSP70 and HSP90 bind HSF-1 and thus downregulate the 
transcriptional activator (Fig.1) (Gibbs et al., 1993; Mizrak et al., 2006; Richter et al., 
2010). 
 
The heat shock factor family is comprised of 4 genes (HSFs 1, 2, and 4; as well as a 
unique avian HSF3), all of which are ubiquitous except for HSF3 (Morimoto, 1998). 
HSF1, although constitutively expressed in most tissues, is activated in response to 
elevated temperatures, heavy metals, amino acid analogs and oxidative stress whereas 
HSF2 is activated in response to hemi-induced differentiation of erythroleukemiac cells 
or hemin treatment (Morimoto, 1998; Trinklein et al., 2004; Ostling et al., 2007; 
Akerfelt et al., 2010). HSF2 is constitutively expressed and was initially thought to 
only be activated in cells involved in differentiation and development (Goodson et al., 
1995). However, HSF2 has been found to be important for both constitutive and stress-
inducible expression of HSP (Wilkerson et al., 2007; Sandqvist et al., 2009). It is 
recruited alongside HSF1 during heat stress; although it depends strictly on the 
presence of HSF1 to relocate to the nucleus (Trinklein et al., 2004; Ostling et al., 
2007). HSF2 aids the regulation of the HSR by forming transcriptionally active 
heterotrimers with HSF1 (Schuetz et al., 1991; Sarge et al., 1993; Akerfelt et al., 2010).  
Such a functional relationship between the two TFs offers an efficient way to control 
gene expression and orchestrate the differential upstream signalling and target gene 
networks (Akerfelt et al., 2010). The third HSF works in conjunction with HSF1 in 
avian systems to regulate the HSR (Nakai et al., 1995). HSF4 is expressed in human 
heart, brain, skeletal muscle, and pancreas tissue; and acts to repress the expression of 
HSP (Nakai et al., 1997; Pirkkala et al., 2001). 
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Figure 1: The Heat Shock Response. 
A schematic diagram illustrating the regulation of the heat shock response in eukaryotic cells. (1) Under 
physiological conditions within the cell, HSF1 is bound in an inactive state by the molecular chaperones 
HSP90 and HSP70. (2) Upon environmental or physiological stress, proteins begin to aggregate. (3) 
HSP70 and HSP90 are recruited to the damaged proteins and, with the aid of the co-chaperone HOP, 
refold the client proteins to a mature conformation. (4) During this process, HSF1 has been released from 
the chaperone complex and is free to trimerise. (5) Once trimerised, the HSF1 complex translocates to 
the nucleus where it is hyperphosphorylated. The hyperphosphorylation activates the DNA binding 
capacity of the complex, (6) whereupon HSF1 binds to heat shock elements (HSE) within the promoters 
of heat shock protein genes. This stimulates an upregulation in the expression of heat shock proteins in 
order to compensate for the stressed conditions of the cell. When proteostasis is achieved, the HSF1 
trimer dissociates and the monomers are bound by HSP90 and HSP70 once more. Adapted from Richter 
et al. (2010) and Morimoto (1998). 
 
1.4 HSP90 as a drug target 
Cancer is a disease which has haunted humans for centuries. It is a complex disease that 
arises as a result of genomic instability and tumour-promoting inflammation (Stratton et 
al., 2009; Hanahan & Weinberg, 2011). Mutations in the human genome either cause 
genes to have a dominant gain of function which are then referred to as oncogenes, or 
they cause genes which were previously considered as tumour suppressor genes to have 
a recessive loss of function (Hanahan & Weinberg, 2000, 2011). The variety of 
mutational combinations that are possible has led to the identification of more than one 
hundred distinct cancers, with further subtypes within each. Cancers are characterised 
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by deregulated cell physiology that affects both cell proliferation and homeostasis 
(Hanahan & Weinberg, 2000, 2011). These deregulations are common across all 
cancers and have become known as the hallmarks of cancer. They are classified into 
eight alterations within the cell which provide the cell with eight new capabilities: cells 
are able to evade apoptosis, they are insensitive to growth suppressors, are self-
sufficient in growth signals, they undergo sustained angiogenesis, have limitless 
replicative potential, and they gain the ability to invade tissues and metastasise 
(Hanahan & Weinberg, 2000, 2011). Additionally, malignant cells are able to avoid 
immune destruction and have deregulated cellular energetics (Hanahan & Weinberg, 
2011). Tumorigenesis occurs by the combination of mutational events within cells that 
lead to the alteration of multiple signalling pathways. These mutations may occur in the 
form of point mutations, rearrangements, translocations, deletions and amplifications of 
genetic material (Stratton et al., 2009; Hudson et al., 2010; Cairns et al., 2011). Some 
of the effects of these mutational events is deregulation of gene expression and altered 
chromatin structure (Stratton et al., 2009). Deregulated gene expression alters the 
balance between tumour-suppressive and tumour progressive gene networks, thereby 
indirectly enabling cells to proliferate, evade apoptosis and metastasize (Kittler et al., 
2013).  
 
Cancer cells have been shown to use the HSP90 chaperone machine to protect mutated 
and/or overexpressed proteins from degradation or misfolding, thereby stabilizing 
tumourigenic cells. Consequently HSP90 has been seen as a critical facilitator of cancer 
cell survival and oncogene addiction (Bagatell & Whitesell, 2004; Sangster et al., 2004; 
Mizrak et al., 2006; Trepel et al., 2010). In a study conducted by (Kubota et al., 2010), 
colon cancer tissues were shown to have an up-regulation of components of the HSP90 
chaperone machine, specifically HOP, HSP90 and HSC70. Furthermore, several client 
proteins (such as B-RAF, fibronectin, FKBP52, CDK4) of HSP90 are known to have an 
involvement in cell proliferation and tumour progression (Scammell et al., 2003; 
Wegele et al., 2004; da Rocha Dias et al., 2005; Zhao & Houry, 2005; Hunter et al., 
2014). Some client proteins have been identified as tumour-promoting signal transducer 
proteins; thus making chaperones targets for anticancer drugs because of their role in 
helping to promote tumour cell adaptation to unfavourable environments (Prodromou et 
al., 1997; Kubota et al., 2010; Horibe et al., 2011). Cells with high levels of HSPs were 
found to have resistance to apoptosis, due to HSPs directly interacting with the 
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apoptotic molecules of the cell, as well as blocking the caspase-independent apoptosis 
pathways (Sreedhar & Csermely, 2004). Alternatively depleting HSP levels in tumour 
cells induces apoptosis.  
 
Numerous HSP90 inhibitors have been designed as drug targets for cancer treatment. 
To date there are ninety seven worldwide clinical trials that have been completed, 
terminated or are in progress for HSP90 drugs as cancer treatments (U.S. National 
Institutes of Health, 2014). However, many HSP90 inhibitors have failed as effective 
inhibitors because they induce the HSR (Fukuyo et al., 2010). Many N-terminal HSP90 
inhibitors (such as geldanamycin, 17-AAG/DMAG, and radicicol) cause the 
dissociation of the HSP90 chaperone complex which has a two-fold consequence 
(Fukuyo et al., 2010). Firstly, the co-chaperone CHIP then preferentially binds to 
HSP90 causing the ubiquitination of HSP90 client proteins and their subsequent 
degradation (Schulte et al., 1997; Xu et al., 2002; da Rocha Dias et al., 2005; Grbovic 
et al., 2006). This is desirable in cancer as many HSP90 client proteins are those 
supporting the oncogenic process. Secondly, upon the dissociation of the HSP90 
chaperone complex, HSF1 is released and goes on to trimerise and induces the 
expression of additional HSPs such as HSP70 (Fukuyo et al., 2010). This is a negative 
side effect with respect to cancer treatment. The induction of HSP70 expression has 
been found to attenuate the cell death effects of the HSP90 inhibitors. However, it has 
been found that by reducing the expression of HSC70 and/or HSP72 in cancer cells, the 
degradation of HSP90 clients and apoptosis of the tumour cells is induced (Powers et 
al., 2008; Davenport et al., 2010). 
 
1.5 The HSP70/HSP90 organising protein 
The HSP90 chaperone machine is comprised of various co-chaperones, one of which is 
the HSP70/HSP90 organising protein (HOP), otherwise known as p60 or the stress 
inducible protein 1 (STIP1). HOP is a TPR co-chaperone or adaptor protein that is 
essential for the full functioning of HSP90 with certain client proteins (Hernández et 
al., 2002; Trepel et al., 2010). Some co-chaperones are required for the mediation 
between clients and chaperones; and such is the case for HOP. HOP is specifically 
responsible for catalysing the client transfer from HSP70 to HSP90, by coordinating the 
cycle of substrate binding and release through modulating the conformational dynamics 
of the chaperones. In doing so, HOP facilitates the folding of nascent polypeptides, the 
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productive assembly of multimeric protein complexes, and the disassembly of proteins 
specific to the HSP70 and HSP90 chaperones (Hernández et al., 2002; Caplan, 2003; 
Song & Masison, 2005; Trepel et al., 2010). Alternate functions for HOP, presumed to 
be independent of HSP90 and HSP70 have also been identified. HOP forms a signalling 
complex with prion proteins on the cell surface. HOP was shown to be a ligand for the 
glycodylphosphatidylinositol (GPI)-anchored cell surface sialoglycoprotein homologue 
(Prion Protein, PrPc); a cell surface ligand for cellular prions (Zanata et al. 2002; 
Martins et al. 1997; Lima et al. 2007; Arantes et al. 2009; Hajj et al. 2013). Beraldo et. 
al. (2013) went on to show that extracellular HOP plays a role in neuroprotection 
specifically against ischemic injury, by preventing neuronal death upon PrPc activation 
of extracellular HOP. Recent research has revealed further insight into the roles of HOP 
within the cell. HOP has been shown to have independent ATPase activity, suggesting 
that HOP may have a role as a chaperone or at least have additional roles to its HSP70-
HSP90 co-chaperone role (Yamamoto et al., 2014). Furthermore, it was recently shown 
that the co-chaperone activity of HOP can be inhibited in vivo by the phosphorylation 
of multiple sites within the protein. Phosphorylation of human HOP decreases the 
proteins affinity for both HSP70 and HSP90 (Röhl et al., 2014). 
 
HOP is ubiquitously expressed and is induced upon cellular stress (Nicolet & Craig, 
1989). It is located predominantly within the cytoplasm however, HOP has also been 
identified within the nucleus (Longshaw et al. 2004), the Golgi apparatus (Honore et al. 
1992), in the extracellular environment or associated with the cell membrane (Hajj et 
al. 2013). HOP deletion mutants in yeast caused a clear reduction in the functioning of 
HSP70 and HSP90 as well as their client proteins (GR and v-Src) (Chang et al., 1997; 
Song & Masison, 2005). Furthermore, cells become hypersensitive to environmental 
changes upon the depletion of HOP, due to the consequent reduction of HSP90 
functioning (Song & Masison, 2005; Li et al., 2012). HOP was also found to have an 
essential role in mammalian embryonic development and cell survival in mice, 
whereupon HOP knockout in mice caused embryonic death (Beraldo et al., 2013). 
Additional co-chaperones could not compensate for the loss of HOP in murine embryos 
suggesting unique roles for differing co-chaperones during different stages of 
development.  
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The assembly of this multimeric HSP90 chaperone machine is dependent on all three 
independent TPR domains within HOP. The TPR motif is a degenerate 34-amino acid 
sequence that forms the scaffold for the various protein interactions (Fig.2) (Das et al., 
1998; Smith, 2004). HOP has 9 TPR motifs that are arranged into the three domains 
(TPR1 and TPR2A, TPR2B) each of which comprise 3 TPR motifs (Prapapanich et al., 
1998; Nelson et al., 2003). HOP also contains two DP domains (aspartic acid and 
proline rich domains) which are otherwise known as STI1 domain sequences as they 
contain the heat shock chaperone binding motif (Fig.2) (Prapapanich et al., 1998; 
Nelson et al., 2003). HOP binds to the C terminal regions (terminating with the amino 
acid sequence EEVD) of both HSP90 and HSP70 simultaneously and thereby creates a 
platform for the transfer of client proteins between them (Scheufler et al., 2000b; 
Carrigan et al., 2004; Makhnevych & Houry, 2012). Furthermore, HOP TPR domains 
can discriminate between the EEVD motifs within HSP90 and HSP70 based on the 
adjacent residues. The TPR domains recognise the MEEVD and GPTIEEVD motifs in 
HSP90 and HSP70 respectively, ensuring that TPR1 binds to HSP70 while TPR2A 
binds to HSP90 (Scheufler et al., 2000a; Odunuga et al., 2003). Additionally, there is 
possibly a second binding site for HSP70 on HOP in the DP2 domain (Fig.2) (Russell 
et al., 1999; Carrigan et al., 2004; Onuoha et al., 2008; Li et al., 2012).  
 
 
Figure 2: HOP acts as a scaffold for interaction between HSP70 and HSP90. 
Schematic diagram of the regions of the co-chaperone HOP that bind to the EEVD motifs found on the 
molecular chaperones HSP70 and HSP90. Dotted lines illustrate the interactions between the proteins. 
These interactions between HSP70-HOP-HSP90 allow for the transfer of client proteins from HSP70 to 
HSP90. 
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TPR1 and TPR2A mediate the interactions of HSP90 and HSP70 with substrate 
proteins through an anchoring function (Odunuga et al., 2004; Horibe et al., 2011). 
Upon the binding of HOP, the HSP90 ATPase activity is inhibited and HSP90 is 
stabilised in an open conformation due to a rotation in the junction of the middle and C-
terminal domains of HSP90 (Southworth & Agard, 2011; Li et al., 2012). In this 
conformation, client binding residues have converged so that HSP90 is positioned for 
client loading by HSP70 with an accessible client binding surface. Simultaneously, the 
N-terminal domain rotates almost 90o and is held in an hydrolysis-incompetent state 
(Southworth & Agard, 2011). This conformation of HSP90:HOP allows for the 
interaction with HSP70. HSP70 binds to TPR1 but additionally makes contact with 
HSP90 (Southworth & Agard, 2011; Kirschke et al., 2014). HSP70 facilitates client 
transfer to HSP90 by partially unfolding the client protein. HSP90 binds ATP, the 
hydrolysis of the ATP contributes to the client transfer by a means of coupling the ATP 
cycles of HSP90 and HSP70 (Kirschke et al., 2014). The coupling of the ATP cycles 
was visualised by Kirschke et al. (2014) using cyroelectron microscopy, whereby they 
identified points of contact between HSP70 and HSP90 in a glucocorticoid receptor 
(GR):HSP70:HSP90:HOP complex. Alvira et al. (2014) identified that the client 
protein binds to the side of the HSP90 dimer opposite the HOP attachment site on the 
dimer. HSP90 then reactivates the client (in this case GR) by refolding it upon the ATP 
hydrolysis of the chaperone and the co-chaperone HOP (Kirschke et al., 2014). HSP90 
moves to a closed conformation upon the binding of ATP, this interaction weakens the 
interaction of HOP:HSP90 and promotes the exit of HOP from the complex. The 
refolded client protein is then released after ATP hydrolysis (Li et al., 2012). 
 
1.6 HOP as a novel drug target 
While the role of HSP90 in cancer is well established, it is now appreciated that co-
chaperones of HSP90, including HOP, may contribute to cancer cell proliferation, 
migration and drug resistance (Erlich et al., 2007; Forafonov et al., 2008; Holmes et al., 
2008; Smith et al., 2009; Horibe et al., 2011). HOP has been identified as 
overexpressed in certain cancers compared to normal cell equivalents. HOP expression 
was linked to invasive potential in seven human pancreatic cancers (Walsh et al., 
2011); a feature also demonstrated in breast cancer cells. There was an increase in HOP 
expression in the cancerous Hs578T breast cell line when compared to the non-
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malignant Hs578Bst cell line, which was derived from the same patient (Willmer 2011, 
unpublished data). Kubota and colleagues (2010), showed HOP levels were up-
regulated in colonic carcinoma tissue samples compared to non-tumour tissues obtained 
from the same colonic carcinoma patients (Kubota et al., 2010) and an increase in HOP 
mRNA and protein expression was detected upon transformation of Rat1 fibroblast 
cells with the oncogene RAS (van der Spuy 2000, unpublished data). Additionally, 
HOP has been found in a constitutive complex with HSP90 in cancer cells, whereas 
complex formation is only induced under specific conditions in normal cells (Kamal et 
al., 2003). Addition of recombinant HOP to glioma cells induced cell proliferation 
(Erlich et al., 2007), while the disruption of the HOP-HSP90 interaction reduced 
proliferation of a range of cancers, including breast, human lung and kidney and 
sensitised cells to inhibitors against HSP90 (Horibe et al., 2011; Pimienta et al., 2011). 
Data from knockdown studies have demonstrated that HOP regulates cancer cell 
migration by numerous mechanisms, including inhibition of matrix metalloproteinases-
2 (MMP2) and regulation of components of the cytoskeleton (actin and tubulin) (Walsh 
et al., 2011; Willmer et al., 2013). The presence of HOP in the extracellular matrix has 
been linked to the invasive properties of these cells by Walsh et al. (2011). While STI1 
deletion mutants were not lethal in yeast, it led to a clear reduction in molecular 
chaperone and client protein function (Chang et al., 1997; Hernández et al., 2002). 
Furthermore, HOP gene knock out was embryonically lethal in mice (Beraldo et al., 
2013). Collectively, these results suggest a role for HOP in malignant cells. 
  
The dependence of cancer cells on molecular chaperones has been deemed the soft spot 
of cancer (Calderwood, 2013). However, depletion of HSP90 has not proved to be the 
best form of inhibition due to the consequent induction of an antiapoptotic HSR 
(Fukuyo et al., 2010). It has been suggested that targeting certain co-chaperones may 
provide another route to inhibit oncogenic HSP90 chaperoning (Smith & Workman, 
2009). The functioning of HSP90 can be hindered by targeting the co-chaperones, such 
CDC37 or p23, so as to alter its contribution to that of the chaperone’s activity 
(Forafonov et al., 2008; Smith & Workman, 2009; Trepel et al., 2010). This would 
inhibit the functioning of the chaperones but prevent an induction of the HSR. Various 
attempts have already been made in targeting the co-chaperones of HSP90. Celastrol 
was found to disrupt the HSP90/CDC37 complex and Gendunin inhibited the HSP90 
co-chaperone p23 (Zhang et al., 2008b; Salminen et al., 2010; Patwardhan et al., 2013). 
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Unfortunately, Celastrol was found to lack specificity but Gendunin was found to 
promote the apoptosis of cancer cells. Although Celastrol treatment was not ideal an 
alternative was found whereby silencing CDC37 or removing the C-terminal of CDC37 
(thereby destroying the HSP90 binding capacity of CDC37) diminished and 
destabilised the kinase client protein binding as well as sensitized the cells to HSP90 
inhibitors (Smith et al., 2009, 2013). Additionally, in the absence of p23, mammalian 
cells were found to be hypersensitive to HSP90 inhibitors (Forafonov et al., 2008). The 
knockdown of AHA1 caused an increase in the sensitivity of cancer cells to 17-AAG 
partly due to a 3-fold increase in apoptosis (Holmes et al., 2008). Thus considering the 
complexities and difficulties that have arisen in designing effective chaperone 
inhibitors, we support the concept of targeting the co-chaperones and suggest that HOP 
specifically represents a novel drug target for anticancer therapeutics.  
 
In the case of developing drugs that specifically target HOP, little research has yet been 
done. However, a study by Horibe and colleagues (2011) revealed that a TPR-modelled 
peptide inhibited the interaction of HOP with the TPR2A domain of HSP90. The result 
of this inhibition was the selective cell death of cancerous cells while normal cells 
remained viable. Furthermore Pimienta and colleagues (2011) developed the compound 
C9 (1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione) which is an 
inhibitor of the interaction of HOP with HSP90. C9 caused the cell death of various 
breast cancer cell lines without inducing the transcription of HSP70. Both of the above 
mentioned inhibitors, by competitively binding to HSP90, prevent the transfer of client 
proteins from HSP70 to HSP90 via HOP and thereby indirectly inhibit a function of 
HSP90 and ensure client proteins of HSP90 remain inactivated. Since the inhibition of 
this process doesn’t induce the prosurvival effect of the transcriptional up-regulation of 
HSP70 (Pimienta et al., 2011), as do many N-terminal ATP binding site HSP90 
inhibitors, the inhibition of the interaction between HOP and HSP90 presents itself as 
an attractive alternative for the indirect inhibition of HSP90. 
 
1.7 Knowledge Gap and Conclusive Remarks 
There is a growing body of evidence linking the co-chaperone, HOP, to the malignant 
nature of tumours. These data have suggested that HOP may be a key regulator of 
oncogenesis and may represent a novel drug target for the treatment of cancer. 
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However, the success rate of the clinical trials of investigational drugs within oncology 
is the lowest of all trials drugs in clinical development (Kamb et al., 2007). It is thus 
essential to understand the drug target of choice. Consequently it is vital to understand 
the factors influencing the gene expression of HOP. To do so, one would be required to 
locate and characterise the core promoter of the HOP gene. It has been stated that 
promoters are the best-characterised transcriptional regulatory sequences in genomes 
due to the predictability of their location immediately upstream of the transcription start 
site (TSS) (Hiang et al., 2010). In the case of HOP, there is minimal in vitro or in vivo 
information to be found on the DNA sequence encoding the promoter. Furthermore, 
even less is known about the regulatory mechanisms that control the expression of 
HOP. Since HOP is known to be up-regulated in human cancers it is possible that 
oncogenic signalling pathways may be involved in the regulation of the HOP promoter. 
 
1.8 Hypothesis and Objectives 
This investigation hypothesizes that the HOP core promoter containing the essential 
transcription factor binding sites and consensus sequences for basal activity will be 
located 100 bp upstream from the transcription start site (-600 to -100), preceded by 
proximal region involved in lesser regulatory reactions. The expression of HOP in 
cancer cells is likely regulated by oncogenic signalling pathways linked to cis-elements 
within the HOP promoter. Hence the aim of this study was to investigate the expression 
of HOP in cancerous cells. The objectives of this study were: 
 
1. Analyse the HOP gene structure across known orthologues; 
2. Identification and characterisation of the HOP promoter; 
3. Identification of the regulatory mechanisms influencing the expression of HOP in 
cancer.   
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Chapter 2 
 
Materials and Methods 
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2.1 Materials 
Hs578T (cat no.: 86082104) human metastatic breast cancer cell line was purchased 
from American Tissue Culture Collection (ATCC), as was the MEF-1 SV40 
transformed mouse embryonic fibroblast cell line (cat. No.: CRL-2214™). MCF-7 non-
metastatic breast cancer cell line, purchased from ATCC (cat no.: HTB-22), was 
obtained from A/Prof Sharon Prince (University of Cape Town). HeLa (cat no.: CCL-2) 
human cervical cancer cell line, purchased from ATCC, was obtained from Prof 
Rosemary Dorrington (Rhodes University). All general reagents were purchased from 
Sigma-Aldrich (Germany) and Saarchem (Merck; South Africa). Tissue culture media 
and reagents, including foetal calf serum [FCS], Dulbecco’s Modified Eagle Medium 
[DMEM] with GlutaMAX™-I and 10 X Trypsin- Ethylenediaminetetraacetic acid 
(EDTA) were from Gibco, (Invitrogen, UK) and Biowhittaker (UK). Insulin was from 
Novorapid. Tissue Culture plasticware was from Corning Incorporated (USA). Western 
Blotting power pack, Hybond Support Nitrocellullose and ChemiDoc™-XRS were 
from Bio-Rad (UK). X-tremeGENE HP DNA Transfection Reagent (cat no.: 
06366236001) was purchased from Roche (Switzerland). Primary antibodies were 
purchased from Cell Signalling (USA); Histone H3 (cat no.: 9715L), Pp44/42 MAPK 
(phospho-Erk1/2) (cat no.: 4370S), pAKT (cat no.: 4060L), pFAK (cat no.: 3281S), 
RhoA (cat no.: 9968S), or Santa Cruz Biotechnology (USA); pJNK (cat no.: sc-6254), 
Pp38 (cat no.: sc-166182), C/EBPβ (cat no.: sc-150), ETS-1 (cat no.: C-20), while HOP 
(cat no.: SRA-1500) was purchased from Assay Designs (USA). αTubulin (cat no.: 
ab7291) and GAPDH-HRP (cat no.: ab185059) primary antibodies as well as HRP 
conjugated donkey anti-rabbit secondary antibody (cat no.: ab16284) and HRP 
conjugated goat anti-mouse secondary antibody (cat no.: ab97110), DyLight 550 
donkey anti-mouse secondary antibody (cat no.: ab96876) and Dylight 488 donkey 
anti-rabbit secondary antibodies (cat no.: ab96891) were from Abcam (UK). 
 
2.2 Methods  
2.2.1 - Maintenance of cancer cell lines 
Hs578T breast cancer cells were maintained in Dulbecco’s Modified Eagle Media 
(DMEM) supplemented with GlutaMAX™-I, 10% (v/v) Foetal Calf Serum (FCS), 
penicillin-streptomycin-amphotericin (PSA; 100 U/ml) and 0.3 U/ml insulin. HeLa 
19 
 
cervical cancer cells were maintained in DMEM supplemented with GlutaMAX™-I, 
10% (v/v) FCS and PSA (100 U/ml). The MCF-7 breast cancer cells were maintained 
in DMEM with GlutaMAX™-I, 5% (v/v) FCS, PSA (100 U/ml). MEF-1 SV40 
transformed mouse embryonic fibroblast cells were maintained in DMEM 
supplemented with GlutaMAX™-I, 10% (v/v) FCS and PSA (100 U/ml). All 
mammalian cell lines were maintained at 37 oC with 9% CO2.  
 
2.2.2 - Bioinformatic analysis of HOP nucleotide and protein sequences 
Sequences for the genomic context analysis and comparison were obtained from 
Ensembl, UniProtK, HomoloGene and NCBI databases. Accession numbers for 
sequences were as follows: Homo sapiens (NT_033903.7, NM_006819.2), Mus 
musculus (NT_082892.2, NM_016737.2), Danio rerio (NM_001007766.2), 
Saccharomyces cerevisiae (NM_001183446.1), Latimeria chalumnae 
(ENSLACT00000019245, H3BB41), Xenopus tropicalis (ENSXETG00000007189), 
Drosophila melanogaster (NT_033779.4, NM_058006.4), Caenorhabditis elegans 
(O16259, NM_070921.6), Pan troglodytes (XP_508521.2), Macaca mulatta 
(XP_001115412.2), Rattus norvegicus (NP_620266.1), Canis lupus (XP_854960.1), 
Bos taurus (NP_001030569.1), Anopheles gambiae (XP_319365.4), 
Schizosaccharomyces pombe (NP_588123.1), Magnaporthe oryzae  (XP_364135.1), 
Kluyveromyces lactis (XP_451313.1) and Ashbya gossypii (XP_319365.4). Multiple 
sequence alignments were performed using T-Coffee (Notredame et al., 2000) and 
pairwise global alignments were performed with BioEdit (Hall, 1999) using default 
parameters for both. Protein structure was analysed by SMART (Schultz et al., 1998) 
using the default parameters to identify conserved protein domains. Nucleotide and 
protein sequences were aligned first by MUSCLE (Edgar, 2004) or Clustal Omega 
(McWilliam et al., 2013) before the phylogenetic maximum likelihood tree was 
constructed using MEGA5.2 (Hall, 2013) with bootstrap replicates of 1000 for protein 
sequences. The tree was compared against trees generated by the neighbour-joining 
phylogenetic method. Alternate transcripts were collected from ENSEMBL 
(www.ensembl.org/Homo_sapiens). Co-expression data was gathered from Gemma 
(Zoubarev et al., 2012) with a stringency of 3 ensuring that genes with at least 3 
supporting cases and no negative support were considered. Differential expression data 
was gathered from Gemma. C0XPRESdb (version 6) (Obayashi et al., 2008) was used 
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in conjunction with Gemma for co-expression analyses. Cytoscape 3 (Cline et al., 
2007) was utilised to construct networks between co-expressed genes or protein-protein 
interaction networks. The HSP90 Chaperone Machine Interactome Database 
(Echeverría et al., 2011) was used to obtain the HOP protein-protein interaction data. 
 
2.2.3 - Transcription factor binding site prediction 
The presence of transcription factor binding sites in the putative HOP promoter 
sequence was predicted in silico using Cister (Wingender et al., 2000; Frith et al., 
2001) using a hidden Markov statistical model, TFSearch (Akiyama, 1995; Heinemeyer 
et al., 1998) using a cut-off threshold of 85.0, ALIBABA (Heinemeyer et al., 1998) 
with a cut-off of 80% matrix conservation, and Promo (Messeguer et al., 2002; Farré et 
al., 2003) using a dissimilarity < 5.0 as a cut-off. CpG islands identified by MethPrimer 
(Li & Dahiya, 2002) the criteria used being a frequency of observed CG dinucleotides / 
frequency of expected CG dinucleotides > 0.6; GC % > 50; and length > 100.  
 
2.2.4 - Cloning of HOP promoter luciferase reporter construct 
The 1535bp putative promoter sequence was chemically synthesised into a pUC57 
vector by GenScript (USA), to create pSAW. The putative HOP promoter sequence 
was digested out of the plasmid vector using 10 U/μl NheI (New England BioLabs, cat 
no.: B7003S) and BglII (Fermentas, cat no.: ER0082), and ligated into the promoterless 
pGL4 vector upstream of the firefly luciferase coding region (Promega, cat no.: E6721) 
to produce pHOP-x, the HOP promoter reporter construct. Digestion products were 
visualised using 1% (w/v) agarose gel electrophoresis (AGE) in TAE buffer (40 mM 
Trizma, 1 mM sodium EDTA) at 100 V for 90 minutes (unless stated otherwise). The 
digested HOP promoter fragment and linearized pGL4 were gel extracted using the 
ZymoClean™ Gel DNA Recovery Kit (Zymo Research, cat no.: D4002) and ligated 
together to form pHOP-x using T4 DNA ligase (Fermentas, EL0015) and 10X T4 DNA 
Ligase buffer (Fermentas, B69). The ligation reaction was incubated overnight (O/N) at 
4oC before the recombinant plasmids were transformed into JM109 E.coli competent 
cells (1 x 108 cfu/µg DNA) (Hiang et al., 2010).   
 
The competent cells were prepared by using the RF1 and RF2 buffer protocol (Hanahan 
et al., 1991). For transformation, JM109 E.coli competent cells were thawed on ice for 
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10 min, and incubated with 20 ng plasmid DNA on ice for a further 30 min. The cells 
were heat shocked for 45 seconds at 42oC and incubated on ice for 2 min. An additional 
500 μl of 2xYT broth without antibiotics (16 g/L tryptone, 10 g/L yeast extract, 5 g/L 
NaCl) was added to the cells and incubated for 1 hr at 37oC with shaking. The 
transformation culture was plated onto 2xYT agar plates (16 g/L tryptone, 10 g/L yeast 
extract, 5 g/L NaCl, 15 g/L agar) containing 100 μg/ml ampicillin and incubated at 
37oC O/N. Plasmids were extracted from O/N liquid culture inoculations using the 
Zyppy Plasmid Miniprep kit according to the manufacturer’s instructions (Zymo 
Research, cat no.: D4013). Restriction enzyme digestions were performed using 10 U 
ScaI (New England BioLabs, cat no.: R0122S), StyI (New England BioLabs, cat no.: 
R0500S) or BglII (New England BioLabs, cat no.: R0144S) and incubated O/N at 37oC 
before being visualised using 1% (w/v) AGE at 100 V for 90 minutes. Endotoxin free 
pHOP-x constructs were obtained by performing an endotoxin free plasmid extraction 
using the EndoFree Plasmid Maxi Kit according to manufacturer’s instructions 
(Qiagen, cat no.: 12362). The plasmid was confirmed by sequencing done by Inqaba 
Biotec (South Africa). 
 
2.2.5 - Transient transfections and luciferase reporter assay 
The HOP promoter constructs were transiently transfected into MEF-1, Hs578T, HeLa 
and MCF-7 cell lines using X-tremeGENE HP DNA Transfection Reagent (Roche, 
Switzerland) according to the manufacturer’s instructions. Briefly, 2 x 105 cells were 
seeded into a 24 well plate (in media without PSA) and incubated at 37oC in a CO2 
incubator O/N. The cell culture medium was removed and 1 µg of the endotoxin free 
HOP promoter DNA reporter plasmid was diluted with 25 µl of Opti-MEM I Reduced® 
Serum Medium and 1 µl X-tremeGENE HP DNA Transfection Reagent and incubated 
for 20 min at room temperature before being added to the cells. The cells were co-
transfected with 1 µg of the control reporter plasmid encoding EGFP (pLV-eGFP, 
Addgene plasmid: 36083). The pLV-eGFP plasmid provided a transfection efficiency 
control that was used to normalize the results obtained from independent transfections 
of the pHOP-x reporter construct. Cells transfected with empty pGL4 vectors or water 
were used as negative controls. The cells were incubated at 37oC in a CO2 incubator for 
48 hours before the promoter activity of the transfectants was determined by measuring 
the levels of luciferase activity. The cells were lysed with 10% (v/v) Triton-X/H2O and 
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each well was split into 3 wells within a black clear bottomed 96 well plate (Corning, 
cat. no.: 3904). The eGFP within the lysate was excited at 488nm and the emitted 
fluorescence was recorded at 509nm (relative fluorescence units [RFU]) in a 
SynergyMx spectrophotometer (BioTek, USA). The sample was subsequently 
transferred into a white bottomed 96 well plate (Corning, cat. no.: 353296) containing 
FLAR Buffer (200 mM Tricine, 100 µM EDTA, 2.67 mM MgSO4, 250 µM Adenosine 
Triphosphate [ATP], 250 µM Luciferin, 17 mM Dithiothreitol [DTT]). The firefly 
luminescence (relative light units [RLU]) was measured in the SynergyMx 
spectrophotometer at a sensitivity of 160. The ratio of RLU:RFU was calculated 
defined as the relative luciferase activity. The results were normalised against the 
negative controls. The P values for the assay were calculated using a one-way analysis 
of variance and the Tukey's Multiple Comparison Test. P values of less than 0.05 were 
considered as statistically significant. 
 
2.2.6 - SDS-PAGE and Western Blot Analysis 
Cells were harvested by scraping with a 200 µl pipette tip into sample lysis buffer (0.5 
mM Tris, pH 6.8, 10% [v/v] glycerol, 10% [w/v] SDS, 5% [v/v] 2-mercaptoethanol) 
and protein concentrations determined using the NanoDrop 2000 Spectrophotometer 
(Thermo Scientific). Samples were prepared for electrophoresis by boiling for 5 
minutes in Sodium-Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) sample buffer (0.5M Tris pH 6.8, 10% [v/v] glycerol, 10% [w/v] SDS, 1% 
[w/v] Bromophenol blue, 5% [v/v] 2-mercaptoethanol). Equal amounts of proteins were 
separated by SDS-PAGE according to the protocol described by Laemmli (1970). 
Proteins were resolved using a 4% (v/v) stacking gel (0.5 M Tris-HCl, pH 6.8) and a 
12% (v/v) resolving gel (1.5 M Tris-HCl, pH 8.8) at 100 V for 90 minutes in SDS-
PAGE running buffer (0.25 mM Tris pH 8.3, 192 mM glycine, and 1% [w/v] SDS). 
PIERCE Prestained Protein MW Marker (ThermoScientific, cat no.: 00026612) was 
used for estimating molecular weights of proteins. Western analysis was performed on 
resolved proteins from SDS-PAGE according to the method of Towbin et. al. (1979). 
Transfer of proteins from the SDS-PAGE gel to the nitrocellulose membrane was 
carried out with the semi-dry blot in transfer buffer (0.13 mM Tris-HCl, 100 mM 
glycine and 20% [v/v] methanol) for 50 minutes at 0.4A. Protein transfer was 
confirmed with Ponceau staining (0.5% [w/v] Ponceau S in 1% [v/v] glacial acetic 
23 
 
acid). The membrane was blocked for one hour with either 5% (w/v) fat free milk 
powder (Santa Cruz Biotechnology, cat no.: sc-232S), in Tris-buffered saline (TBS; 50 
mM Tris pH 7.5, 150 mM NaCl), or in 5% (w/v) Bovine Serum Albumin (BSA) 
(Promega, cat no.: R396D) diluted in TBS. The membrane was incubated with primary 
antibody (1:1000 for HOP, C/EBPβ and ETS-1; 1:2500 for Histone and RhoA; 1:5000 
for pERK1/2, pAKT, pFAK,; 1:100 for pJNK) diluted in either 5% (w/v) milk or 5% 
(w/v) BSA O/N at 4oC. The membrane was washed with Tris-buffered saline 
containing Tween-20 (TBST; 0.001% [v/v] Tween-20 in TBS) twice for 20 minutes 
before incubation with species-matched peroxidase-conjugated secondary antibody 
(1:5000 for all unless otherwise stated) diluted in 5% (w/v) milk, 5% (w/v) BSA for an 
hour at room temperature. Membranes were washed in 4 changes of TBST for a total of 
one hour and detection of proteins carried out using a chemiluminescence developing 
kit (Clarity™ Western ECL Substrate, BioRad, USA; or Luminal/Enhancer Solution 
and Stable Peroxide Solution, Thermo Scientific, USA) on AGFA Medical X-ray film 
(AGFA HealthCare NV, Belgium) or using the ChemiDoc™-XRS and ImageLab 
Software (BioRad, USA). Densitometry was performed using ImageJ software 
(Schneider et al., 2012). 
 
2.2.7 - Quantitative Real Time PCR 
Cells were fixed in 1 ml TRIzol® Reagent (a mono-phasic solution of phenol and 
guanidinium thiocyanate). The RNA was isolated from cells using the Trizol 
(Invitrogen) extraction method and no DNase treatments were performed. RNA was 
quantified immediately using the Nanodrop2000, and once quantified, the RNA 
samples were stored at -80°C until used.  Samples were used within a week for qRT-
PCR. The Nanodrop2000 quantification provided a means of measuring the purity, 
RNA samples with an A260/A280 ratio between 1.8 and 2.0 only were used for qRT-
PCR. A total of 100 ng of RNA was used in the KAPA SYBR® FAST One-Step qRT-
PCR kit (KAPA Biosystems, cat no.: KK4650) in 20 µl reactions, with each reaction 
including 1x KAPA SYBR® FAST qPCR master mix (containing KAPA SYBR® Taq 
DNA polymerase and SYBR Green 1) (KAPA Biosystems, cat no.: KM4108), 200 nM 
forward primer, 200 nM reverse primer and 1x KAPA RT mix (wildtype M-MuLV 
Reverse Transcriptase and RNase Inhibitor). In addition to the experimental and control 
samples, no template controls (NTC) and no reverse transcriptase controls (NRT) were 
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also included in the qRT-PCR. All kit components and samples were kept on ice during 
experiment setup. The reaction was run in the MiniOpticon System MJ Minipersonal 
thermal cycler (BioRad, USA) for 5 min at 42°C for cDNA synthesis. The reverse 
transcriptase was inactivated by a consecutive 5 min at 95°C. PCR cycling and 
detection next performed by a further 40 cycles of 10 seconds at 95°C, 30 seconds at 
50°C, with a melt curve performed for each from 55°C to 95°C with increments of 
0,5°C for 10 seconds.  
 
Data was analysed using the Bio-Rad CFX Manager 3.0 (BioRad, USA). The results 
were normalized against the quantification of the best of the 3 reference genes; 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta cytoskeletal actin (ACTB) 
or hypoxanthine phosphoribosyltransferase (HPRT1). The relative quantification 
method was used to determine the gene expression levels (Mankame et al., 2010) by 
calculating the threshold cycle (Ct) values of the housekeeping genes for each sample 
so as to normalize the HOP Ct value in each sample. The delta Ct value of HOP was 
used to quantify the relative amount of HOP mRNA expressed under different 
conditions (Mankame et al., 2010). Primers utilised were commercially available from 
Integrated DNA Technologies (IDT, USA) and are outlined in Table 1. If the NRT or 
NTC samples had Ct values that were less than 7 cycles greater than the experimental 
and control groups, the samples were considered contaminated with genomic DNA and 
thus excluded from the analysis. Each qRT-PCR experiment had three biological 
replicates, with three technical replicates for each biological replicate. 
 
Table 1: qRT-PCR HOP and control gene primer details. 
 
*RT-PCR primers obtained from IDT. 
Sequence Tm (°C)
Length 
(bp)
Location GC (% ) Sequence Tm (°C)
Length 
(bp)
Location GC (% )
HOP
NM_00681
9
77
110225356
c1
All
CCTTAC
AGTGCT
ACTCCG
AAGC
62.4 22 68-89 55
ATAGGC
AGCAGA
ACGGTTG
C
62.9 20 144-125 55
GAPDH
NM_00125
6799
197
378404907
c1
All
GGAGCG
AGATCC
CTCCAA
AAT
61.6 21 108-128 52
GGCTGTT
GTCATA
CTTCTCA
TGG
60.9 23 304-282 48
ACTB
NM_00110
1
250 4501885a1 All
CATGTA
CGTTGCT
ATCCAG
GC
60.8 21 393-413 52
CTCCTTA
ATGTCA
CGCACG
AT
60.2 21 642-622 48
HPRT1
NM_00019
4
131
164518913
c1
All
CCTGGCG
TCGTGAT
TAGTGA
T
61.9 21 16-36 52
AGACGT
TCAGTCC
TGTCCAT
AA
60.5 22 146-125 45
Reverse Primer *
Gene 
Target
GenBank 
Accession
Amplicon 
size (bp)
PrimerBa
nk ID
Splice 
Variant 
Detection
Forward Primer *
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2.2.8 - Effect of mutated RAS on the expression of HOP 
Three plasmids were obtained from Addgene and used to determine the effect of 
mutated RAS on the activity of the HOP promoter. One plasmid encoded wildtype 
HRAS (mEGFP-HRas, plasmid: 18662), another encoded a mutated HRAS G12V 
(mEGFP-HRas G12V, plasmid: 18666) that was constitutively active, and another 
mutated HRAS S17N (mEGFP-HRas S17N, plasmid:18665) that was dominant 
negative (Yasuda et al., 2006). MCF-7, HeLa and Hs578T breast carcinoma cells were 
seeded into a 24 well plate at a density of 2 x 105 cells/500 µl media. The cells were 
transiently transfected, as described above, with one of the three RAS plasmids, along 
with pHOP-x. A total of 500 ng of the plasmids was transfected per well. Luciferase 
assays were performed as described before to determine the effect of RAS on the 
promoter activity of HOP in Hs578T and HeLa cells. The quantitative iScript One-Step 
RT-PCR Kit was utilised to determine the effect of RAS on the HOP mRNA levels. 
RNA was extracted from MCF-7 cells transfected with the HRAS plasmids using the 
Trizol method and 100 ng of RNA was used for qRT-PCR. The experimental groups 
were RNA samples from the cells that had been transfected with a RAS plasmid, while 
the control group was the RNA samples from untransfected cells. Western Blot 
analyses of transfected Hs578T and HeLa cell lysates were utilised to determine the 
effect of RAS on the protein expression of HOP using the procedure described 
previously. 
 
2.2.9 - Cell Cytotoxicity assays 
Cells were seeded at a density of 1 x104 cells/well in 50 µl culture media in a 96 well 
plate and allowed to adhere O/N at 37oC in 9% CO2. The next day the cells were treated 
with an additional 50 µl media containing various concentrations of alpha hydroxyl 
farnesyl phosphoric acid (αHFPA) (Santa Cruz Biotechnology, cat no.: sc-205200), 
sorafenib (BAY 43-9006) (Santa Cruz Biotechnology, cat no.: sc-220125), U0126 (Cell 
Signalling Technology, cat no.: #9903) or 3-(2-Aminoethyl)-5-((4-et
hoxyphenyl)methylene)-2,4-thiazolidinedione (Sigma, cat no.: A6355) as indicated in 
figure legends. The cells were incubated at 37oC in 9% CO2 for 72 hrs, after which 10 
µl of WST-1 Cell Proliferation Reagent (Roche, cat no.: 11644807001) (diluted in 40 
µl media) was added to each well, and incubated at 37oC in 9% CO2 for 4 hrs. The 
absorbance was read at 450nm and dose response cell cytotoxicity curves were 
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constructed as the log concentration of the drugs versus normalised absorbance. The 
IC50 values were calculated as the drug concentration that caused a 50% reduction in 
cell viability in comparison to the control cells. 
 
2.2.10 - Effect of MAPK pathway inhibitors on the expression of HOP 
Hs578T cells were seeded at 5 x 105 cells/well into a 6 well plate and treated with 3.568 
µM Sorafenib, 37.7 µM U0126, 30 µM αHFPA or 60 µM ERK2i and incubated for 48 
hrs at 37oC in 9% CO2. RNA was extracted using the Trizol method and 100 ng of 
RNA was used for perform qRT-PCR to determine the effect on the mRNA expression 
of HOP. The experimental groups were RNA samples from the cells that had been 
treated with inhibitors, while the control groups were the RNA samples from cells that 
had been treated with the vehicle controls (DMSO, EtOH). Alternatively, cells were 
harvested for the proteins by scraping into sample lysis buffer and 100 µg of protein 
was used for Western Blot analyses as previously described to determine the effect of 
RAS on the protein expression of HOP. 
 
2.2.11 - Time Course Study of the effect of Sorafenib on HOP protein levels 
Hs578T cells were seeded into a 6 well plate at a density of 2.5 x 105 cells/well and left 
to adhere O/N at 37oC with 9% CO2. The cells were treated with 3.568 µM Sorafenib 
and lysed with cell lysis buffer at varying time points (12hr, 24hr, 36hr, 48hr). Cell 
lysates were sonicated at 40 Hz for 5 seconds in 10 second intervals for a total of 2 
minutes. The lysates were used in SDS-PAGE and Western Blot analysis, consequently 
making use of ImageJ (Schneider et al., 2012) to perform densitometry to determine the 
relative levels of HOP at each time point. 
 
2.2.12 - Immunofluorescence staining and Fluorescent Microscopy 
Hs578T cells were seeded at a density of 2 x 105 cells/ml into a 24 well plate containing 
a glass coverslip and incubated overnight at 37oC with 9% CO2. Cells were fixed by a 5 
second treatment with ice-cold methanol (-20oC) and allowed to air dry. Cells were 
blocked with 1% (w/v) BSA in PBS [8 g/l NaCl, 200 mg/ml KCl, 1.15 g/l Na2HPO4. 
200 mg/ml KH2PO4] (BSA/PBS) for 45 minutes at room temperature and incubated 
with primary antibodies in 1% (w/v) BSA/PBS at 4oC O/N. After incubation, cells were 
washed twice in 0.1% (w/v) BSA/PBS for 5 minutes followed by incubation with 
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appropriate species-specific fluorophore-conjugated secondary antibodies at room 
temperature for 2 hours in the dark in 0.1% (w/v) BSA/PBS. Cells were washed twice 
with distilled water and the nucleus stained with Hoechst-33342 (DAPI) (1 μg/ml in 
distilled water) before mounting with DAKO fluorescent mounting medium. 
Immunofluorescence staining was visualised using the Zeiss AxioVert AI FL-LED 
inverted fluorescence microscope or the Zeiss LSM 780 Confocal Microscope (Carl 
Zeiss Microscopy, USA) and analysed using ZEN lite 2012 software (Carl Zeiss 
Microscopy, USA). Imaging was performed using the 40x, 60x and 100x objectives. 
Details of individual treatments are described in the figure legends. The fluorescence 
intensity of a protein within the nucleus and the cytoplasm was determined by plotting 
the grey value profile of the fluorescence channel of interest for each cell using ImageJ 
(Fig.3). The borders of the nuclei were determined by overlaying the channel that 
detected the fluorescence of the Hoechst with that of the channel that detected the 
fluorescence of the protein of interest (Fig.3A). The grey values were totalled within 
the nucleus and cytoplasm (Fig.3B). The totalled grey value was divided by the length 
of the either the nucleus or of the cell (excluding the nucleus, thus the cytoplasm was 
considered the signal which was on either side of the nuclear signal) (Fig.3B). A 
minimum of 10 cells were utilised for the analysis. 
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Figure 3: Measurement of fluorescent intensity within a cell.  
The location of the nucleus within the cell was determined for one z-stack (A). The profile of the grey 
values (indicating fluorescence intensity of the protein of interest) within a cell was plotted (B). The grey 
values were added and totalled for the cytoplasm and nucleus respectively. The totals were divided by the 
length of either the nucleus or the cell (excluding the nucleus) to give the fluorescence intensity within 
the nucleus or the cytoplasm. 
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Chapter 3 
 
Comparison of the HOP gene across species and a bioinformatic 
analysis of the putative HOP promoter 
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3.1 Introduction 
Model organisms are of vital importance in furthering our knowledge in the study of 
human diseases and the mechanisms by which genes function. To provide an in depth 
study of the molecular functioning of a protein of interest, one needs to make use of a 
model organism that most closely represents the cellular and molecular make-up of the 
human cell (Armengaud et al., 2014). This refers to the representational scope of the 
model organism, which describes the extent to which the data obtained from an 
experimental organism can be projected onto other organisms, or in other words the 
organisms for which the experimental organism is acting as a proxy (Ankeny & 
Leonelli, 2011). The representational target in turn refers to the concept, process or 
entity that is to be explored through the use of the experimental organism (Ankeny & 
Leonelli, 2011). Thus the preferred range of the representational scope is determined by 
the representational target. Through a statistical analysis, Nabhan & Sarkar (2014) were 
able to present a means of predicting the most suitable model organisms for the study of 
various human cancers and infectious diseases. They performed a structural and 
functional analysis of disease-related genetic pathways and matched them to molecular 
interaction networks of 14 model organisms. From there they could predict which 
model organism was most suitable as a specific disease model. For all 12 cancer 
subtypes analysed in the study, Mus musculus and Rattus norvegicus were by far the 
best disease models. However, in the case of melanoma and renal cell carcinoma it was 
observed that Danio rerio was a more suitable disease model than murine and rat 
(Nabhan & Sarkar, 2014). Making use of the most suitable model organism or disease 
model would thus be the most cost effective and time sensitive means of furthering the 
knowledge of the functioning of HOP in human diseases. 
 
HOP has been either predicted or identified in many model organisms such as the 
nematode (Song et al. 2009), fruit fly (Grigus et al. 1998), zebrafish (Woods et al. 
2005; Tastan Bishop et al. 2013), mouse (Blatch et al. 1997), rat (Demand et al. 1998), 
frog (Klein et al. 2002), fish (Andreassen et al. 2009), parasites (Webb et al. 1997; 
Hombach et al. 2013) and plants (Zhang et al. 2003; Chen et al. 2010), as well as in the 
coelacanth (Amemiya et al. 2013; Tastan Bishop et al. 2013) and human genomes 
(Honore et al. 1992). This chapter presents a study comparing the HOP gene across 
species in an attempt to determine what organism is best suited to being a model 
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organism for the study of HOP in humans. More specifically, since the murine model is 
the animal model most commonly utilised in studying human disease, we address the 
question of whether the murine model is a sufficient model for the study of human HOP 
by determining how similar the HOP genes within the murine and human systems are. 
Additionally we analyse the factors influencing the transcriptional regulation of HOP, 
specifically within the human system. 
 
3.2. Results 
3.2.1 - Phylogenetic analyses of the HOP orthologues 
 
This study identified that the HOP gene is observed once per genome across all species 
tested. Table 2 summarises some of the pertinent information on the HOP gene that will 
be discussed in more detail throughout this chapter. The length of the HOP gene is 
similar amongst the orthologues, although the HOP gene in yeast, fruit fly and 
nematode is one tenth the size of the HOP gene found in the other orthologues. 
Additionally, all orthologues contain 14 exons in the HOP gene, besides the Coelacanth 
which has 13. The HOP gene in yeast, fruit fly and nematode has only one exon. The 
HOP gene is found on the positive strand for all orthologues besides mouse and yeast. 
The HOP mRNA transcript length is similar across all orthologues although it is shorter 
in yeast and the frog, and it is less than half the size in nematodes. The translated 
protein sequence of HOP is similar across all orthologues but again is almost half the 
length in nematodes. The 5` and 3`UTR regions of the HOP gene contain no pattern 
across the orthologues.  
 
An initial study of the evolution of the HOP speciation was performed across the 
identified orthologues obtained from HomoloGene, NCBI. Phylogenetic analyses of the 
protein sequences of the HOP orthologues were performed using MEGA5.2 (Fig.4). 
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Table 2: Summary of the comparison of the genomic structure and location of HOP orthologues. 
           
Species 
Chromosome 
Location of 
STIP1 
Start 
Position 
Stop 
Position 
Gene 
length 
(bp) 
Strand 
Coding 
exons 
Transcript 
length 
(bp) 
Protein 
length 
(aa) 
5` 
UTR 
(bp) 
3` 
UTR 
(bp) 
Homo sapiens 11q13 63953587 63972020 18433 + 14 2196 543 147 417 
Mus musculus 19A 7020696 7040026 19330 - 14 2173 543 138 403 
Danio rerio XV 69801144 69817741 16597 + 14 2462 542 37 796 
Saccharomyces 
cerevisiae 
5 381053 382822 1769 - 1 1770 589 0 0 
Latimeria 
chalumnae 
Unassembled 
genome 
1752251 1772059 19808 + 13 2137 576 250 156 
Xenopus 
tropicalis 
Unassembled 
genome 
211042 223291 12249 + 14 1914 543 35 247 
Drosophila 
melanogaster 
2L 295122 297449 2327 + 1 2023 590 151 400 
Caenorhabditis 
elegans 
V 773592 774716 1124 + 1 963 320 0 0 
*Data from ENSEMBL and NCBI databases. 
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Figure 4: Molecular Phylogenetic analysis of the orthologous HOP protein sequences by the 
Maximum Likelihood method. 
The evolutionary history was inferred by using the Maximum Likelihood method based on the Whelan 
And Goldman model (Whelan & Goldman, 2001). The optimal tree with the sum of branch length = 
2.49973822 is shown. The tree with the highest log likelihood (-3504.7577) is shown. The percentage of 
trees in which the associated taxa clustered together is shown above the branches. Initial tree(s) for the 
heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a 
matrix of pairwise distances estimated using a JTT model, and then selecting the topology with superior 
log likelihood value. A discrete Gamma distribution was used to model evolutionary rate differences 
among sites (5 categories (+G, parameter = 3.7753)). The rate variation model allowed for some sites to 
be evolutionarily invariable ([+I], 17.1146% sites). The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site (branch lengths are shown below the branches). The 
analysis involved 18 amino acid sequences. All positions with less than 95% site coverage were 
eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at 
any position. There were a total of 261 positions in the final dataset. Evolutionary analyses were 
conducted in MEGA5 (Tamura et al., 2011). 
 
The maximum likelihood tree was an unrooted tree produced from the protein coding 
sequences and indicated the suspected evolutionary conservation across the orthologues 
(Fig.4). Within the protein tree, the evolutionary pathway of the HOP protein could be 
traced from the unicellular eukaryotes to plants, to fish and amphibians and then to land 
mammal. All branch lengths between nodes were observed to be less than 0.33, with 
most mammals having branch lengths of zero (Fig.4). Low branch lengths indicated 
low numbers of substitutions per site in the amino acid sequences but did not correlate 
with high bootstrap values (Hall, 2013). Within the land mammals, the HOP protein 
evolves from cattle, to the murine, to the lower primates and finally to the human. The 
yeast and fungal species were separated from animals by the first branching of the tree. 
Certain branches had bootstrap values above the 95% threshold, those being the 
branching between Danio rerio and the transition to amphibians, the coelacanth and the 
transition to the amphibians, between mouse and rat, and between lower primates and 
greater primates (including human) (Fig.4). The branching between the various yeasts 
and fungi were either very high or very low. Those with particularly low bootstrap 
values (less than 70%) were the branching between Homo sapiens and Pan troglodytes, 
between murine and primates, between cattle and the greater mammals, between 
Xenopus tropicalis and mammals, and lastly branching between nematode and 
amphibians (Fig.4). 
 
3.2.2 - Exon and Protein Organisation of HOP between species 
The organisation of the exons and introns within the HOP gene was compared across 
the orthologues (Fig.5A). The HOP gene transcript in yeast, the fruit fly and the 
34 
 
nematode was observed to be comprised of a single exon, as is commonly observed in 
these genomes, while the remaining orthologues were comprised of 14 exons, or 13 in 
the case of the coelacanth orthologue (Table 2, Fig. 5A). The gene length along the 
chromosome ranged from 1 kb in nematodes to 19 kb in the coelacanth (Table 2). 
Whereas the mRNA transcript lengths had a smaller size range across the orthologues, 
with the length ranging from 0.9 kb in nematodes, to 2.9 kb in the zebrafish (Table 2, 
Fig.5A). All orthologues had 5`UTR and 3`UTR sequences of varying lengths, except 
yeast and nematode which did not have either according to the ENSEMBL and NCBI 
databases (Table 2, Fig. 5A). The distribution of the exons had no regularity or pattern 
across the orthologues. 
 
Next, the domain structure of the HOP proteins was compared across the orthologues. 
Three tetratricopeptide repeat domains (TPR) were conserved across all species except 
the nematode which had only two (Fig. 5B). All species were found to have the two 
conserved aspartic acid and proline rich domains (DP), otherwise known as the heat 
shock chaperone binding motif (STI1 domain sequences). However, again the 
nematode had only one conserved domain (Fig. 5B). The human and the mouse each 
had three TPR domains (TPR1, TPR2A and TPR2B). The individual TPR domains 
were specifically linked to the exons encoding them (Fig. 5B). TPR2A was found to be 
the most degenerate domain of the three, with the lowest sequence identity and 
similarity in the nucleotide and protein composition across the different species. Within 
human and murine HOP amino acid sequences, which have a high degree of sequence 
identity in TPR1 (98%) and TPR2B (91%), the sequence identity for the TPR2A 
domain was 4.7%. The nucleotide sequences encoding TPR1 within the human coding 
sequence spanned exons 1 and 2; TPR2A spanned exons 5, 6 and 7; while TPR2B 
spanned exons 8 and 9. TPR1 of the mouse coding sequence spans exons 1 and 2; 
TPR2A spans exons 5, 6 and 7; while TPR2B spans exons 8, 9, 10 and 11.  
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Figure 5: Comparison of the exon organisation and protein structure of HOP orthologues.  
A) Schematic diagram depicting the exon structure of the HOP gene across orthologues within Homo 
sapiens (human), Mus musculus (mouse), Danio rerio (zebrafish), Saccharamyces cerevisiae (yeast), 
Latimeria chalumnae (coelacanth), Xenopus tropicalus (frog), Drosophila melanogaster (fruit fly) and 
Caenorhabditis elegans (nematode) species. The black boxes illustrate the exon positions along the 
mRNA transcript. The spaces between the black boxes represent the intron sequences. The white boxes 
illustrate the 5` and 3` untranslated regions (UTR) at either end of the mRNA transcript. B) Schematic 
diagram comparing the protein structures of HOP. Black boxes represent tetratricopeptide repeat motifs 
(TPR motifs), three TPR motifs comprising a TPR domain. The blue boxes represent DP (aspartic acid 
and proline rich domains) or STI1 domain sequences (heat shock chaperone binding motif). The amino 
acid length of each protein is given at the end of the protein. 
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3.2.3 - Analysis of the alternate transcripts of the human HOP gene. 
Alternate splicing is considered the process of identical mRNA transcripts being spliced 
in different ways; usually this is a positive tool within organisms as it creates protein 
diversity from a single gene sequence. However splicing has also been identified with 
the cause of many diseases (Venables, 2004; Srebrow & Kornblihtt, 2006). This, hence, 
led to an initial identification of alternate transcripts of HOP within humans (Table 3). 
 
Table 3: Comparison of the alternate protein coding transcripts of human HOP. 
Alternate 
Transcript 
Transcript 
length (bp) 
Protein 
length 
(aa) 
Exons 
Sequence Identity to  
STIP1-001 (%) * 
Protein Domains 
Evidence ** 
Nucleotide Protein DP/STI TPR motif 
STIP1-001 2196 543 14 100 100 2 9 
Evidence at the 
protein and 
transcript level 
STIP1-010 2743 590 14 99.63 99.45 2 9 
Evidence at the 
transcript level 
STIP1-003 1900 519 14 100 97.69 2 8 
Evidence at the 
transcript level 
STIP1-008 877 137 4 90.34 87.59 1 3 
Evidence at the 
transcript level 
STIP1-012 772 236 5 95.5 95.76 1 3 
Evidence at the 
transcript level 
*Sequence identity was determined by a pairwise alignment to STIP-001 (allowing the ends to slide). 
Thus the size difference between transcripts was ignored and the regions contained within the transcripts 
were focussed on. 
** Data obtained from the ENSEMBL database. STIP-001 is the transcript for the known HOP protein. 
Evidence at the transcript levels indicates evidence of the expression of the mRNA transcript, although 
not strictly proven at the protein level. 
 
Five putative protein coding, alternate transcripts were identified for human HOP 
(Table 3). The first isoform (STIP1-001) is the known and functional co-chaperone 
HOP, while the remaining isoforms had evidence of their existence at the mRNA 
transcript level. Although the splice variants are truncated to varying degrees, the 
sections that remain have a high similarity to the known HOP (STIP-001). STIP1-010 
and STIP1-003 have similar gene and protein structures to that of STIP1-001. The only 
difference in STIP1-010 protein was that it had an additional 140 bp in the 5` region of 
the HOP coding sequence. STIP1-003 was missing 70 bp within the HOP coding 
sequence, resulting in it missing the third TPR motif within the TPR1 domain. STIP1-
008 is a truncated transcript of HOP at the 5` end, such that the nucleotides only encode 
two of the TPR motifs within the TPR2B domain. STIP1-012 is also a truncated HOP 
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transcript however is truncated at the 3` end, such that it only encodes the first TPR1 
domain.  
 
3.2.4 - Comparison of the genomic context of HOP between orthologues. 
Having determined that HOP was conserved amongst different species, the genomic 
context of the HOP orthologues was compared in relation to the surrounding genes. 
Synteny was identified within the loci containing the HOP gene for each species. 
Synteny is the conservation of a series of neighbouring genes on a chromosome across 
related species, each being derived from a common ancestor (Nadeau, 1989).  
 
Local synteny was observed between the genes neighbouring HOP across the human, 
mouse, frog and the coelacanth orthologues (Fig.6). The degree of synteny decreased as 
the distance between the species identified by the phylogenetic tree increased (Fig. 4). 
The syntenic region within the mouse was found to have the identical order of genes to 
the human region, however in an inverted orientation and with a differing location of 
the HOP and fermitin family member 3 (FERMT3) genes (Fig. 6). The human HOP 
gene was localised between and partially overlapped the nucleoside diphosphate-linked 
moiety X motif 22 (NUDT22) and an HSP40 homologue (subfamily C, member 4) 
(DNAJC4), while the murine HOP gene was localised between tRNA 
phosphotransferase (TRPT1) and fibronectin leucine rich transmembrane protein 
(FLRT1) (Fig.6). The frog orthologue was also found to retain the same neighbouring 
genes as human and mouse, however in a shuffled order. Furthermore, in both human 
and murine chromosomes FKBP2, VEGFB, DNAJC4, NUDT22, FERMT3 and TRPT1 
were clustered with smaller distances between them in comparison to the remaining 
neighbouring genes (Fig.6). The coelacanth region of interest had a mere 3 homologous 
genes (Fig.6). For both the frog and coelacanth regions, the HOP genes were localised 
adjacent to FERMT3. The zebrafish orthologue had merely one corresponding gene. No 
synteny was observed for the yeast, nematode and fruit fly orthologues (Fig.6).  
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Figure 6: Conserved synteny of the HOP gene.  
Schematic diagram of the genomic representations of HOP across Homo sapiens (human), Mus musculus 
(mouse), Danio rerio (zebrafish), Saccharamyces cerevisiae (yeast), Xenopus tropicalus (frog), 
Drosophila melanogaster (fruit fly) and Caenorhabditis elegans (nematode) species. Triangles represent 
genes, the point of the triangle points to gene orientation on the chromosome. The white triangle in all 
cases represents the HOP gene. Coloured triangles represent genes with synteny across at least two 
species. The names of the genes are listed below the corresponding triangles. Numbers within triangles 
represent the size of the gene in kb. Numbers between the triangles represent the distance between the 
genes in kb. Negative numbers represent overlapping genes and the distance across which they overlap. 
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Table 4: The differential expression of HOP mRNA in cancers. 
Up-regulation of HOP in cancers 
Case 
Syntenic 
genes with 
same exp. 
pattern 
Reference Case 
Syntenic 
genes 
with same 
exp. 
pattern 
Reference 
Compared 
to normal 
tissue 
Microsatellite 
Instability (MSI 
colorectal cancer) 
1 
(Alhopuro et 
al., 2012) Compared 
to wildtype 
Coronary Endothelial 
Cell (induced hypoxia) 
4 
(Chi et al., 
2006) 
Lung adenocarcinoma 
(late) 
2 
(Lo et al., 
2012) 
Smooth Muscle Cell 
(induced hypoxia) 
3 
(Chi et al., 
2006) 
Cytomegalovirus 
Infected alpha-beta T  
cells 
1 
(Baitsch et al., 
2011) 
Compared 
to 
surroundin
g tissue 
Cholangiocarcinoma 
Surrounding Liver 
3 
(Andersen 
et al., 2012) 
Cytomegalovirus 
Infected alpha-beta T  
cells 
1 
(Baitsch et al., 
2011) 
Cholangiocarcinoma 
Tumour 
2 
(Andersen 
et al., 2012) 
Gastric 
Adenocarcinoma 
1 
(Cho et al., 
2011) 
Interstitial Lung 
Disease 
0 
(Lindahl et 
al., 2013) 
Gastrointestinal 
Stromal Tumour 
1 
(Cho et al., 
2011) 
Other 
Undifferentiated stem 
cells vs. Differentiated 
stem cells 
5 
(Kim et al., 
2012) 
Recurrent Bladder 
Tumour 
4 
(Kim et al., 
2010) 
TaY-E10 vs MT-2 vs 
MT-4 (mock vs 17-
AAG, 100nM)  
0 
(Kurashina 
et al., 2009)  
Bladder Mucosae 
Surrounding Cancer 
4 
(Kim et al., 
2010) 
TaY-E10 vs MT-2 vs 
MT-4 (mock vs 17-
AAG, 300nM) 
0 
(Kurashina 
et al., 2009) 
Urinary Bladder 
Cancer 
4 
(Kim et al., 
2010) 
TaY-E10 vs MT-2 vs 
MT-4 (mock vs 17-
AAG, 500nM) 
0 
(Kurashina 
et al., 2009) 
Universal Human 
Reference RNA 
0 
(Skotheim et 
al., 2005) 
TaY-E10 vs MT-2 vs 
MT-4  (mock vs 17-
DMAG, 150nM) 
1 
(Kurashina 
et al., 2009) 
Embryonal Carcinoma 0 
(Skotheim et 
al., 2005) Down-regulation of HOP in cancers 
Stomach Cancer 0 
(Leung et al., 
2002) Case 
Syntenic 
genes 
with same 
exp. 
pattern 
Reference 
Liver Failure: Acute 2 
(Nissim et al., 
2012) 
Compared 
to normal 
tissue 
Cytomegalovirus 
Infected alpha-beta T  
cells 
3 
(Baitsch et 
al., 2011) 
BRCA-1 0 
(Richardson et 
al., 2006) 
Cytomegalovirus 
Infected alpha-beta T  
cells 
4 
(Baitsch et 
al., 2011) 
Glioblastoma 8 
(Sun et al., 
2006) 
Leukaemia 2 
(Paul et al., 
2011) 
Astrocytoma 8 
(Sun et al., 
2006) 
Testicular Seminoma 0 
(Skotheim 
et al., 2005) 
Oligodendraglioma 8 
(Sun et al., 
2006) 
Aggressive 
vs. Non-
aggressive 
HT-1080 
(fibrosarcoma) vs. 
colorectal 
adenocarcinoma 
1 
(Haga et 
al., 2010) 
Oesophageal 
Carcinoma 
1 
(Shimokuni et 
al., 2006) 
Ovarian Serous Tumour 
Malignant 
6 
(Anglesio 
et al., 2008) 
Interstitial Pneumonia 0 
(Lindahl et al., 
2013) 
Normal Testicular 
Germ Cell (vs. 
neoplastic tissue) 
0 
(Skotheim 
et al., 2005) 
Inactive Ulcerative 
Colitis 
3 
(Planell et al., 
2013) 
Compared 
to 
WildType 
Breast Epithelial Cell 
(induced hypoxia) 
5 
(Chi et al., 
2006) 
Ulcerative Colitis 
Involved Active 
2 
(Planell et al., 
2013) 
MT-4 (Interleukin 2-
independent ATL cell 
line) 
1 
(Kurashina 
et al., 2009) 
Ulcerative Colitis 
Non-involved Active 
5 
(Planell et al., 
2013) 
MT-2 (Interleukin 2-
independent ATL cell 
line) 
0 
(Kurashina 
et al., 2009) 
Non-small Cell Lung 2 
(Sanchez-
Palencia et al., 
2011) 
Colon Cancer (TCF4 
knock-out) 
2 
(Wang et 
al., 2013) 
Cholanaiocarcinoma 
surrounding Liver 
3 
(Andersen et 
al., 2012) 
Other 
TaY-E10 vs MT-2 vs 
MT-4 (mock vs 17-
AAG, 700nM) 
0 
(Kurashina 
et al., 2009) 
Cholanaiocarcinoma 
Tumour 
3 
(Andersen et 
al., 2012) 
Oesophagus 
Squamous Cell 
Carcinoma 
1 
(Tong et al., 
2012) 
  
40 
 
In an attempt to further elucidate any relationships or connections between the HOP 
syntenic genes, an in silico analysis of HOP expression in human cancers was 
performed (Table 4). Deregulated HOP expression was identified using the GEMMA 
gene expression database and tool (Zoubarev et al., 2012), any correlating deregulation 
of the expression of the syntenic genes was highlighted. More specifically, the number 
of syntenic genes that had the same expression pattern as HOP was recorded. The data 
depicted in Table 4 shows 38 studies with an up-regulation of HOP in cancers, with 
only 12 studies showing down-regulation of HOP. Within the majority of the studies 
observed at least one of the HOP syntenic genes had a similar expression profile (Table 
4). 
 
3.2.5 - The co-expression profile of HOP in cancer 
The high synteny previously observed between the mammals (Fig.6) and the similar 
expression patterns observed between the syntenic genes in human cancers (Table 5) 
led to the investigation of the possibility of the co-expression of the syntenic genes. 
Using the Gemma gene expression database and tool (Zoubarev et al., 2012), all human 
cancer datasets were searched for co-expression evidence between the syntenic genes. 
It has been previously observed that genes sharing similar functions were often found in 
clusters and were co-expressed in mammalian genomes (Michalak, 2008). 
 
HOP was observed to be co-expressed with both MACROD1 and TRPT1 only, 
however with minimal supporting evidence (Table 5, Fig. 7). Several of the remaining 
genes from the syntenic locus were found to have in vitro evidence in a variety of 
datasets to suggest co-expression between them (Table 5, Fig. 7). NUDT22 was co-
expressed with TRPT1, DNAJC4 and FKBP2; also having the greatest number of 
supporting datasets. DNAJC4 was co-expressed with VEGFB, MACROD1 and 
FKBP2. The only genes that were not co-expressed with any of the others were 
FERMT3 and FLRT1. 
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Table 5: Co-expression of HOP syntenic genes in human cancers. 
 
*Stringency set to a minimum requirement of 2 datasets with supporting evidence. Specificity refers to 
the measure of specificity of the co-expression of the gene with others in its taxon. Data obtained from 
Gemma gene expression database and tool. 
**HOP is referred to as STIP1 in the study. 
 
Figure 7: A co-expression network of HOP syntenic genes. 
The co-expression network between the HOP syntenic genes was compiled from data gathered from the 
Gemma (Zoubarev et al., 2012) and C0XPRESdb (version 6) (Obayashi et al., 2008) databases and 
visualised using Cytoscape 3.0 (Cline et al., 2007). The nodes represent proteins that are connected by 
edges. These edges represent in vitro evidence for co-expression between the proteins. HOP is shown as 
STIP1. 
Query Gene
Query 
Gene NCBI 
Id
Coexpressed 
Gene
Coexpressed 
Gene NCBI Id Specificity
Positive 
Support *
Negative 
Support
Datasets 
tested
NUDT22 84304 TRPT1 83707 0,6005 22 0 178
NUDT22 84304 DNAJC4 3338 0,8861 9 0 146
NUDT22 84304 FKBP2 2286 0,6767 9 0 181
TRPT1 83707 DNAJC4 3338 0,8861 7 0 157
VEGFB 7423 DNAJC4 3338 0,8861 6 0 228
TRPT1 83707 FKBP2 2286 0,6767 6 0 186
TRPT1 83707 VEGFB 7423 0,8109 6 0 189
DNAJC4 3338 FKBP2 2286 0,8861 4 0 227
NUDT22 84304 VEGFB 7423 0,8109 4 0 178
MACROD1 28992 DNAJC4 3338 0,8861 3 0 221
VEGFB 7423 FKBP2 2286 0,8109 2 0 265
STIP1 ** 10963 MACROD1 28992 0,9059 2 0 256
TRPT1 83707 STIP1 ** 10963 0,9059 2 0 186
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Figure 8: Identification and Categorisation of all genes co-expressed with HOP in cancers.  
A) The co-expression network of HOP was compiled from data gathered from the Gemma (Zoubarev et 
al., 2012) and C0XPRESdb (version 6) (Obayashi et al., 2008) databases and visualised using Cytoscape 
3.0 (Cline et al., 2007). The nodes represent proteins that are connected by edges. These edges represent 
in vitro evidence for co-expression between HOP and the proteins. HOP is shown as STIP1. B) Using the 
Gemma database, the genes found to have evidence of co-expression with HOP particularly in human 
breast, ovarian and prostate cancers were categorised according to functionality. Genes were categorised 
as DNA replication, transcription or translation related; cell signalling proteins; cytoskeletal proteins; 
chaperone or heat shock proteins; translocation proteins; or other proteins. Stringency was set to a 
minimum requirement of 3 datasets with supporting evidence. 
 
The analysis was then expanded to search for any genes (regardless of synteny) that had 
supporting in vitro evidence for their co-expression with HOP (Fig. 8A). A vast number 
of genes were identified within ovarian, prostate and breast cancer datasets and were 
grouped into categories related to function (Fig. 8B). HOP was found to be co-
expressed with 10 other heat shock proteins or co-chaperones within breast cancers 
(HSPC3/HSP90AB1, HSPD1/HSP60, HSPA8/HSC70, ASHA1, HSPH2/HSPA4, 
HSP90AB4P, HSPH1/HSP105, DNAJB6/Mrj, DNAJB1/HSP40). The profile of genes 
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co-expressed with HOP in ovarian and breast cancers was similar, with the majority of 
genes (32.1% and 34.2%) being involved with DNA replication, transcription or 
translation (Fig. 8B). In both cancer types, between 10-11% of the genes were 
chaperones or heat shock proteins, and a similar proportion was observed (9-12%) for 
genes involved in translocation and cell signalling. A small percentage of genes (4-5%) 
were also found to encode cytoskeletal proteins. A slightly different co-expression gene 
profile was observed for prostate cancer. 
 
The HSP90 Chaperone Machine Interactome Database (Hsp90Int) (Echeverría et al., 
2011) was used to obtain all of the known HOP protein-protein interaction data to date 
(Fig. 9A,B). This provided a visual representation of the network of proteins that are 
linked to the HOP protein (Fig. 9B) and thus generated a thorough view of the HOP 
interactome. As expected, molecular chaperones are the largest group of proteins that 
interact with HOP. However other groups of proteins included those involved in 
transcriptional regulation, DNA synthesis, protein synthesis, metabolism and kinases 
involved in signal transduction (Fig. 9A). These groups indicate proteins that are 
involved in the functioning of a variety of normal cellular processes. Furthermore, these 
proteins in turn have protein-protein interactions with a vast array of other proteins 
(Fig. 9B). No supporting data was found for the interaction of HOP with the syntenic 
genes. However the following proteins that were co-expressed with HOP in cancer 
were also found to interact with HOP: DNAJB1/HSP40, HSP90AA1, HSPA4, HSPA8, 
HSPH1, RRM1, NME2, PRPF4 (Johnson et al., 1998; Scheufler et al., 2000a; Ho et 
al., 2002; Wegele et al., 2003; Ewing et al., 2007; Tarassov et al., 2008; Mandal et al., 
2010).  
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Figure 9: The regulation of HOP expression influences more than a single gene. 
A) The visualisation of the individual proteins HOP has been found to directly interact with. The nodes 
represent proteins which are connected to HOP (shown as STIP1) via edges. The nodes are colour coded 
to protein function. The edges represent protein-protein interactions. B) The HOP protein-protein 
interaction network (HOP Interactome). The black node in the centre represents HOP (shown as STIP1). 
Coloured nodes represent the proteins that directly interact with HOP and are coloured coded as in (A) by 
protein function. White nodes represent all other proteins in the network. The size of the node 
corresponds to the degree of connectivity of that protein within the Interactome (the greater the degree 
the larger the node size). The edges connecting nodes for the protein-protein interactions between HOP 
and various proteins are in black, the edges connecting nodes for the protein-protein interactions between 
HSP90 (shown as HSP90AA1) and proteins within the HOP Interactome are in teal. All other edges are 
in grey and depict the protein-protein interactions between all other proteins. Data was gathered from the 
HSP90 Chaperone Machine Interactome Database (Echeverría et al., 2011) and visualised using 
Cytoscape 3.0 (Cline et al., 2007).  
 
3.2.6 - Sequence analysis and identification of promoter elements upstream of the 
HOP gene  
Despite growing evidence for a role for human HOP in cancer, relatively little is known 
about the mechanisms that control HOP expression. It is hence essential to look into the 
factors influencing the gene expression of HOP proteins. To do so, one would be 
required to locate and characterise the core promoter of the HOP gene in silico and in 
vitro. Once the promoter region has been identified, cis-elements could then be 
identified. This could be done by searching for motifs on the promoter sequence that 
correspond to various transcription factor binding sites (TFBS). The identification of 
these motifs is essential in understanding the gene expression regulation of the 
promoter. However, the region corresponding to the HOP promoter has not been 
demonstrated in vitro, there is no in vivo information to be found on the DNA sequence 
encoding the HOP promoter and there is a paucity of data on the factors that control 
HOP expression in cancer. Therefore, bioinformatic analysis of the putative HOP 
promoter was performed, in order to predict the regulatory DNA region responsible for 
controlling HOP expression, and allow for an initial investigation into the factors that 
alter the rate of the transcription of HOP in cancer cells. 
 
In order to determine any conserved regions upstream of the HOP gene, the sequences 
corresponding to the region of the HOP gene from -500 to +100 bp across four species 
were aligned and compared using T-Coffee (Notredame et al., 2000) (Fig.10). No 
specific regional conservation was observed between the human, mouse, yeast and 
zebrafish sequences. A further pairwise global alignment of this region by BioEdit 
(Hall, 1999) gave human-mouse identity as 67%, human-yeast as 43%, human-
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zebrafish as 40%, mouse-zebrafish as 44%, mouse-yeast as 43% and zebrafish-yeast as 
45%.  
 
The sequences were searched for specific elements that were known to signify the 
presence of a promoter (Liu et al., 2008; Anish et al., 2009). Putative TATA boxes 
were identified in murine (TATATATA) and yeast (TATAAAAG) sequences at 
positions -102 and -30 from the transcriptional start sites (TSS), respectively (Fig.10). 
Both of these sequences matched the TATA consensus sequence of 
TATA(T/A)A(A/T)(A/G), but neither matched the more stringent TATA consensus 
sequence of TATA(A/T)A(A/T). The human sequence had two and the murine 
sequence a single GC box (encoding both GGGCGG and stimulatory protein 1 (Sp1) 
sites) and 6 repeats of CCAAT sequences upstream of the TSS (Fig.10). Zebrafish had 
a single CCAAT sequence upstream of the TSS, yeast also had a single CCAAT 
sequence but it was located downstream of the TSS (Fig.10). Since half of the 
sequences did not contain a TATA box, the sequences were scanned for CpG islands. 
The region of -452 to -137 (316 bp) in the human sequence met the criteria of a CpG 
island, as did the region of -240 to -47 (194 bp) in mouse (Fig.10). The criteria were a 
frequency of observed CG dinucleotides / frequency of expected CG dinucleotides that 
was greater than 0.6, as well as a GC % greater than 50 and a length greater than 100 bp 
(Li & Dahiya, 2002). 
 47 
 
Hs   CGGCACTCGG-----GAGCGAGAGGGAAAGCA---A-CCCAGAGGCCCCG  -459 
Mm   --AGACTCAG-----GGA--AAACAGCTTGTA---A-CGCTGTAGTT--A  -465 
Sc   AA-TTTTCCC--CCCG---TCATAAGTTCCTATACACGGCTGGC------  -462 
Dr   GC--TCTCTTTACAGGTCCTGGAAAGTTTGTA---G-CGCTAAG------  -462 
 
Hs   CAGCCGCCGGCGACACAGCTACAGACCCCG-A-CTGCAGCCGGTACTCCC  -411 
Mm   AAG-CCTAGGCGACACCGGGCCAGATG------CTCGACT------CCCC  -428 
Sc   -----TCTGATGGCATAATTTCATGCTGGA-ACCTACAA-----ACCCGC  -423 
Dr   -----AATTCTTGCAAAGCTCTGGAACATTCAGCATTACT----TTTCTC  -421 
 
Hs   ATATATCAGGGGCGGGGCGAAACCCGG-CCTTTTGAAGGGCAGCGAT-TT  -363 
Mm   ACGAACCACCAGCCAGCCG-AGCACCC-C--CTTACAGGGCAGCGGC-AT  -383 
Sc   AAGAAA-ATAAAAAAT----TTCGCCAAATTTAACGAAGACAGCGTGGTT  -378 
Dr   AACAAC-TTTAGCTCTCG-TTTCACCA----ATAATA----AACGGC--T  -383 
 
Hs   AAACCAATCAGCGCAAAGAGTTGGCAA-------CC-C------------  -333 
Mm   AAACCAATCAGCGCCAGGAATGGCCAAATTTTTTTTTTTCCC---CACCC  -341 
Sc   AAAA--------------------TTGCTTGTTCGGACAATATTCTATGT  -348 
Dr   GATCCAATCAGTGACGAGAGCG--CTGCTTCTTCTGTTGACA---AATGT  -338 
 
Hs   -TCCGCCCAATTGGAATCG--CTCTCATTCTGAAGGC-GGTTCCGACATG  -287 
Mm   ATCCACCCAATT-GAAT----GTTTCCTCTGAAAGGC-GGTTCCGTCTAG  -297 
Sc   --CTGGCAACTTCTGATGATACTTTCAAGACAAACGCCGCAATTGACCAA  -300 
Dr   --AACGTAAC-ACTTTTCAGTCCTTCCACTCGTATGTCACTTTTAGCCGG  -291 
 
Hs   GAGTCCGGCAGCCCAATGGGAG--------AGGTGGAAATTTCCAGAA--  -247 
Mm   GAGTCCTTCAGCCCAATGAGAG--------TTGTGGAAATTTCCAGAA--  -257 
Sc   --ACTATTGAACTAAACGCAAG--------TT----CAATATACATAATA  -264 
Dr   --GTTGCCATGCGCAACGCATCGATTCAAAAT--TTCATTTTCTAGAA--  -247 
 
Hs   -----CGATCAGAACCAATGGGCGCGGCCAGCGCGGCTACGATTGGC--A  -204 
Mm   -----AGAACAGGACCAATGGGTGCGGCCAGGCCAGCTACAATTGAC--G  -214 
Sc   TTTGACTATGAGAACT----------GATATCTTCGTGAAGATTCGTGTA  -224 
Dr   -----TTTTCTGGAGA----------CTTTGATT----------C--ACA  -224 
 
Hs   GTGCAAAAGACCAATCCGTGTCGCAGAAGTTCG-CTCCTCC--CTCCATT  -157 
Mm   GACTAACCAACCAATCCGTGTCGTCAAGACCCG-CTCCTCC--CTCAGTT  -167 
Sc   GTATGATAGAACATTCCAGA-AAAAAAATTCAGATTCATCGCTCTCTCTT  -175 
Dr   GTTTGATTCATTATTAAAGA-TATTATA-TTG----TATTAGTGATTAAT  -180 
 
 
Hs   CGTGGAG-CCTGAGAT------------GGG-TGGGT-TTATAG--AGGA  -124 
Mm   AGCCTAGCCCTGAAAT------------AGG-CGGGACTTGCCG--CGGA  -132 
Sc   CGCTTCT-CCTCCTTTAAGGAATAAAGAAA-AAATCACATACATA---GA  -130 
Dr   TACTTA------GTTTAA-TTATAAACAGGGTAAGGACGTGTTTGTAAGA  -137 
 
Hs   GCGCCCAATCCTGAGGTGCG-----------GGGGA-GGCAGGGTTGAGG  -86 
Mm   GTGTCCAATCCGGAGGTGCA-----------GAGGA-GGCAGGGCTGAAG  -94 
Sc   TTAAGTAAATAGGATCTGCTAGAAAAATTATATATAGATCAATCATC---  -83 
Dr   ATGT-TAATCT------GTTTAAATTATTTCAGA-ACGTCAAACTTCA--  -97 
 
Hs   GAATTACTCCCCGCTGTCCA-ATGAGAAGGAAGTGGAGATGATGGGCTGG  -37 
Mm   AGAAGACCCGTAAAAAACCA-ATGAAAGAGAAGTCACGATGATTGACTGA  -45 
Sc   ----------TTATTAAGGT-ATCTTGTTTAAGCC----CAAAAGTCTGC  -48 
Dr   ------CTAGTCAAAAACTTTACTTTTCATGAGGT----AATAATTCAAC  -57 
 
Hs   ACCT--CAAGCC--AATAGT-AGAGCAGCACAGACATTCCCCctagaag-  +7 
Mm   ACTT--TAAGCC--TATAAAAGGGGCGAGCAGAGC----CTCCTGGACg-  +1 
Sc   TCCC--AAATTC--CTCACT-GTAGCTACTAAAACAACCTATACGCAAG-  -4 
Dr   AACTGGCAACCCATCTCTCT-G---CAACATTGATAATAGGCAGAGAGGC  -11 
 
Hs   --aactcgaccagtgagcaggcgaggaaggg--gcgggagccg--gggtc  +50 
Mm   --tgttcaaccagtgagcaggcgaggaaggg--gcggtaacctgggggtc  +39 
Sc   --AAAGatgtcattga-cagccgatgaatac--aa-acaaca-aggtaac  +39 
Dr   GGGGCTTCGCTagtgtcttgg---tagattctgga-acatca-tccccac  +34 
 
Hs   ccggtagcttctagta---ggttccagaaggcggcgc---gt-gcggt--  +91 
Mm   ccggcagcttctagta---ggttccagaaggcggcgc---gt-gcggt--  +80 
Sc   gctgcatttaccgctaaggattacgataaagcgata----ga-gctcttc  +85 
Dr   gctatggagaaagtaagtaacttgtattgaacagcttattttaaacattc  +84 
 
Hs   --------tgggaac----gc                               +100 
Mm   --------tgggaacgcggag                               +93 
Sc   actaaagctattgccaataa----gt                          +107 
Dr   tgaaaaatagttttc----gt                               +101 
 
T-Coffee alignment of human (Hs), murine (Ms), yeast (Sc) and zebrafish (Dr) upstream 
sequences of the HOP genes. Sequences aligned from -500 to +100 with respect to the 
transcriptional start site (TSS). The putative TATA boxes were coloured green, the GC 
boxes (GGGCGG) were coloured cyan and the CCAAT boxes were coloured red. The TSS 
was indicated by the transition of uppercase to lowercase lettering. Nucleotides that were 
conserved between at least three orthologues were coloured grey. DNA encoding CpG 
islands were identified by MethPrimer (Li and Dahiya, 2002) and were underlined. BioEdit 
(Hall, 1999) gives human-mouse identity as 67%, human-yeast as 43%, human-zebrafish as 
40%, mouse-zebrafish as 44%, mouse-yeast as 43% and zebrafish-yeast as 45%. 
 
Figure 10: Sequence alignment of HOP genomic DNA to identify a putative 
promoter. 
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3.2.7 - Analysis of Transcription Factor Binding Sites in the human HOP promoter 
The putative human HOP promoter sequence identified above, including 2000 bp upstream, 
was analysed to identify potential TFBS. Cister revealed that the region containing the 
highest density of cis-elements was found to be within 1500 bp upstream of the gene itself 
(data not shown). Cis-elements are known to be found upstream of the TSS of genes, or 
within the promoter itself. The increased density of cis-elements within the upstream region 
of the TSS suggested this region may have the potential for promoter activity. Additionally, 
the GC content of the majority of the upstream 1.5 kb region was above 50%. Hence, the 
analysis was focussed on this region that could potentially contain a promoter (Fig.11). Three 
prediction programs were utilised to investigate the -1500 to +100 bp region of the human 
HOP gene (Appendix A). Although minimal correlation was found across the predictions by 
TFSearch, PROMO and Alibaba, the high cut off thresholds used in the prediction aimed to 
reduce the number of false positives identified. A total of 480 putative TFBS were identified. 
Stimulatory protein 1 (Sp1) had the highest prediction rate, predicted to have 73 motifs; while 
CCAAT enhancer binding proteins (C/EBP) was the second most frequent motif at 55 
predicted sites (Fig.11).  
 
Figure 11 also shows the density of the putative cis-elements across the region, many of 
which were found in clusters. The greatest density of cis-elements was observed within the 
first 500 bp of the putative promoter. Core promoter elements such as CEBPα/β, NF-Y and 
TFIID were found in highest abundance within the first 600 bp of the putative HOP promoter 
(Fig.11). The mapped STAT4, AP-2, p53 and Pax-5 elements were found to be spread 
throughout the putative promoter. NFKB and Egr-1 were found to be restricted to the first 
900 bp upstream from the TSS. Four probable HSEs for HSF1 and HSF2 were identified. 
Each HSF1 element was overlapped by an HSF2 element (Fig.11). Additionally, Figure 11 
highlights the cis-elements for various TFs that are activated by oncogenic pathways found 
within the putative HOP promoter. Of note were the single sites were observed for c-Myc, c-
Fos and c-Jun, and the five sites observed for ETS-1, which may provide a link to the 
increased expression of HOP in cancers. 
 49 
 
 
Figure 11: Putative transcription factor binding sites within the HOP promoter.  
The line graph illustrates the density of the putative transcription factor binding sites within 50 bp segments of the putative HOP promoter sequence.
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The distribution of selected putative transcription factor binding sites of interest was shown as boxes correlating 
to their position along the promoter (drawing is not to scale). Numbers indicate position relative to the 
transcription start site (+1). CCAAT/enhancer-binding proteins (C/EBP) shown in green, stimulatory protein 1 
(Sp1) shown in blue, activator protein 2 (AP2) shown in orange, heat shock transcription factor 1 and 2 
(HSF1/2) shown in red, signal transducer and activator of transcription 4 (STAT4) shown in yellow, nuclear 
factor kappa B (NFKB) shown in lilac, general transcription factor (TFII-I/D) shown in pink, early growth 
response 1 (Egr-1) shown in dark green, nuclear factor I or CCAAT-binding transcription factor (NF-1/Y) 
shown in maroon, p53 tumour suppressor protein (p53) and the paired box transcription factor 5 (PAX-5) shown 
in navy blue, Activator protein 1 (Ap1) shown in brown, octamer binding transcription factor (Oct-1) shown in 
lilac, member of the ETS oncogene family (Elk-1) and ETS domain transcription factor (c-Ets-1) shown in lime 
green, the c-Myc shown in purple, c-Fos and c-Jun shown in magenta. The CpG islands with GC content > 50% 
shown. Transcription factor binding sites identified by Alibaba, TFSearch and PROMO prediction tools. Note: 
Results for the CpG island prediction differs from that in Fig. 9 due to the size difference of the sequences 
analysed. 
 
3.3 Discussion 
3.3.1 - HOP is conserved across taxa and is syntenic across H.sapiens, M.musculus and 
X.tropicalis 
The topology of a branch in a phylogenetic tree is considered correct if the bootstrap value is 
above 95%, and those nodes with less than 70% are not considered reliable (Hall, 2013). 
With this in mind, some of the branches within the tree generated in this study were true 
reflections of historical relationships while others were not. Furthermore, although the 
leftmost node within the phylogenetic tree could be presumed the common ancestor, this is 
incorrect as the tree is unrooted (Hall, 2013). The common ancestor of the HOP gene is 
unknown. However, we could determine the extent to which the homologues have changed 
by using the branch lengths. All branch lengths were very low implying that overall, from 
fungi through to humans, the HOP protein sequence has undergone minimal evolution (Hall, 
2013). It must be noted though that Saccharomyces cerevisiae was separated from Homo 
sapiens at the first branching of the tree suggesting the least protein conservation between the 
two species.  
 
Synteny is not usually found between genes that are not orthologues (Jun et al., 2009). A 
defined region of a chromosome is considered to be syntenic to a chromosome of another 
species when at least 2 genes are homologous. Homology does not require that the genes be 
in the same orientation, on the same strand or co-linear (Nadeau, 1989; Jun et al., 2009). This 
allows us to make the conclusion that the regions of the chromosome containing the HOP 
gene in H.sapiens, M.musculus and X.tropicalis are syntenic and that the organisms may 
share a common ancestor. The gradual loss of synteny observed between the remaining 
orthologues could be explained by deletions, rearrangements and insertions that have 
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occurred over time with evolution (Jun et al., 2009), explaining the complete lack of synteny 
observed for the yeast, nematode and fruit fly orthologues. Additionally, synteny between the 
ortholgoues decreased as the branching between the orthologues on the phylogenetic tree 
increased. This further illustrated the evolutionary progress from the unicellular organisms to 
the mammals. The prokaryote gene order has been found to be more variable than that of 
eukaryotes (Jun et al., 2009). For example, the gene order surrounding HSP90 in prokaryotes 
is different to that in eukaryotes, and the HSP90 gene in prokaryotes is different to that of 
eukaryotes. Prokaryotic HSP90 does not require co-chaperones for function whereas in 
eukaryotes HSP90 co-chaperones are essential (Li et al., 2012). The consequence for this 
study was that prokaryotes do not contain HOP. 
 
Synteny across numerous species can identify functional relationships between the syntenic 
genes (Michalak, 2008). The similar expression patterns observed between the syntenic genes 
in human cancers further supported this likelihood. This suggested the possibility of a 
functional relationship between HOP, NUDT22, FERMT3, DNAJC4, TRPT1, FLRT1, 
VEGFB and FKBP2. This also suggested that cis-elements in these gene loci may be shared 
by the syntenic genes, allowing for the possibility of co-regulation or co-expression. 
Furthermore, many of the syntenic genes were cancer related, hence it being of interest that 
they were in such close proximity. The first syntenic gene of interest was the DnaJ (HSP40) 
homologue, subfamily C, member 4 (DNAJC4). DNAJC4 (HSPF2/MCG18) is a molecular 
chaperone that interacts with HSP70, which is a partner protein of HOP (Sugito et al., 1995; 
Calderwood, 2013). DNAJC4 is a type III HSP40, containing the J-domain, which is a 70 
amino acid signature region that stimulates the ATPase activity of HSP70 and provides an 
interaction platform for HSP70 (Kampinga & Craig, 2010). The only other domain structure 
that DNAJC4 has is a transmembrane domain. As yet both the function and localisation of 
DNAJC4 within the cell is unknown (Kampinga & Craig, 2010). The second gene of interest 
was FK506-binding immunophilin 2 (FKBP2), as it too is a chaperone protein (Scammell et 
al., 2003). It acts as a co-chaperone containing a TPR domain and plays a role in 
immunoregulation. It is able to bind HSP90 and is known to interact with dynein, suggesting 
that it may increase nuclear transport within the cell (Riggs et al., 2007). Furthermore, 
FKBP2 has been found to play a role in breast and prostate cancers (Calderwood, 2013). The 
third gene of interest was the vascular endothelial growth factor B (VEGFB) for it is involved 
in regulating the growth of endothelial cells, but has been found to play an important role in 
inducing tumour angiogenesis and is expressed in various cancers (Cheung et al., 1998; 
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Ruohola et al., 1999; Shintani et al., 2004). VEGFB has been identified in stimulating the 
formation of blood vessels within tumours (Shintani et al., 2004).  
 
Despite the synteny observed across H.sapiens, M.musculus and X.tropicalis, each species 
contained a different promoter. A reason for the lack of conservation observed, especially 
between the murine and human promoters, may be due to the fact that CpG-rich promoters 
are significantly less conserved than CpG-poor promoters (Wang & Hannenhalli, 2006). 
Furthermore, the presence of a TATA box in the murine system suggests the murine HOP 
may be more so a context- or tissue-specific gene, while human HOP, in part due to the large 
CpG island, is less so (Sandelin et al., 2007). However, the conservation observed between 
the human and murine promoters was much greater than between human and frog or yeast. 
Additionally, the conservation of the GC and CCAAT boxes within the human and murine 
promoters suggest that although the promoters are different between the two species, they 
may be controlled by similar signalling networks. Thus if human xenografts are utilised in 
murine systems, one may overcome the problems of differing promoters between the species. 
 
3.3.2 - There are potentially multiple isoforms of HOP in eukaryotes 
In the extracellular environment of cells, HOP functions like a cytokine rather than a co-
chaperone and is known to activate a variety of signalling pathways (Caetano et al. 2008; 
Arantes et al. 2009; Beraldo et al. 2013; Wang et al. 2010; Tsai et al. 2012). More 
specifically, HOP has also been identified to act as the receptor to the Prion protein (PrPc). It 
acts independently of the HSP90 and HSP70 chaperones, and instead interacts directly with 
the PrPc. This interaction between extracellular HOP and the PrPc has a series of 
consequences on cell growth, survival and differentiation; mediating these effects by the 
activation of downstream signalling pathways (Lima et al. 2007; Zanata et al. 2002; Arantes 
et al. 2009). Little is known about how intracellular HOP is exported from the cell, although 
it is currently assumed that extracellular HOP is derived from the intracellular isoform. These 
two drastically different functions of HOP do not seem consistent with a single isoform. Our 
analysis predicts the presence of possible alternative transcripts of HOP leading to distinct 
protein isoforms. Therefore, it may be possible that there is in fact more than one isoform of 
HOP being produced by the cell, and that the intracellular and the extracellular versions of 
HOP are distinct. To date there is no experimental data beyond presence of the transcripts to 
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prove such a theory, yet it is unknown how the single isoform could adapt to such differing 
processes.  
 
The presence of alternative HOP isoforms was also supported by comparing the exon and 
protein organisation of the HOP orthologues. It was observed that the distribution of the 
exons had no regularity. However, the distribution of the TPR domains across numerous 
exons in the human suggested that it could be possible for the alternate splicing of the HOP 
mRNA transcripts to give rise to the different HOP isoforms within human and murine 
species. Upon searching for possible splice variants, several had been predicted in the 
available databases, although most of these predicted isoforms retained the same order of 
exons. STIP1-010 was the most similar to the known HOP (STIP-001) except it contained an 
additional N terminal extension. A possible reason for such similarity may be due to the use 
of an alternative promoter (alternative transcription initiation) or intron retention (Srebrow & 
Kornblihtt, 2006). The consequence of the exclusion of exon 2 within STIP-003, which is 
predicted  to result in a missing third TPR motif within the TPR1 domain, may affect the 
binding specificity of the protein for HSP70 (Onuoha et al., 2008). The truncated transcripts 
STIP1-008 and STIP1-012 suggest a vast exon deletion in each but resulting in a maintained 
binding specificity for HSP70 while forfeiting binding specificity for HSP90 (Onuoha et al., 
2008). These splice variants are reminiscent of the HOP orthologue within C.elegans. 
Nematodes contain merely two TPR domains and 1 DP domain within the HOP gene, yet the 
gene still encodes a functional HOP protein. More specifically it lacks TPR1 domain and the 
linker region that connects it to TPR2A. Despite the missing regions, the HOP within 
C.elegans is still able to interact with HSP70 and HSP90 although only the interaction with 
HSP90 is strong. The consequence of this is that in C.elegans HOP cannot bind HSP70 and 
HSP90 simultaneously as HSP90 requires both interaction sites on the remaining TPR 
domains to regulate ATPase activity (Gaiser et al., 2009). 
 
These transcripts suggest that there may be isoforms of HOP with differing enzymatic 
activity or differing substrate specificity to the known HOP protein. These isoforms could 
have the ability to interact with a differing set of substrates and proteins entirely (Möröy & 
Heyd, 2007). These isoforms could also have differing subcellular localisation or be tissue 
specific. This raises a question of whether a particular HOP isoform could be partially or 
indirectly responsible for malignant transformations (Venables, 2004; Möröy & Heyd, 2007). 
A single point mutation in the genomic DNA is all that is required to alter the proteins 
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influencing the splicing mechanism of a gene, this being a probable possibility within cancer 
cells (Krawczak, Reiss & Cooper 1992; Cartegni, Chew & Krainer 2002; Faustino & Cooper 
2003). Cells have been known to be transformed by the accumulation of the overexpression 
of the alternately spliced protein isoforms such as Ron or Rac1 (Srebrow & Kornblihtt, 
2006), suggesting the possibility of the build-up of HOP isoforms having the potential to do 
the same. However, the high sequence similarity may make it difficult to identify the 
different transcripts using microarray or qPCR approaches.  
 
The most direct interaction the genome has with its environment is through TFs (Thorne et 
al., 2009). Thus an additional possibility is that distinct isoforms could be expressed in 
differing cell types or tumour cells due to the specific nature of the transcription machinery in 
those cells. Various TFs have been found to be overexpressed in cancer cells (for example: c-
myc, STATs, ETS, E2F) and the disruption of the equilibrium of TFs in malignant cells 
influences the regulation of a gene’s promoter (Ponzielli et al., 2005; Seth & Watson, 2005; 
Tsantoulis & Gorgoulis, 2005; Thorne et al., 2009; Santos & Costa-Pereira, 2011). Thus the 
identification of the splice variants of HOP also suggests the possibility of HOP isoforms 
with differing subcellular localisations. It would be of great interest to take this idea further 
and attempt to identify the presence of these splice variants at a protein level. 
 
3.3.4 - The HOP gene has large interaction and co-expression networks 
The Gemma gene expression database allowed for the identification of in vitro evidence of 
human HOP being co-expressed with two syntenic genes, MACRO domain containing 1 
(MACROD1 or LRP16) and TRPT1. The TRPT1 protein is responsible for catalysing tRNA 
splicing, while MACROD1 acts as a transcriptional co-activator for the estrogen α- and 
androgen receptors (ERα and AR) (Spinelli et al., 1998; Hopper et al., 2010; Han et al., 
2011). Interestingly, ERα and AR are both HSP90 client proteins (Nemoto et al., 1992; 
Bouhouche-Chatelier et al., 2001; Lee et al., 2002). In a proteomic study on the effect of 
knockdown HOP in transformed cells, when looking specifically at the HOP syntenic genes 
we observed that TRPT1 protein levels were unchanged, while MACROD1 and FKBP2 were 
both up-regulated though not significantly (personal communication). This was interesting as 
the co-expression data would suggest that both MACROD1 and TRPT1 (and possibly the 
other syntenic genes) would be deregulated upon the knockout of HOP. Additionally it has 
been shown that MACROD1 is overexpressed in human cancers, with specifically high levels 
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in endometrial carcinoma, gastric carcinoma, colorectal carcinoma and breast carcinoma 
(Liao et al., 2006; Meng et al., 2007; Li et al., 2009; Xi et al., 2010; Zhao et al., 2010).  
 
The co-expression profile of human HOP specifically within breast, ovarian and prostate 
cancers identified numerous co-expression networks of functionally related genes that had 
included the human HOP gene. These cancer subtypes were chosen because HOP has been 
found to be up-regulated in each of them (Wang et al., 2010; Tan et al., 2011; Willmer, 
2011). To further substantiate this, it would be of interest to look at the promoter profiles of 
the co-expressed genes to determine if they have identical over-expressed transcription 
factors that regulate them; thereby determining whether those co-expressed genes may also 
be co-regulated. For example, 47 gene promoters were found to share the same promoter 
profile as the ionotropic AMPA glutamate receptor (GRIA) and of them 16 were also found 
to be co-expressed with GRIA (Chong et al., 2007). Of further interest was that HOP was 
found to be co-expressed with DNAJB1/HSP40, HSPH2/HSPA4, HSPH1/HSP105, 
HSP90AA1, HSPA8, RRM1, NME2 and PRPF4; and HOP was also found to interact with 
these proteins (Echeverría et al., 2011).  
 
The generation of the HOP Interactome illustrated the magnitude of proteins that may be 
influenced by the up-regulation of the HOP gene in malignant cells. This is not saying that 
these proteins are dependent on HOP directly for stability. However HSP90 is considered a 
critical facilitator of cancer cell survival and oncogene addiction because it protects mutated 
and/or overexpressed proteins from degradation or misfolding (Bagatell & Whitesell, 2004; 
Sangster et al., 2004; Mizrak et al., 2006; Trepel et al., 2010). Thus the over expression of 
HOP in cancers, coupled with the over expression of HSP90 in cancers, would allow for the 
stabilization of tumorogenic cells via the protection of many of the proteins within the HOP 
Interactome. This provides further evidence of the importance of HOP in cancer and the 
suitability of HOP as a novel drug target. Additionally, in order to accurately determine the 
effect of overexpressed HOP in malignant cells, we need to elucidate the molecular networks 
involving HOP in the cell. By doing so one could begin to identify the protein-protein 
interactions that may be affected to some degree by HOP inhibition. A practical example of 
the importance of such knowledge was shown by Fierro-Monti and colleagues (2013). Fierro-
Monti et al. (2013) quantified the changes in the HSP90 dependent proteome upon HSP90 
inhibition by geldanamycin. Through this proteomic study they identified a large cohort of 
previously unknown and unexpected side effects of HSP90 inhibition. They identified a 
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consequent down-regulation of the protein synthesis machinery as well as a remodelling of 
the HSP90 chaperone machine; both having potentially far-reaching consequences. 
Furthermore, they identified an enrichment of several oncoproteins and a parallel depletion of 
several tumour suppressors which were previously unidentified. This was concluded to be a 
pro-survival response which then suggested that there are unwanted implications for the use 
of geldanamycin derivatives in anti-cancer therapy (Fierro-Monti et al., 2013). This works to 
show the importance of having a thorough understanding of the effect of the inhibition of a 
protein on the proteome. By proposing HOP as a potential drug target, we suggest a 
concurrent need to define the proteomic effect of inhibiting HOP. 
 
3.3.5 - The HOP gene is regulated by a TATA-less promoter 
For transcription to commence RNA polymerase II is required to bind in the correct 
orientation to core DNA elements found within a 100 bp region of the core promoter. These 
generally are the TATA-box or initiator element, CCAAT box and the GC-Box (Bucher, 
1990; Lee & Young, 2000; Pandey & Krishnamachari, 2006). Likewise, in eukaryotes 
synthesis only occurs with the supplementation of certain general TFs (GTFs) (Pedersen et 
al., 1999). The CCAAT box is one of the most common elements within promoters and is 
known to play an important, if not essential, role in promoter activity and the binding of 
CBF/NF-Y to CCAAT elements is required to recruit TFIID to the promoter (Ronchi et al., 
1995; Frontini et al., 2002). Additionally approximately 50% of human and murine 
promoters are known to be associated with CpG islands, thus using the presence of CpG 
islands is now a common tool to identify vertebrate promoters (Li & Dahiya, 2002). A mere 
10-20% of mammalian promoters have been found to contain a functional TATA box, 
suggesting that TATA-driven gene expression is the exception rather than the rule for 
eukaryote promoters (Shi & Zhou, 2006; Sandelin et al., 2007). TATA boxes, instead, have 
been found to be restricted to sharp strong tissue-specific promoters and evolve slower than 
TATA-less promoters (Sandelin et al., 2007). TATA-less promoters are most often found to 
be broad promoters characterised by a lack of TATA boxes, but with numerous Sp1 motifs, 
CCAAT boxes and CpG islands across the promoter region (Bjornsdottir & Myers, 2008). 
Additionally, broad promoters are known to contain multiple TSSs and are linked to 
epigenetic transcriptional control (Carninci et al., 2006). The lack of a TATA box in the 
human HOP sequence, as well as the presence of multiple CCAAT cis-elements, a GC box 
and a CpG island, suggested it may be a TATA-less promoter. On the other hand mouse and 
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zebrafish may each be regulated by a TATA containing promoter. Upon further analysis of 
the -1500 to +100 bp region of human HOP, the presence and high abundance of Sp1 motifs 
within the region further supported the hypothesis that human HOP may be regulated by a 
TATA-less broad promoter (Carninci et al., 2006).  
 
The region of -450 to -100 bp of the human HOP was thus identified as the putative core 
promoter, while the region of -300 to -100 bp of the murine transcript was identified as the 
putative core promoter of murine HOP. However, further analysis of the presence of cis-
elements required for basal activity was necessary to confidently assign the core promoter 
regions. The lack of specific regional sequence conservation observed upstream of the HOP 
gene across the human, mouse, yeast and zebra fish demonstrated that although the upstream 
sequences could share a functional correlation across species, they did not share sequence 
identity. The core promoter initiates basal transcription at a low rate therefore additional 
regulatory elements to the general TFs are required to sustain and regulate the rate of 
transcription in eukaryotic cells (Pedersen et al., 1999; Lee & Young, 2000; Wray et al., 
2003). NF-Y, TFIID, AP2 and ETS are cis-elements commonly found within promoters 
(Frith et al., 2001); elements which were also found upstream of the TSS of human HOP. 
These TFs activate transcription by recruiting basal transcription machinery to the core 
promoter through protein-protein interactions either directly or via adaptor proteins 
(Matthews, 1992; Stargell & Struhl, 1996; Ptashne & Gann, 1997; Pedersen et al., 1999). Due 
to their presence within the upstream region of HOP, the region of the putative core promoter 
could be extended to the first 900 bp upstream of the TSS. However, this would need to be 
confirmed in vitro. 
 
The clusters of TFBS indicated overlapping sites and possible competitive binding pairs 
between proteins. Additionally, it suggested that the elements may not all be active at once, 
but the functioning of the TFBS would be dependent on the physiological context of the cell 
at the time (Wray et al., 2003). The clusters may also provide a means for the transcription 
factors to interact and work in conjunction with each other due to their close proximity, 
thereby forming composite elements allowing for further regulation of the promoter (Wray et 
al., 2003; Chong et al., 2007). The large number of cis-elements predicted was due to the 
prediction programs compromising specificity for sensitivity, thus many of the results 
observed would be false positives. However for the sake of this analysis that shortcoming 
could be over looked, for to identify a potential promoter region one needs to identify the 
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region upstream of the coding region of the gene of interest that contains over-represented 
cis-elements in comparison to the levels observed within the coding region itself.  
 
The HSEs identified in the HOP promoter were of interest because HSF-1 is involved in 
regulating HSP gene expression. The presence of HSF-1 binding sites within the HOP 
promoter had already been proposed by Ruckova et al. (2012), and the binding of HSF-1 to 
the suggested HOP promoter region determined by chromatin immunoprecipitation. It was 
also shown that the protein levels of HSF-1 bound to the putative HOP promoter region 
increased in cancer cell lines upon the addition of the HSP90 inhibitor 17AAG (Ruckova et 
al., 2012). The in vitro evidence from Ruckova et al. (2012) supports, firstly, that the region 
analysed in this study was in fact the HOP promoter; secondly, that the in silico HSF-1 sites 
were functional sites instead of false positives, and thirdly that the HOP promoter is a 
transcriptional target of HSF-1. 
 
3.3.6 - Conclusion 
Our phylogenetic analysis of HOP suggested that the gene is ancient and conserved 
throughout eukaryotes. This was anticipated and would suggest a conserved function.  
However, although the homologues are conserved, there is evidence to suggest that the 
structure and possibly the function of HOP in each species differs. For example, HOP is an 
essential gene in the mouse (Beraldo et al. 2013), but not in yeast (Chang et al. 1997). This 
raises the question of whether the traditional animal systems can be used as a model organism 
(such as yeast) when studying the function of HOP within humans. This is of vital importance 
when analysing HOP as a drug target in humans. This study provided a thorough analysis of 
the HOP gene across known orthologues so as to determine the differences between them. 
Murine HOP was found to be most similar to humans while our study suggests that yeast 
would not be the best model to use when studying the function of HOP within humans. An in 
depth analysis of the co-expression profile of human HOP in cancers was performed. This 
identified co-expression profiles for HOP that differed amongst differing cancers. 
Additionally, this study identified a putative promoter for HOP with a core promoter region 
of the first 900bp upstream of the TSS and with a proximal promoter region continuing up to 
at least 1 500bp upstream of the TSS. This putative promoter region became the focus of the 
subsequent analysis into the regulation of HOP expression.   
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Chapter 4 
 
Characterisation of the HOP promoter: the regulation of HOP expression 
by RAS 
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4.1 Introduction 
4.1.1 - RAS signalling in Cancer Cells 
RAS genes encode for small monomeric guanine triphosphate (GTP) bound proteins that act 
as molecular switches, liaising between extracellular signals and intracellular signalling 
cascades (Guerrero et al., 2000; Calvisi et al., 2011; Borrego-Diaz et al., 2012). Upon RAS 
activation, several downstream effector pathways are stimulated, such as the extracellular 
signal-related kinase pathway (ERK pathway), Jun amino-terminal kinase pathway (JNK 
pathway), p38-kinase pathway, phosphatidylinositol 3-kinase pathway (P13K pathway) and 
the RAS like (RAL) pathway (Borrego-Diaz et al., 2012). These pathways in turn, by up-
regulating downstream targets, are involved in the control of various cellular processes 
including cell cycle progression, apoptosis, cell migration, growth, senescence and 
cytoskeletal changes (Fernández-Medarde & Santos, 2011; Ho et al., 2012). The balance 
between the crosstalk within this signalling network is essential for determining the outcome 
of the cellular responses within the cell (Fernández-Medarde & Santos, 2011). 
 
RAS is found within close proximity to plasma membranes as it has fatty acid moieties itself 
(Borrego-Diaz et al., 2012). It is characterised by two conformations (Fig.12), an inactive 
guanine nucleotide diphosphate (GDP)-bound and an active guanine nucleotide triphosphate 
(GTP)-bound state, that are controlled by guanine nucleotide exchange factors (GEFs) and 
RAS GTPase activating proteins (GAPs), respectively (Iwashita & Song, 2008; Calvisi et al., 
2011). It has been identified that approximately 33% of all human tumours express an 
oncogenic form of RAS, which through a desensitisation of GAPs, locks the protein into the 
active conformation (Calvisi et al., 2011; Fernández-Medarde & Santos, 2011). These 
proteins become oncogenic through point mutations within the highly conserved sequence 
between amino acids 1-165 on codons 12 and 61 (Omerovic et al., 2008; Fernández-Medarde 
& Santos, 2011). The three most common RAS isoforms are the HRAS, KRAS and NRAS 
genes, whereby the mutations render them in a permanently active conformation due to being 
insensitive to the RAS GAPs (Barbacid, 2008). These oncogenes were the first oncogenes to 
be discovered within human tumours and became the founding members of the RAS gene 
family (Fernández-Medarde & Santos, 2011). RAS amplification has not been linked to 
cancer development, rather it is oncogenic RAS mutations that have been found to almost 
exclusively link RAS genes to human tumour development (Fernández-Medarde & Santos, 
2011).  
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Figure 12: Regulation of RAS activation.  
Schematic diagram illustrating the RAS activation cycle. RAS is in an activated conformation when in a guanine 
nucleotide triphosphate (GTP)-bound state, which is initiated by the exchange of guanine nucleotide 
diphosphate (GDP) for GTP regulated by guanine nucleotide exchange factors (GEFs). RAS is in an inactivated 
conformation when in a GDP-bound state, which is initiated by the exchange of GTP for GDP by RAS GTPase 
activating proteins (GAPs). 
 
Various possibilities have been considered in an attempt to inhibit RAS signalling. One of the 
first strategies was to target the posttranslational modification responsible for the association 
of RAS with the plasma membrane (Casey et al., 1989; Pompliano et al., 1992). 
Farnesyltransferase (FTase) is the enzyme that catalyses the transfer of a farnesyl group from 
farnesyl diphosphate to the thiol of a C-terminal cysteine residue of RAS, thereby forming a 
thioester bond and displacing a pyrophosphate (Pompliano et al., 1992). The loss of this 
posttranslational modification prevents the consequent in vivo activity of RAS. Numerous 
small molecules were screened and developed as potential FTase inhibitors (FTIs). However 
most did not pass clinical trials, as it was identified that when FTase is inhibited, RAS can 
serve as a substrate for geranylgeranyltransferase type I (GGTase-I). The addition of a 
geranylgeranyl isoprenoid group acts as an effective substitute for the farnesyl group thereby 
allowing membrane association (Cox et al., 1992). Moving away from direct RAS inhibition, 
inhibitors of the downstream RAF-MEK-ERK mitogen-activated protein kinase (MAPK) 
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cascade were in turn considered as an indirect method of RAS inhibition. This has become an 
attractive target due to the non-overlapping occurrence of mutations within BRAF and RAS 
in cancers, suggesting equivalent roles for both mutagenic proteins in RAS-mediated 
oncogenesis (Dhomen & Marais, 2007).  
 
A possible link between HOP and RAS was first proposed when an increase in HOP mRNA 
and protein expression was detected upon transformation of Rat1 fibroblast cells with the 
oncogene RAS (unpublished data; van der Spuy, 2000). Our in silico co-expression analysis 
revealed that Rho is co-expressed with HOP in human cancers. Rho proteins are a family of 
GTPases that are associated with the RAS signalling pathway. There are three isoforms, 
namely RhoA, RhoB and RhoC, that have differing but connected functions in cell migration 
(Karnoub et al., 2004). In particular, the expression of RhoC has been found to increase 
metastasis in cancer cells and the expression of RhoC was found to increase as tumours 
become more metastatic (Ridley, 2004; Wheeler & Ridley, 2004; Wu et al., 2004). Previous 
research from our group showed that the knock-down of HOP in cancer cells caused a 
reduction in the expression of RhoC (Willmer et al., 2013). The previous chapter revealed 
cis-elements within the putative HOP promoter region that were activated by oncogenic 
pathways (c-Myc, c-Fos, c-Jun, ETS-1). Hence this data that linked HOP to RAS, together 
with the previous findings from our research unit, led to the investigation of the effect of the 
RAS signalling pathway on the regulation and production of HOP. This chapter presents an 
in vitro study of the HOP promoter as well as an analysis of the mechanisms involved in the 
up-regulation of HOP in cancer cells with a focus on RAS as a mechanism of HOP 
regulation.  
 
4.2 Results 
4.2.1 - The upstream region of the human HOP gene encodes a functional promoter in 
vitro 
To confirm that the putative HOP promoter identified in Chapter 3 was functional in vitro, a 
luciferase reporter construct containing the -1520 to +16 bp region of the human HOP gene 
(numbering relative to the TSS) was produced (pHOP-x) (Fig.13). This enabled an analysis 
of whether the region upstream of the HOP gene had promoter activity.  
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The pSAW plasmid was synthesised by GenScript, which was a pUC57 vector containing the 
1.5 kb sequence upstream of the TSS of the HOP gene (HOP-x) (Fig.13A). pSAW was 
digested with BglII and NheI restriction enzymes (RE) to release HOP-x. pGL4 (the 
promoterless vector) was digested with the same RE. HOP-x and pGL4 were gel purified and 
quantified by the Nanodrop 2000. The HOP-x insert was subsequently ligated into pGL4 
cloning vector (Fig. 13B,C). The ligation product was transformed into competent JM109 
E.coli cells and the plasmids were extracted from 8 successful transformants (identified by 
ampicillin screening). To confirm the identity of the plasmids, the plasmids were digested 
with restriction enzymes and the band patterns observed were analysed (Fig. 13D). Endotoxin 
free plasmid extractions were performed for each plasmid required for the luciferase assays 
(pGL4 and pHOP-x, as well the transfection control plasmid pLV-eGFP). The plasmid 
identities were again confirmed by restriction enzyme digestion and DNA sequencing. 
 
The promoterless pGL4 vector was digested with BglII and two bands were observed; the 
first being at 6500 bp and the second at 5599 bp (Fig.13D). The size of the plasmid was 5599 
bp and hence the larger band observed was considered to be due to partial digestion of the 
DNA. The pSAW plasmid, containing the synthesised putative HOP promoter sequence, was 
digested with BglII and NheI resulting in two bands observed at 2892 and 1541 bp (Fig.13D). 
The sizes correlate to the size of the HOP-x insert and the backbone of the pUC57 plasmid. 
Lastly, pHOP-x (containing the putative HOP promoter sequence upstream of the luciferase 
coding sequence) was digested with BglII and NheI where four bands were observed 
(Fig.13D). The first two bands of approximately 7000 and 6000 bp were considered to be due 
to partial digestion, while the remaining two bands observed at approximately 5605 and 1541 
bp were identified as the HOP-x promoter insert and the pGL4 backbone. The plasmid was 
confirmed by sequencing and subsequently used in reporter assays to assess the ability to 
drive expression of the luciferase protein. 
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Figure 13: Generation of a Luciferase Reporter Construct for the HOP promoter.  
A) Plasmid map of pSAW synthesised by GenScript. pSAW contained the 1.5 kb region upstream of the HOP 
gene, labelled as HOP-x. B) Plasmid map of pGL4.17, the empty luciferase reporter plasmid. C) HOP-x was 
cloned out of pSAW and into the pGL4 vector to produce pHOP-x, the reporter construct containing the putative 
HOP promoter. D) Restriction digestion confirmed the plasmids required for the luciferase assay. Lane 1 
contained the contained pGL4 digested with BglII to lineraise the plasmid, lane 2 contained pSAW digested 
with BglII and NheI thereby releasing HOP-x from the backbone, lane 3 contained pHOP-x digested with BglII 
and NheI thereby releasing HOP-x from the construct. Numbering on the left hand side represent the positions 
of the molecular weight marker used. Bands were resolved by 1% (w/v) agarose gel electrophoresis in TAE run 
at 90 V for 90 minutes and visualised by ethidium bromide staining under UV light. Plasmid maps constructed 
using BioEdit (Hall, 1999). 
 
The luciferase assays were performed 48 hours after transfection of the reporter plasmid 
(pGL4 or pHOP-x) and transfection efficiency reference plasmid (pLV-eGFP) into three cell 
lines; a transformed mouse embryonic fibroblast cell line (MEF-1), a human cervical cancer 
cell line (HeLa) and a human breast cancer cell line (Hs578T) (Fig. 14). The firefly luciferase 
activity was normalised against the GFP fluorescence produced by the reference plasmid, 
then further normalised against the control plasmid pGL4 to determine the relative promoter 
activity. The reporter plasmid in the murine cells produced minimal promoter activity. The 
reporter plasmid showed between 5 and 8 fold higher promoter activity in the cancer cell 
lines. The Hs578T cell line produced promoter activity 0.5 times greater than that observed 
within the HeLa cell line (Fig.14). These data confirmed that the HOP gene sequence (from -
1520 to +16) contained a functional promoter.  
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Figure 14: The upstream region of the HOP gene encodes a functional promoter.  
The 1.5kb upstream region of the human HOP gene was analysed for promoter activity using a luciferase 
reporter construct (pHOP-x). The promoter activity was compared across two cancer cell lines and a murine 
transformed line; a human cervical cancer cell line (HeLa) and a human breast cancer cell line (Hs578T), and a 
SV40 transformed mouse embryonic fibroblast (MEF-1) cell line. Luminescence was measured in relative light 
units (RLU). The luciferase activity was determined by normalising the firefly luciferase activity against the 
fluorescence produced by the control reporter plasmid (pLV-eGFP). The results from the HOP promoter 
analysis were normalised against the results of the empty vector (pGL4). The results are represented as the mean 
values of three independent biological replicates with three technical replicates for each. The bars represent the 
standard error. One way ANOVA and Tukey’s Multiple Comparison Tests were performed to determine 
statistical significance (*P < 0.01, **P<0.001). 
 
4.2.2 – Consequences of the RAS signalling cascade on HOP expression 
Gemma, as well as the prediction tool CoExSearch (Obayashi et al., 2008), found Rho to be 
co-expressed with HOP. Gemma found Rho to be co-expressed in both ovarian and breast 
cancers, but not in prostate cancer. Thus a link to the RAS signalling pathway had been 
predicted from the in silico study of the HOP promoter and the co-expression analysis. In 
order to investigate the effect of mutated RAS on HOP production, mutated RAS was 
introduced into cell lines that contained no known RAS mutations. Three RAS plasmids were 
utilised: wildtype HRAS gene, constituently active mutated HRAS (G12V) or a dominant 
negative mutated HRAS (S17N) (Yasuda et al., 2006). Cells would already contain the 
HRAS gene, however by introducing the G12V HRAS we would determine if there was any 
effect on HOP expression in the presence of a constitutively active RAS protein. G12V 
HRAS would be insensitive to the regulative signals that usually control RAS functioning. 
Introducing the dominant negative S17N HRAS into cells would act as a control. S17N 
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HRAS should not cause the effects observed in both wildtype HRAS and constitutively active 
HRAS as it cannot be activated (Yasuda et al., 2006). 
 
The MCF-7 and HeLa cell lines were chosen due to the absence of mutated RAS in these cell 
lines (Sepp-Lorenzino & Rosen, 1998). The Hs578T cell line has the Q61L RAS mutation 
(Eckert et al., 2004). MCF-7 breast carcinoma cells were transfected with one of three RAS 
plasmids: wildtype HRAS, G12V HRAS or S17N HRAS. qRT-PCR was performed on the 
RNA extracted from each MCF-7 sample and the relative quantity of HOP mRNA present in 
each determined (Fig. 15A). Each of the RAS plasmids increased the levels of HOP mRNA 
compared to MCF-7 cells without the mutated RAS (Fig. 15A), however the increases were 
not significant. HRAS G12V induced the greatest increase in expression of HOP mRNA with 
a 2.5 fold difference, while HRAS S17N induced no change in HOP mRNA levels. Wildtype 
HRAS caused a mean increase less than 1.5 fold.  
 
HeLa and Hs578T cell lines were subsequently transfected with the RAS plasmids and the 
effect on the HOP promoter activity was analysed (Fig. 15B). Additonally, cell lysates were 
produced from each transfection and the levels of HOP protein within each determined using 
SDS-PAGE and Western Blot (Fig. 15C,D). Mutated HRAS had no effect on the HOP 
promoter activity within the HeLa cells when compared to that of the HOP promoter alone 
(Fig. 15B). However HRAS caused a significant increase in the HOP promoter activity of up 
to 6 fold within the Hs578T cells when comparing to the HOP promoter alone. HRAS caused 
a 5 fold increase in the HOP promoter activity, G12V HRAS caused a 6 fold increase and 
S17N HRAS caused a 3 fold increase; all of which were significant. However, surprisingly, 
the protein levels of HOP in both HeLa and Hs578T cells transfected with HRAS showed no 
significant change relative to that of cells with wildtype RAS (Fig. 15C,D). Thus HRAS 
caused an up-regulation the promoter activity of Hs578T cells but not the HOP mRNA and 
protein expression levels.  
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Figure 15: Mutated RAS increased the levels of HOP. 
The effect of mutated RAS on HOP mRNA levels was analysed (A). MCF-7, Hs578T and HeLa cells were 
transfected with wildtype HRAS, constituently active HRAS (G12V) or dominant negative HRAS (S17N). 
RNA was extracted from MCF-7 cells after a 48 hr incubation and used for real-time reverse-transcription 
polymerase chain reaction (qRT-PCR). The Ct value of HOP was measured in all samples, and normalised 
against the Ct value of GAPDH to give a relative quantification of HOP (ΔCt). The ΔCt value for each control 
sample was subtracted from the ΔCt value  of the corresponding inhibitor sample to determine the ΔΔCt value, 
the normalised expression. The fold difference of HOP in each sample was then determined from the 2 -ΔΔCt value. 
The results are represented in a box and whiskers plot as the mean values of three independent experiments with 
duplicates for each sample. B) The effect of mutated RAS on HOP promoter activity was analysed. HeLa and 
Hs578T cells were co-transfected with the RAS plasmids and pHOP-x. The luciferase activity of the pHOP-x 
was measured after 48hrs. Luminescence was measured in relative light units (RLU). The luciferase activity was 
determined by normalising the firefly luciferase activity against the fluorescence produced by the eGFP gene on 
each of the RAS plasmids. The results from the HOP promoter analysis were then normalised against the results 
of pHOP-x and HRAS. The results are represented as the mean values of three independent biological replicates 
with three technical replicates for each. The effect of mutated RAS on protein levels was analysed. HeLa cells 
(C) and Hs578T cells (D) were transfected with the RAS plasmids. Cell lysates were produced after 48hrs for 
each sample and used to perform Western Blot analyses (using 100 µg protein). RAS was detected using GFP. 
Densitometry analysis was performed for each sample using the ImageJ software. For each sample the 
expression of HOP was normalised against a GAPDH loading control, each inhibitor sample was then 
normalised against the corresponding control sample (HeLa) or the HRAS alone (Hs578T) to determine the fold 
difference of HOP expression. The bars represent the standard error. One way ANOVA and Tukey’s Multiple 
Comparison Tests were performed to determine statistical significance (*P < 0.05, **P<0.01). 
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We had observed mutated RAS was having an effect on the HOP promoter but we were yet 
to elucidate why this was so. RAS signalling is mediated by numerous downstream signalling 
pathways, namely the RAF/MEK/ERK (or MAPK) pathway, the PI3-kinase/AKT/mTOR 
pathway, PLCƐ, RAC and Ral GTPase pathways (Fig.16) (Stephen et al., 2014). The MAPK 
signalling cascade was focussed on due to the identification of four putative cis-elements in 
the HOP promoter. The TFs which bind to those cis-elements were downstream targets of the 
MAPK signalling pathway (ETS-1, c-Jun, c-Fos, c-Myc, C/EBPβ) (Fig.16) (Oikawa & 
Yamada, 2003; Roskoski, 2012). Additionally, JNK was also known to activate c-Jun and c-
Fos TFs (Davis, 1999). Thus in an attempt to determine which RAS pathways were 
responsible for regulating the  HOP promoter activity, Hs578T cells were treated with one of 
four inhibitors of the MAPK signalling cascade: α-hydroxy Farnesyl Phosphonic Acid 
(αHFPA) (RAS inhibitor), Sorafenib (RAF inhibitor), U0126 (MEK inhibitor) or 3-(2-
Aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedione (ERK2i, ERK2 inhibitor) 
(Fig.16).  
 
αHFPA blocks the association of RAS with the plasma membrane thereby inhibiting the 
processing of RAS and preventing it from being biologically activated (Pompliano et al., 
1992; Gibbs et al., 1993). It does this by inhibiting the farnesyl-protein transferase which is 
responsible for the post-translational modification of RAS by farnesylation (Pompliano et al., 
1992; Gibbs et al., 1993). By blocking the signalling of RAS, we would be able to observe 
whether HOP expression is dependent on the RAS signalling cascade (Fig.16). Sorafenib 
supresses the activity of RAF thereby inhibiting the phosphorylation of MEK1/2, and 
subsequent activation of ERK1/2 (Wilhelm et al., 2004; Liu et al., 2006). By supressing the 
activity of RAF, we would be able to begin to discriminate which RAS signalling pathways 
were involved in regulating HOP expression (Fig.16). If HOP expression decreased upon 
RAF inhibition, it would signify that the MAPK cascade was involved in the regulation of 
HOP expression. If HOP expression did not decrease, it would signify that another RAS 
signalling pathway was involved instead (such as PI3K). U0126 selectively inhibits the 
kinase activity of MEK1/2 (Favata et al., 1998). This inhibitor, like RAF inhibition, would 
allow for the determination of the involvement of the MAPK signalling cascade in the 
regulation of HOP expression. The ERK2 inhibitor (ERK2i) inhibits the docking domain of 
ERK2 and thereby prevents ERK2 from interacting with substrates (Hancock et al., 2005). 
This inhibitor would enable us to discriminate between the roles of ERK1 and ERK2 in the 
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regulation of HOP expression. If HOP expression decreased it would signify that ERK2 is 
possibly responsible for the activation of the TFs that could regulate HOP expression (Fig.16) 
 
A WST-1 cell cytotoxicity assay was performed for each inhibitor to determine suitable EC50 
values for each when working with Hs578T cells (Fig.17). Sorafenib, U0126 and ERK2i 
decreased the cell viability of Hs578T cells resulting in IC50 values of 3.6 µM, 37.7 µM and 
60 µM respectively. The data generated from Sorafenib (Fig. 17B) treatment was considered 
the most accurate due to the high R2 value of 0.82 and very low standard deviations. Data 
obtained for U0126 and ERK2i treatments (Fig. 17C,D) had lower R2 values of 0.65 and 0.77 
respectively. U0126 data contained standard deviations of up to 75% while ERK2i data 
contained standard deviations of up to 50%. This suggested that the accuracy of the data 
obtained for U0126 and ERK2i treatments was less than that obtained for the Sorafenib 
treatment. αHFPA, with a negative R2 value of -10.66, was ineffective as an inhibitor in this 
cell line (Fig. 17A). The Q61L HRAS mutation found within Hs578T cells alters the binding 
capacity of HRAS, causing it to bind to GGPTase I instead of FTPase (Pompliano et al., 
1992; Gibbs et al., 1993). Since αHFPA is a FTI it would not affect the binding of Q61L 
HRAS to GGPTase I. αHFPA was thus used as a negative control. 
 
Upon determining the subtoxic concentrations of each inhibitor the effect of these three 
inhibitors on HOP expression in Hs578T cells was determined through qRT-PCR and 
western blot analysis (Fig.18). Hs578T cells were treated with either 30 µM αHFPA, 3.6 µM  
Sorafenib or 37.7 µM U0126. Although no significant differences were observed in the levels 
of HOP mRNA isolated from inhibited cells versus the controls, both Sorafenib and U0126 
decreased the levels of HOP mRNA relative to the control (Fig.18A). Treatment of cells with 
αHFPA resulted in varied levels of HOP mRNA. Sorafenib also reduced the levels of HOP 
protein by half that of the control (Fig. 18B). Results from the U0126 treatments were not 
reproducible, but the average of the HOP mRNA observed was greater than the control 
expression. 
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Figure 16: Inhibition of the RAS signalling pathways.  
Schematic diagram illustrating the positions of inhibition of the four inhibitors along the mitogen-activated 
protein kinases (MAPK) / extracellular signal-regulated kinases (ERK 1 and ERK 2) signalling pathway and the 
phosphoinositide 3-kinase (PI3K) signalling pathway. α-hydroxy Farnesyl Phosphonic Acid (α HFPA) is a RAS 
inhibitor, Sorafenib is a RAF inhibitor, U0126 a MEK inhibitor and 3-(2-Aminoethyl)-5-((4-et
hoxyphenyl)methylene)-2,4-thiazolidinedione (ERK2i) is an ERK2 inhibitor. 
 
 72 
 
 
Figure 17: Chemosensitivity of Hs578T cells to RAS signalling inhibitors.  
The cytotoxicity of RAS signalling inhibitors on the mammalian breast epithelial cell line Hs578T was tested 
using the cell proliferation reagent WST-1 and an incubation period of 96 hrs. A) α-hydroxy Farnesyl 
Phosphonic (αHFPA) Acid, with a concentration range of 0.001 µM to 100 µM, B) Sorafenib with a 
concentration range of 0.001 µM  to 10 µM, C) U0126 with a concentration range of 0.002 to 100 µM. D) 3-(2-
Aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedione (ERK2i) with a concentration range of 0.01 
to 100 µM. 
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Figure 18: Inhibition of RAS signalling effects the expression of HOP.  
Hs578T cells were treated with either 30 µM αHFPA, 3.6 µM  Sorafenib, 37.7 µM  U0126 or the cooresponding 
dimethyl sulfoxide (DMSO) or Ethanol vehicle controls and incubated for 48 hrs. A) RNA was extracted from 
Hs578T cells and used for real-time reverse-transcription polymerase chain reaction (qRT-PCR). The Ct value 
of HOP was measured in all samples, and normalised against the Ct value of GAPDH to give a relative 
quantification of HOP (ΔCt). The ΔCt value for each control sample was subtracted from the ΔCt value  of the 
corresponding inhibitor sample to determine the ΔΔCt value, the normalised expression. The fold difference of 
HOP in each sample was then determined from the 2-ΔΔCt value. B) Cell lysates were produced for each sample 
and used to perform Western Blot analyses (using 100 µg protein). Densitometry analysis was performed for 
each sample using the ImageJ software. For each sample the expression of HOP was normalised against a 
histone control, each inhibitor sample was then normalised against the corresponding control sample to 
determine the fold difference of HOP expression. The results are represented as the mean values of three 
independent experiments with duplicates for each sample. The bars represent the standard error. One way 
ANOVA and Tukey’s Multiple Comparison Tests were performed to determine statistical significance (P < 
0.05). 
 
4.2.3 - Consequences of the RAF signalling on HOP production 
Since the RAF inhibitor, Sorafenib, was the only drug that caused a substantial decrease in 
the levels of HOP protein, we decided to focus on the effect of RAF signalling on the 
expression of HOP. To determine the effect of the downstream signalling effectors of RAF 
upon RAF inhibition, Hs578T breast cancer cells were treated with the RAF inhibitor 
Sorafenib (Fig. 16). The phosphorylation of the signalling molecules within the downstream 
cascades was used to indicate their activation, and thus the loss of phosphorylation would 
indicate reduced activation of the proteins. The change in the levels of phosphorylation of 
RAF activated signalling molecules was determined by Western blot analyses for pFAK, 
pERK1/2 and pJNK (Fig. 19A), and by changes in subcellular localisation for pFAK and 
ppERK1/2 using confocal microscopy (Fig. 19B). Our antibody for pJNK was not compatible 
with fluorescent staining and we were unable to detect the levels of p38 (data not shown). 
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The phosphorylation of RAF downstream signalling molecules was deactivated upon 
treatment with Sorafenib. The pERK1/2 antibody detected p44 (ERK1) and p42 (ERK2) 
MAP kinases when phosphorylated. For FAK, the 46 kDa band of JNK, and ERK1/2 there 
was a decrease in phosphorylation compared with their control counterparts upon RAF 
inhibition (Fig. 19A). Phosphorylated ERK2 was detected in the control sample in greater 
quantities than phosphorylated ERK1, identified by the band at molecular weight 42 kDa 
with a greater intensity than the intensity of the band observed at molecular weight 44 kDa 
(Marais et al., 1993; Kortenjann et al., 1994). The reduction in phosphorylated ERK2 upon 
Sorafenib treatment was greater than that observed for phosphorylated ERK1. The pAKT and 
RhoC signals were not decreased by the inhibition of RAF. Fluorescent microscopy was 
utilised to visualise individual cells. Both pFAK and pERK1/2 were observed to be mainly 
within the nuclei of the cells (Fig. 19B). Upon Sorafenib treatment, there was a gradual loss 
of the pERK1/2 protein within the nuclei as the proteins dispersed into the cytoplasm. This 
trend continued at 24 hrs for pERK1/2. A total loss of pFAK was observed within the cells by 
24hrs of Sorafenib treatment. 
 
Since Sorafenib inhibited the phosphorylation of various MAPK signalling effectors, we next 
looked at the effect of Sorafenib on HOP protein levels. The levels of HOP were also 
decreased upon treatment with the RAF inhibitor (Fig. 19C), as identified previously in 
Figure 18. A time course study of the effect of Sorafenib on HOP protein levels was 
performed (Fig. 19D). Hs578T cells were treated with Sorafenib over varying time periods 
and the consequent levels of HOP protein detected using Western Blot analyses. The 
densitometry for the triplicates is shown. The levels of HOP within Hs578T cells treated with 
Sorafenib decreased at a 48 hr incubation period with the inhibitor, although the cells 
expressed an increased level of HOP relative to the untreated cells at time points 12, 24 and 
36 hrs (Fig. 19D). Between time points 36 and 48 hrs the levels of HOP dropped by half 
relative to the untreated cells. Lastly, we considered inhibiting the last effector within the 
MAPK signalling pathway, ERK2 (Fig. 16). Hs578T cells were thus treated with 60 μM 
ERK2i and the consequent protein levels of HOP determined (Fig. 19E). Western Blot 
analyses revealed a significant reduction in the protein levels of HOP in Hs578T cells treated 
with ERK2i compared to those without the inhibitor treatment. 
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Figure 19: HOP is down-regulated by inhibition of the MAPK pathway.  
Hs578T cells were treated with 3.6 µM  Sorafenib or dimethyl sulfoxide (DMSO) acting as the vehicle control. 
Cell lysates were produced for each sample after a 48 hr incbation at 37 oC and used to perform Western Blot 
analyses (using 100 µg protein) (A). Various signalling molecules within the RAS signalling pathway were 
probed: phosphorylated Akt (pAKT), the signalling G protein RhoC, phosphorylated focal adhesion kinase 
(pFAK), phosphorylated c-Jun N-terminal kinase (pJNK), and phosphorylated mitogen-activated protein (MAP) 
 76 
 
kinases ERK1 and ERK2 (pERK1/2). Histone H3 and GAPDH were used as a loading control for total protein. 
The images represent experiments done in triplicate. B) The subcellular localisation of pFAK and ppMAPK 
(pERK1/pERK2) in Hs578T cells was determined using indirect immunofluorescence staining and fluorescence 
microscopy. Hs578T cells were seeded overnight onto glass coverslips and treated with 3.6 µM  Sorafenib or 
dimethyl sulfoxide (DMSO) for 12 or 24 hours. Cells were incubated with pFAK or ppMAPK primary 
antibodies (1:50 dilution) followed by donkey anti-rabbit-488 secondary antibody (green). The nuclei were 
stained with Hoechst-33342 (blue). Images captured using the Zeiss AxioVert AI FL-LED inverted fluorescence 
microscope with a 100x objective and were analysed by Zen Lite 2012. All samples were captured with 
equivalent laser settings. The scale bars indicate a length of 10 µm. Images shown are representative of triplicate 
images captured from randomly selected fields, with the dominant morphology shown. C) The cell lysates 
produced from Hs578T cells treated with 3.6 µM  Sorafenib or dimethyl sulfoxide (DMSO) were used in 
Western blot analyses and HSP70/HSP90 organising protein (HOP) was probed. Densitometry analysis was 
performed for each sample using the ImageJ software. For each sample the expression of HOP was normalised 
against a Histone loading control, each inhibitor treated sample was then normalised against the corresponding 
DMSO control sample to determine the fold difference of HOP expression. The results were represented as the 
mean values of three independent experiments. The bars represent the standard error. One way ANOVA and 
Tukey’s Multiple Comparison Tests were performed to determine statistical significance (*P < 0.05). D) Time 
course study on the effect of Sorafenib on the levels of HOP protein. Hs578T cells were treated with 3.6 µM 
Sorafenib or dimethyl sulfoxide (DMSO). Cell lysates were produced for each sample after increasing 
incubation times at 37 oC and used to perform Western blot analyses (using 100 µg protein) and densitometry. 
GAPDH was used as a loading control for total protein. One way ANOVA and Tukey’s Multiple Comparison 
Tests were performed to determine statistical significance (P < 0.05). E) Hs578T cells were treated with 60 µM  
ERK2i or dimethyl sulfoxide (DMSO). Cell lysates were produced for each sample after a 48 hr incbation at 37 
oC and used to perform Western blot analyses (using 100 µg protein). GAPDH was used as a loading control for 
total protein. Densitometry analysis was performed for each sample. One way ANOVA and Tukey’s Multiple 
Comparison Tests were performed to determine statistical significance (*P < 0.02). 
*For an electronic copy of the fluorescence images see Electronic Appendix B. 
 
4.2.4 – ETS-1 and C/EBPβ cis-elements are linked to HOP regulation 
Next, to determine which downstream targets of the MAPK signalling pathway may have 
been involved in the regulation of HOP expression, the levels and localisation of two key TFs 
were analysed upon Sorafenib treatment. Cis-elements identified in the in silico HOP 
promoter analysis that were targets of TFs involved in the MAPK signalling pathway were 
ETS-1 and C/EBPβ (Fig 16). Confocal microscopy was utilised to visualise the protein levels 
and subcellular localisation of C/EBPβ and ETS-1 within Hs578T cells with and without 
Sorafenib treatment. The change in the protein levels of the TFs was determined by Western 
Blot analyses (Fig.20). 
 
Under normal conditions, C/EBPβ was found with a punctate staining dispersed throughout 
the cell but with a strong presence in the nucleus. Upon Sorafenib treatment the protein was 
identified specifically in clusters along the periphery of the cell (Fig. 20A, clusters identified 
by white arrows), still maintaining the punctate staining pattern, with a reduction in protein 
levels observed in the nuclei. To confirm the difference observed in fluorescence intensity in 
the treated versus the control cells, an analysis of the fluorescent intensity (mean grey values) 
of the C/EBPβ fluorescence in the cytoplasm compared to the nuclei was performed for 10 
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cells from each treatment. The overall fluorescence intensity decreased in the Sorafenib 
treated cells, with a statistically significant reduction of fluorescence intensity within the 
nuclei of Sorafenib treated cells (Fig. 20C). 
 
ETS-1 was also found dispersed throughout the cell under control conditions, with a strong 
presence in narrow regions along the cell periphery (Fig. 20B). Upon Sorafenib treatment, the 
peripheral staining was lost and a pronounced reduction of protein was observed within the 
nucleus. Overall staining was more punctate than under normal conditions, especially within 
the nucleus. Additionally, the protein was observed in particularly high levels immediately 
surrounding the nucleus. An analysis of the fluorescence intensity identified a reduction in 
protein levels in the cytoplasm upon Sorafenib treatment and the ratio of ETS-1 within the 
cytoplasm versus the nuclei was reduced (Fig. 20D). This suggested that ETS-1 protein 
moved from the cytoplasm into the nucleus. Additionally, both C/EBPβ and ETS-1 total 
protein levels were reduced upon Sorafenib treatment (Fig. 20E). 
 
The last effectors within the MAPK signalling pathway to be considered was ERK1/2 (Fig. 
16). ERK2 is the effector that directly activates ETS-1 and C/EBPβ TFs via phosphorylation 
(Yang et al., 1996; Hanlon et al., 2001). Hence, ERK2 was inhibited in order to discriminate 
between the role of ERK1 and ERK2 in HOP expression. It may also prevent cross-talk 
between the MAPK signalling cascade with other effectors that activate ERK2. Hs578T cells 
were treated with ERK2i and confocal microscopy was utilised to determine the subcellular 
localisation of ETS-1 upon ERK2 inhibiton compared to normal conditions (Fig.21). ETS-1 
was found to be dispersed almost evenly throughout the cell under both control and treated 
conditions (Fig. 21A). However, a significant reduction in the ETS-1 fluorescence levels 
were observed upon ERK2i treatment (Fig. 21B). The ratio of ETS-1 fluorescence detected 
within the cytoplasm compared to within the nuclei of cells was observed to stay the same 
between control and ERK2i treatments.  
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Figure 20: C/EBPβ and ETS-1 protein levels are down-regulated by RAF Inhibition.  
The subcellular localisation of (A) C/EBPβ and (B) ETS-1 in Hs578T cells was determined using indirect 
immunofluorescence staining and confocal microscopy. Hs578T cells were seeded overnight onto glass 
coverslips and treated with 3.6 µM  Sorafenib or dimethyl sulfoxide (DMSO) for 24 hours. Cells were incubated 
with C/EBPβ or ETS-1 primary antibodies (1:50 dilution) followed by donkey anti-rabbit-488 secondary 
antibody (green). The nuclei were stained with Hoechst-33342 (blue). Images captured using the Zeiss LSM 780 
Confocal Microscope with 60x and 100x objectives and were analysed by Zen Lite 2012. All samples were 
captured with equivalent laser settings. The scale bars represent a length of 10 µm or 20 µm as indicated. White 
arrows indicate C/EBPβ staining in peripheral clusters within the Hs578T cells. Images shown are representative 
of triplicate images captured from randomly selected fields, with the dominant morphology shown. The 
fluorescence intensity of (C) C/EBPβ and (D) ETS-1 observed within the cytoplasm and nuclei of the Hs578T 
cells was determined by comparing the fluorescence intensity (mean grey values) within each and dividing the 
total by the distance of the subcellular compartment. The results were represented as the mean values of 10 
Hs578T cells for each treatment. The bars represent the standard error. One way ANOVA and Tukey’s Multiple 
Comparison Tests were performed to determine statistical significance (*P<0.5, **P<0.01, ***P<0.001). (E) 
Cell lysates were produced for each sample after a 48 hr incbation at 37 oC and used to perform Western Blot 
analyses (using 100 µg protein), the CCAAT/enhancer-binding protein β (C/EBPβ) and ETS domain 
transcription factor (Ets-1) were probed. The images represent experiments done in triplicate. Densitometry 
analysis was performed for each sample. One way ANOVA and Tukey’s Multiple Comparison Tests were 
performed to determine statistical significance. 
*For an electronic copy of the confocal images see Electronic Appendix B. 
 
 80 
 
 
Figure 21: ETS-1 protein levels are down-regulated by ERK2i.  
The subcellular localisation of ETS-1 in Hs578T cells was determined using indirect immunofluorescence 
staining and confocal microscopy (A). Hs578T cells were seeded overnight onto glass coverslips and treated 
with 60 µM  ERK2i or dimethyl sulfoxide (DMSO) for 24 hours. Cells were incubated with ETS-1 primary 
antibodies (1:50 dilution) followed by donkey anti-rabbit-488 secondary antibody (green). The nuclei were 
stained with Hoechst-33342 (blue). Images captured using the Zeiss LSM 780 Confocal Microscope with a 100x 
objective and were analysed by Zen Lite 2012. All samples were captured with equivalent laser settings. The 
scale bars indicate a length of 20 µm. Images shown are representative of triplicate images captured from 
randomly selected fields, with the dominant morphology shown. (B) The fluorescence intensity of ETS-1 
observed within the cytoplasm and nuclei of the Hs578T cells was determined by comparing the mean grey 
values within each and dividing the total by the distance of the subcellular compartment. The results were 
represented as the mean values of 10 Hs578T cells for each treatment. The bars represent the standard error. 
One way ANOVA and Tukey’s Multiple Comparison Tests were performed to determine statistical significance 
(***P<0.001). 
*For an electronic copy of the confocal images see Electronic Appendix B. 
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4.3 Discussion 
The data presented in this study provided the in vitro evidence that the 1.5 kb region 
upstream of the HOP gene TSS had promoter activity. Our inhibition of RAS signalling did 
reduce the levels of HOP protein observed specifically through the MAPK signalling 
cascade, however we did not conclusively demonstrate that this was due to changes of the 
promoter activity of HOP. Additionally, the reduction of HOP levels observed upon the 
inhibition of the MAPK signalling pathway may be independent of the HOP promoter 
activity and may have been due to the degradation of HOP protein. 
 
4.3.1 – The HOP promoter is differentially activated 
The luciferase assays performed confirmed that the promoter region of HOP predicted in 
silico was able to drive transcription of the luciferase coding region in vitro. This confirmed 
that the -1520 to +16 bp region of the human HOP gene was in fact the HOP promoter. To 
determine which region within the promoter is the core promoter, sequential truncations of 
the HOP-x sequence would need to be produced and ligated back into the pGL4 vector. 
Analysis of whether these truncated sequences of the HOP promoter could drive transcription 
of the luciferase coding region, would ascertain which region is responsible for the core 
promoter activity. The promoter activity of HOP in the non-cancerous cell line MEF-1 was 
minimal, whereas the HOP promoter activity within the cancer cell lines was much greater. 
This suggested that just as protein levels of HOP have been found to be up-regulated in 
numerous cancers (Kubota et al., 2010; Walsh et al., 2011; Willmer, 2011), so too is the HOP 
promoter activity up-regulated in cancer cell lines. Furthermore this suggested that within 
cancer cells the HOP promoter may be in a constant state of activation. This activation may 
be due to epigenetic factors, cellular stresses or deregulated signal cascades. To confirm this 
conclusion one would need to determine the HOP promoter activity levels in normal human 
cell lines.  
 
Alternatively, the lack of HOP promoter activity in MEF-1 cells may be due to the fact that 
these cells are murine and our promoter sequence is from the human HOP gene. The HOP 
promoter in murine cells may be regulated differently to the HOP promoter within human 
cells. It was observed in the bioinformatics comparison of the upstream regions of the HOP 
gene in the orthologues that the murine and human upstream regions were different, with low 
sequence identity. The human promoter sequence was regulated by a TATA-less, broad 
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promoter while the murine HOP promoter contained a TATA box cis-element and thus was 
most likely a TATA regulated promoter. Additionally, the sequence identity between the 
promoters was 67% suggesting that the promoters would be regulated by different cis-
elements. This would lead one to question the viability of using mouse models to study the 
mechanism of HOP functioning with the purpose of extending the scope of the analysis to 
humans. However, it did provide a useful control for the luciferase assay study to 
demonstrate that promoter activity from this construct was context dependent. 
 
There may be numerous possible reasons as to why the HOP promoter activity was higher in 
the Hs578T cell line compared to the HeLa cell line. Genes are known to be differentially 
transcribed according to environmental conditions, in differing tissue types, in differing sexes 
and according to each stage of the life cycle (Wray et al., 2003). Additionally, the activation 
of TFs is context dependent, thus the cellular environment within each cell type may be 
sufficiently different to provide differing TF ensembles within each the nuclei of the two 
tissue types (Wray et al., 2003). This would support our observation of differing tissue types 
(HeLa cells being cervical and Hs578T cells being breast) having different HOP promoter 
activity levels. Of particular interest in this study was that the Hs578T cell line contained a 
mutated RAS gene whereas the HeLa cell line had no known RAS mutation. The Hs578T cell 
line contains the Q61L HRAS mutation that is prevalent in tumours; the mutation renders 
HRAS in a constitutively active state (Eckert et al., 2004). Furthermore, oncogenic and 
wildtype RAS has been found to have differential roles in signal transduction (Young et al., 
2013). And various genes related to the MAPK signalling pathway have been identified as 
up-regulated in triple negative breast cancers (TNBC) (Creighton et al., 2006; Hoeflich et al., 
2009; Mirzoeva et al., 2009), similar to the Hs578T cell line.  
 
4.3.2 – Mutated RAS activates the HOP promoter but did not significantly alter the 
mRNA and protein levels 
Introducing HRAS into cells that otherwise had no known RAS mutations had no effect on 
the HOP promoter activity or on the production of HOP protein in cancer cells. However, 
upon introducing HRAS into a cell line that already had a mutated version of RAS (Hs578T), 
the activity of the HOP promoter increased significantly. A study by Petanidis et. al. (2013) 
revealed that upon introducing HRAS into the MCF-7 cell line there were no significant 
changes in cell viability or cell proliferation, merely an increase in the expression of the 
HRAS protein. A study by Omerovic et. al. (2008) showed that HeLa cells (transfected with 
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HRAS G12V) did not activate the expressed HRAS protein until stimulated with human 
growth factors (specifically hepatocyte growth factor [HGF] or epidermal growth factor 
[EGF]). It has been proposed once before that a definable amount (as yet unquantified) of 
activated RAS is required before RAS-dependent signalling processes can occur (Hamilton & 
Wolfman, 1998). Such observations from Petanidis et. al. (2013), Omerovic et. al. (2008) and 
Hamilton and Wolfman (1998) along with the data presented here suggest that introducing a 
RAS mutation into cell lines that do not already have a mutated form of RAS is not enough 
on its own to produce the effects of an active oncogenic RAS protein. Thus the HeLa cells 
containing the transfected HRAS plasmids were not able to activate the HRAS proteins in a 
sufficient quantity to see the effect of the oncogenic RAS, due to a lack of the extracellular 
signals required for induction. Whereas, introducing an additional mutated form of RAS 
(HRAS G12V) into a cell line that already contained a different RAS mutation (HRAS 
Q61L), seemed to amplify the effect of the oncogenic RAS within the cells. Since the HRAS 
Q61L mutant is in a constitutively active state, it does not require the RAS activators that 
accumulate within the cell to activate it. Thus, the introduction of further wildtype HRAS into 
the cells may have allowed for the utilisation of the RAS activators and caused a further 
increase in MAPK signalling.  
 
The HRAS S17N gene expressed a dominant negative protein, which in theory should have 
blocked HRAS functioning. There are two schools of thought on the mechansim by which the 
HRAS S17N mutant inhibits RAS signalling. The first is that the mutant sequesters the RAS 
activators and GEFs within the cell and thereby blocks the activation of endogenous RAS. 
The alternative argument is that the S17N mutant has a low affinity for GTP in addition to the 
inability of GTP to activate the S17N mutant, thereby preventing the mutant from binding 
and activating downstream effectors (Farnsworth & Feig, 1991; Stacey et al., 1991; Nassar et 
al., 2010). However, since the Hs578T cell line already contained a constitutively active 
mutant, HRAS Q61L, the inhibitory effect of the HRAS S17N mutant could have been 
undermined to a certain extent. This does not explain how HRAS S17N increased the HOP 
promoter activity in the presence of the HRAS Q61L mutant. Although the effect of the 
HRAS S17N on HOP promoter activity decreased by approximately half of that of HRAS 
(wildtype and G12V), it still caused a 3 fold increase in promoter activity. This suggested 
that, specifically within the Hs578T cell line, RAS signalling cascades may have been 
activated via an alternative mechanism that was not hindered by the HRAS S17N mutation. A 
possible pathway could be the Protein Kinase C (PKC) –RAF-1 – ERK signalling pathway. 
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Active PKC has been shown to activate RAS, as well as activate RAF-1 in a RAS 
independent manner (Sözeri et al., 1992; Cacace et al., 1996; Hirai, 1996; Kawakami et al., 
2003). PKC mediated activation of RAF via phosphorylation occurs in the presence of human 
growth factors (HGF and EGF), which are also known to cause the activation of RAS (Corbit 
et al., 2003).  
 
Elevated promoter activity does not necessarily mean there will be an elevated rate of 
translation (Hill & Treisman, 1995; Kapeli & Hurlin, 2011). In this study, the 6 fold increase 
in the HOP promoter activity within Hs578T cells, in the presence of the HRAS mutation, did 
not correlate to a subtantial increase in HOP protein levels. Hence the protein levels observed 
may be due to slow rates of protein translation. From our data, we could then conclude that 
RAS was influencing the exogenous HOP promoter activity but it did not influence the levels 
of endogenous HOP mRNA and protein synthesis, despite the fact that inhibiting signalling 
pathways downstream from RAS reduced the levels of endogenous HOP protein. Could this 
be due to the saturation of the transcriptional and/or translational machinery in the cells 
containing HRAS Q61L (Studier & Moffatt, 1986)? Constitutively active HRAS would be 
causing the up-regulation of numerous promoters throughout the cell, however there is a 
limited supply of transcriptional and translational machinery available. Or the rate limiting 
step may be the posttranslational modifications required for mature protein synthesis. 
 
To test this proposition we inhibited RAS signalling instead of inducing it in the cells that 
already contained constitutively active RAS. However the RAS inhibitor we had available, 
αHFPA, was not toxic to the Hs578T cells. The Q61L mutation involves the last amino acid 
in the CAAX peptide within the HRAS sequence. The CAAX residues are the substrate for 
farnesylation which facilitates the membrane association of RAS. The C represents a cysteine 
residue while the A represents aliphatic residues and the X represents any amino acid. The 
substitution of the X has great consequences on what type of transferase the peptide will bind 
to. By substituting the glutamine to a leucine, the peptide will bind to GGPTase I rather than 
FPTase (Pompliano et al., 1992; Gibbs et al., 1993). Since αHFPA was a FTI it would not 
affect the mutated HRAS (Q61L) found within Hs578T cells and explained the lack of 
toxicity of the compound in the cell line. Although this explained the lack of toxicity to the 
cell line, at first, it did not explain the slight reduction in the mRNA and proteins levels of 
HOP observed when Hs578T cells were treated with αHFPA. It is important to note that RAS 
is not the only protein that is a substrate for FPTases. Therefore, while αHFPA may have had 
 85 
 
no effect on HRAS within the cells, it would still have inhibited the farnesylation of 
numerous other prenylated substrates within the cell (Baines et al., 2011). Most prenylated 
proteins are those involved in signal transduction cascades with downstream targets involved 
in normal cellular functions (Li & Sparano, 2003). This could have had inhibitory 
consequences for the cell. For example, the Rheb small GTPase is a substrate for FTPase, 
which requires farnesylation before it can activate the mammalian target of rapamycin 
(mTOR). mTOR in turn is a downstream signalling molecule within the phosphoinositide 3-
kinase (PI3K) pathway (PI3K-AKT-mTOR), the deregulation of which is a common 
characteristic of cancer (Basso et al., 2005). This is an example of the inhibition of the 
functioning of just one protein via αHFPA and suggests a possible reason for the observation 
of the reduction HOP expression. However, these effects could probably be considered minor 
given that the αHFPA was not toxic to the cells. 
 
Since HRAS could not be directly inhibited using αHFPA in the Hs578T line, inhibitors of 
the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade were considered an 
indirect method of RAS inhibition. Inhibitors of two intermediates within the pathway were 
utilised – RAF1 and MEK1/2. MEK1 and MEK2 are the only known catalytic substrates of 
RAF1, whereas ERK1 and ERK2 are the only known substrates of MEK1/2 (Baines et al., 
2011). However one cannot over simplify this pathway by linearizing it as ERK1/2 is a 
substrate for several other kinases. This would explain why inhibiting MEK1/2 with U0126 
did not give reproducible results, and why Sorafenib treatment didn’t provide a complete 
reduction in the levels of HOP. By suppressing the MAPK signalling pathway one does not 
wholly block ERK1/2 activation by mutated RAS, additional pathways that phosphorylate 
ERK1/2 may have compensated for the lack of RAF and MEK1/2 signalling (Baines et al., 
2011). The activation of alternative signalling pathways has been observed twice in clincial 
trials for the RAF inhibitor PLX4032 (Johannessen et al., 2010; Nazarian et al., 2010). This 
suggested that HOP protein expression could be regulated by more than a single signalling 
pathway (Favata et al., 1998).  
 
The consequence of Sorafenib treatment on HOP production suggested that the greatest 
inhibiting effect on HOP protein levels was observed after 36 hrs. However, in order to 
completely nullify the effect of mutated RAS in the Hs578T cell line, we should have used a 
combination of inhibitors that would have targeted both the MAPK and PI3K-AKT signalling 
pathways. Such combination therapies have shown greater effective inhibition of mutated 
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RAS in human melanoma cells, hepatocellular carcinoma and non-small cell lung cancer 
(Molhoek et al., 2005; Legrier et al., 2007; Wang et al., 2008; Saini et al., 2013). Due to the 
dependence of cells on these pathways for survival, one would require to determine effective 
subtoxic concentrations of each inhibitor when used in combination. Due to the high toxicity 
of a combinatorial approach one would expect large scale side effects, some of which would 
not be observed in vitro but only in vivo. Thus although initial clinical benefit of dual 
inhibition has been shown (phase I clinical trials), phase II data is yet to be released and will 
be a better representative of the feasibility of dual inhibition of these pathways in vivo (Saini 
et al., 2013). 
 
4.3.3 - RAF and ERK2 regulate HOP protein levels through the MAPK signalling 
cascade 
RAF inhibition decreased the activation of ERK1 and ERK2 within Hs578T cells but not to 
the same degree; ERK2 was deactivated to a greater degree than ERK1 (Marais et al., 1993; 
Kortenjann et al., 1994). ERK2 has been found to have higher protein levels than ERK1 in 
the Hs578T cancer cell line when compared to that of less aggressive cancer cell lines such as 
MCF-7 (Marais et al., 1993; Kortenjann et al., 1994; Chrestensen et al., 2007), which 
correlates to the difference in phosphorylated ERK1/2 levels observed in our experiments. 
This suggested that ERK1 and ERK2 may have had functional differences within Hs578T 
cells. 
 
FAK phosphorylation is known to be induced by two different signalling pathways, the one 
being PI3K dependent and the other ERK pathway dependent (Hunger-Glaser et al., 2004). 
ERK1/2 phosphorylates FAK on Ser-910 while Tyr-397 is phosphorylated by PI3-kinase 
(Hunger-Glaser et al., 2003). A direct link between ERK and FAK was observed in our study 
whereby the detection patterns of the signalling molecules upon the treatment of Sorafenib 
were similar. It suggested that the phosphorylation of pERK1/2 was deactivated in the 
presence of Sorafenib, which in turn may have caused the deactivation of the phosphorylation 
of FAK (Hunger-Glaser et al., 2003, 2004; Sawhney et al., 2006; Zheng et al., 2009). 
Phosphorylation of AKT did not decrease upon Sorafenib treatment suggesting that the 
MAPK signalling pathway, and not the P13K-AKT signalling pathway, was linked to the 
regulation of the HOP levels. A study by Eckert et al. (2004) supports this proposition as they 
found that, particularly within the Hs578T cell line, AKT was activated by a RAS 
independent mechanism. The Jun amino-terminal kinase, or JNK protein kinases (JNK1, 
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JNK2, JNK3), are expressed as 46 kDa and 55 kDa proteins, and are all a part of a parallel 
MAPK signalling cascade (Davis, 1999). Although JNK is not directly activated by RAS-
RAF, JNK is activated by phosphorylation via two MAP kinase kinases (MKK4 and MKK7) 
(Ip & Davis, 1998). MKK4 and MKK7 are in turn activated via phosphorylation by MEKK1 
and MLK3. MEKK1 is activated directly by RAS or by PAK1/2 in the PI3K pathway. 
However, since the AKT signalling did not seem to be affected by RAF inhibition, it suggests 
that the activation of MEKK1 and/or MLK3, or MKK4 and/or MKK7 may have been 
inhibited instead.  
 
Phosphorylation of FAK and ERK1/2 represent the activation of these signalling molecules 
within the cell (Khokhlatchev et al., 1998). Under resting conditions wherein the proteins are 
inactivated, FAK and ERK1/2 can be observed anchored within the cytoplasm of cells (Shaul 
& Seger, 2007). Upon activation the majority of the phosphorylated signalling molecules are 
released from the anchors and translocate to the nuclues where they in turn activate various 
TFs. The lack of pFAK and the reduction of pERK1/2 observed in the nuclei of Hs578T cells 
when treated with Sorafenib further indicates the loss of protein phosphorylation and hence 
the activation of the two signalling molecules (Hamilton & Wolfman, 1998). Thus the 
analysis revealed that each protein was activated specifically by the MAPK pathway.  
 
The reduction of HOP proteins levels corresponded to the reduction in phosphorylated 
ERK1/2, FAK and JNK upon RAF inhibition with Sorafenib. This suggested a possible link 
between the activation of these effectors with the regulation of HOP expression. Furthermore, 
ERK2 inhibition resulted in a reduction in HOP protein levels. This suggested that it was 
ERK 2, instead of ERK1, that was involved in the regulation of HOP expression. 
 
4.3.4 - C/EBPβ and ETS-1 are associated with the transcriptional regulation of HOP 
Oncogenic RAS has already been found to cause the activation of C/EBPβ via 
phosphorylation in fibroblasts, erythroblasts and p19 embryonic carcinoma cells (Nakajima et 
al., 1993; Kowenz-Leutz et al., 1994). More specifically, ERK2 has been determined to 
phosphorylate the transcription factor C/EBPβ via a T188 phosphorylation site (Hanlon et al., 
2001; Zhu et al., 2002). Oncogenic HRAS activation of C/EBPβ is dependent on T188 
phosphorylation and thus the endogenous C/EBPβ protein has been classified as a 
downstream mediator of oncogenic HRAS signalling (Zhu et al., 2002). This was interesting 
due to the large number of putative CCAAT elements identified within the HOP promoter 
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region. Our results supported the findings of Zhu et. al. (2002) in that we observed in the 
Hs578T cell line that C/EBPβ protein levels decreased upon RAF inhibition. The consequent 
reduction of the TF observed in the nucleus suggests that the deactivation of ERK2 by RAF 
inhibition blocked the phosphorylation of C/EBPβ. Since the reduction of C/EBPβ 
corresponded to the reduction of HOP observed upon the inhibition of RAF, this led to the 
proposal that the MAPK signalling pathway may regulate HOP expression through C/EBPβ 
cis-elements within the HOP promoter. 
 
ETS-1 is a well characterised TF and was identified as a nuclear target of the RAS signalling 
pathway in 1996 by Yang et al. The function of ETS-1 relies on the phosphorylation of the 
protein, the consequence of which is the ability of the protein for DNA binding, protein-
protein interactions, and transcriptional activation (Seth & Watson, 2005). Phosphorylation of 
ETS-1 at Thr-38 occurs via ERK2 (Callaway et al., 2010). Being one of the last effectors at 
the end of the RAS signalling pathways, the functioning of ETS-1 is also altered upon the 
deregulation of RAS in cancers. An example of such deregulation was identified in breast 
cancer where ETS-1 was found to be up-regulated within the Hs578T cell line (Behrens et 
al., 2001). A similar trend of elevated ETS-1 levels has been observed in colon, thyroid, lung 
and pancreatic cancers; with these elevated levels corresponding to tumour progression 
(Simpson et al., 1997; Ito et al., 1998, 2002; Nakayama et al., 1999).  
 
ETS-1 interacts with various TFs such as AP-1, PAX-5 and NF-Kβ and in doing so co-
regulates the expression of a variety of genes (Li et al., 2000). The putative cis-elements for 
each of those TFs were identified within the HOP promoter. This led to the investigation of 
the effect of ETS-1 on the expression of HOP in cancer cells. Upon ERK2 inhibition, a 
significant reduction of ETS-1 was identified within the nuclei of the Hs578T cells. This 
suggested a loss of phosphorylation of ETS-1 would have occurred as well, which would in 
turn explain a loss of function for the protein as a TF, the ability of the protein to bind to 
DNA and to interact with other TFs (Oikawa & Yamada, 2003). The inhibition of ETS-1 in 
both Sorafenib and ERK2i treated Hs578T cells correlated with the reduction of HOP protein 
levels in these cells. This might suggest that the RAS pathway regulated HOP expression 
through the ETS-1 cis-elements within the HOP promoter as well and that ETS-1 may be one 
of the regulating factors causing the observed increase in HOP levels in cancer cells.  
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However, to truly confirm whether HOP is a target gene for ETS-1 and C/EBPβ proteins, 
chromatin immunoprecipitation analysis of the putative cis-elements within the HOP 
promoter would be required to determine whether ETS-1 and C/EBPβ functionally binds any 
of those sites (Mukhopadhyay et al., 2008). An attempt was made to perform an initial 
analysis into the function of ETS-1 cis-elements within the HOP promoter using truncations 
of the HOP promoter reporter construct. The designed truncation excluded two of the 
predicted ETS-1 cis-elements at positions -1102 bp and -1044 bp while including another two 
predicted ETS-1 cis-elements at positions -690 bp and -62 bp (Appendix C). The truncation 
was to be ligated into the pGL4 vector and transfected into Hs578T cells. Luciferase assays 
would have utilised to determine the level of promoter activity of the truncated promoter 
versus the full length promoter. A reduced level of promoter activity in the truncated 
promoter, compared to that of the full length, would have indicated in vitro evidence for the 
position of the core promoter of HOP, as well as suggested the necessity of the ETS-1 cis-
elements for promoter activity. Additionally, if the transfected cells had been treated with 
Sorafenib prior to the luciferase assay, a change or lack thereof in the levels of the promoter 
activity for the truncated and full length promoters would have confirmed whether the ETS-1 
elements were active or not and whether they were regulated by the MAPK signalling 
pathway. The aforementioned truncation was synthesised and inserted into a pUC57 vector 
by GenScript (USA). The insert was successfully digested out of the pUC57 vector using 
BglII restriction enzymes but the consequent blunt end cloning of the insert into a pGL4 
vector was unsuccessful. Of the 25 transformants screened for the correct direction of the 
insert, only 1 clone contained the insert and it was in the wrong direction (Appendix C). A 
possible reason for this difficulty could have been due to the high GC content of the 
truncation. These experiments are ongoing and will be used to support our conclusions on the 
role of ETS-1 in HOP promoter activity in the future. 
 
4.3.5 – Conclusion 
 
The data presented here indicates that upon the inhibition of the MAPK cascade HOP protein 
levels are decreased. However, our data does not conclusively suggest that this is due to a 
decrease in the promoter activity of HOP. An alternative possibility is that the blocking of the 
MAPK signalling pathway may have been independent of the activity of HOP promoter and 
may have led to the degradation of HOP protein. To test this hypothesis, cells would be 
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treated with a MAPK pathway inhibitor (αHFPA, Sorafenib, or U1026). Next these cells 
would be treated with or without the proteasome inhibitor MG132. Treatment with MG132 
would prevent the degradation of any protein synthesised after treatment of the cells (Lee & 
Goldberg, 1998). Thus, if we observed greater HOP protein levels (or ubiquitin bound HOP) 
in the cells treated with MG132 compared to those cells without MG132 treatment, it would 
indicate that inhibition of the MAPK cascade led to the degradation of HOP protein. 
 
In conclusion, our data suggest that in cancer cell lines containing mutated and contitutively 
active HRAS, the HOP promoter may be regulated by a mechanism involving but not 
exclusive to the MAPK signalling pathway, potentially through the ETS-1 and C/EBPβ cis-
elements within the HOP promoter. Our data further serves as a reminder that RAS signalling 
cascades are not simply linear, that there is vast crosstalk across the signalling pathways that 
can both enhance or block RAS-mediated signalling. 
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Conclusion 
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This research has allowed us to decipher a small part of the biological systems governing 
HOP expression as well as elucidate the importance of HOP in cancer. The putative HOP 
promoter region was identified in silico and in vitro. In cancer cell lines containing mutated 
RAS (Hs578T), HOP was up-regulated via a mechanism involving the MAPK signalling 
pathway, possibly involving the Ets-1 and C/EBPβ cis-elements, within the HOP promoter 
(Fig.22). These findings suggest for the first time that HOP expression in cancer may be 
regulated by RAS activation of the HOP promoter and further advocates HOP as a novel drug 
target for anticancer therapeutics. At present we assume that these data represent the known 
HOP. However, depending on the nature of the probe used to identify them and the similarity 
of the sequence between the regions that are conserved, it is possible that some of the 
expression analyses may in fact reflect the alternative isoforms of HOP predicted in our in 
silico analysis. Additionally, we provided in silico evidence for murine systems being the 
best available model organism for the in vivo study of HOP functioning in human disease, 
due to the similarity observed between the two in synteny, gene structure and co-expression 
analyses. A comparison of HOP within model organisms had yet to be presented to the 
scientific community. From here, both CHIP analyses of the ETS-1 cis-elements as well as 
HOP promoter truncations need to be performed to confirm our presented data. Further 
luciferase assays should be performed to determine the HOP promoter activity in the 
presence of Sorfenib, U0126 and ERK2i so as to further elucidate the mechanism by which 
the MAPK signalling cascade regulates HOP expression. An in vitro analysis of the HOP 
splice variants should be performed to elucidate the existence of HOP isoforms at the protein 
level. If the existence of such isoforms is confirmed, it would be of importance and interest to 
characterise those isoforms and determine their function within the cell. 
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Figure 22: A proposed model for the regulation of HOP in cells containing mutated RAS.  
The MAPK signalling pathway activates the transcription factors C/EBPβ and ETS-1; which in turn possibly 
regulate the HOP gene expression in cancer cells. Arrows represent the direction of activation. P represents 
phosphorylation of effectors or transcription factors. TSS represents the transcription start site of the HOP gene. 
The numbers represent the positions within the HOP promoter relative to the TSS. Triangles represent putative 
ETS-1 cis-elements and the dots represent the putative C/EBPβ cis-elements. 
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Table 1: Putative cis-elements identified within 
the HOP promoter 
Cis - 
element 
Position 
along 
promote
r in 
relation 
to TSS 
Prediction Tool 
TF 
Search 
PROMO Alibaba 
GR-beta -1497   X   
C/EBPbet
a -1494   X   
GR-alpha -1490   X   
AP2-alpha -1490   X   
Sp1 -1490     X 
Pax-5 -1489   X   
P53 -1489   X   
RXR-
alpha -1482   X   
YY1 -1476   X   
Sp1 -1467     X 
AP2-alpha -1466   X   
C/EBPbet
a -1453   X   
Sp1 -1452     X 
IRF-2 -1451   X   
Ik-2 -1448 X     
C/EBPbet
a -1432   X   
C/EBPbet
a -1419   X   
GATA-2 -1418 X     
NF-1 -1415     X 
C/EBPbet
a -1414   X   
AR -1408   X   
TFII-D -1402   X   
C/EBPbet
a -1401   X   
GR-beta -1397   X   
CPE -1396     X 
CACCC -1396     X 
YY1 -1396   X   
Sp1 -1395     X 
MyoD -1390     X 
Pax-5 -1389   x   
P53 -1389   x   
E1 -1389     X 
Olf-1 -1389     X 
STAT4 -1381   X   
GR-beta -1380       
GATA-1 -1373     X 
AP2-alpha -1370   X   
Sp1 -1369     X 
Sp1 -1362     X 
AP-1 -1361     X 
C/EBPbet
a -1357   X   
NF-1 -1349     X 
GR-alpha -1342   X   
RAR-beta -1331   X   
RXR-
alpha -1329   X   
MIG1 -1328     X 
AP-2alpha -1323     X 
STAT4 -1320   X   
GATA-1 -1318   X   
OCT -1315     X 
GATA-1 -1314   X   
HNF-1 -1313     X 
GR-beta -1312   X   
GR-alpha -1301   X   
PEA3 -1292   X   
T3R-alpha -1290     X 
T3R-beta -1290     X 
AR -1285   X   
Sp1 -1279     X 
C/EBPbet
a -1271   X   
Pax-5 -1276   X   
ENKTF-1 -1264   X   
RXR-
alpha -1258   X   
c-Jun -1252   X   
c-Fos -1251   X   
XBP-1 -1250   X   
TCF-
1alpha -1239     X 
GR-alpha -1238   X   
LEF-1 -1237   X   
SRY -1237   X   
C/EBPbet
a -1235   X   
STAT4 -1234   X   
STATx -1231 X     
c-Ets-1 -1229   X   
STAT4 -1227   X   
C/EBPbet
a -1223   X   
AP2-alpha -1222   X   
RXR-
alpha -1217   X   
ER-alpha -1216   X   
C/EBPbet
a -1205   X   
GR-beta -1203   X   
Net -1198     X 
OCT -1196     X 
GR-beta -1196   X   
Sp1 -1189     X 
STAT4 -1172   X   
c-Ets-1 -1171   X   
C/EBPbet
a -1161   X   
AML-1a -1160 X     
AP2-alpha -1154   X   
Pax-5 -1153   x   
P53 -1153   x   
Sp1 -1149     X 
AP2-alpha -1145   X   
Sp1 -1133 X   X 
Pax-5 -1131   X   
P53 -1131   X   
AP2-alpha -1120   X   
Pax-5 -1119   X   
Sp1 -1118     X 
CdxA -1112 X     
P53 -1107   X   
ER -1093     X 
AP2-alpha -1088   X   
GR-alpha -1088   X   
ER-alpha -1082   X   
FOXP3 -1081   X   
C/EBPbet
a -1080   X   
AP-1 -1074 X   X 
GR -1070     X 
GR-alpha -1046   X   
USF -1033     X 
Sp1 -1025     X 
MZF1 -1024 X     
Sp1 -1019     X 
P53 -1018   X   
GR-alpha -1009   X   
Ftz -1002     X 
STAT4 -996   X   
E2F-1 -995   X   
N-Myc -993 X     
Sp1 -992     X 
USF -990 X     
FOXP3 -984   X   
C/EBPbet
a -983   X   
GR-beta -971   X   
STAT4 -970   X   
Sp1 -966     X 
GR-alpha -954   X   
C/EBPbet
a -948   X   
NFI/CTF -948   X   
GCF -942   X   
Sp1 -939     X 
GCF -935       
GATA-1 -931     X 
GR-alpha -927   X   
RXR-
alpha -924   X   
AML-1a -918 X     
STAT4 -916   X   
NFI/CTF -899   X   
C/EBPbet
a -899   X   
E2F-1 -895   X   
Sp1 -894     X 
TFII-I -892   X   
Sp1 -887     X 
Pax-5 -885   X   
NF-kappa -872     X 
YY1 -867     X 
AP2-alpha -860   X   
GR-alpha -859   X   
TFII-I -858   X   
Sp1 -857     X 
Pax-5 -854   X   
P53 -854   X   
YY1 -851     X 
C/EBPbet
a -849   X   
Pax-5 -848   X   
P53 -848   X   
NFI/CTF -843   X   
C/EBPbet
a -843   X   
YY1 -839     X 
NF-muE1 -837     X 
Arnt -831     X 
USF1 -830   X   
RXR-beta -830     X 
GBF2 -829     X 
HBP-1b -829     X 
USF -829 X   X 
ER-alpha -829   X   
c-Myc -826   X   
USF1 -826   X   
c-Rel -825 X     
NF-kap -825 X     
N-Myc -824 X     
SREBP -824 X     
GR-beta -820   X   
STATx -820 X     
STAT4 -818   X   
HSF2 -815 X     
HSF1 -813 X     
TFII-I -818   X   
c-Ets-1 -817   X   
STAT4 -812   X   
PR-B -810   X   
PR-1 -810   X   
GR-beta -809   X   
AP-2alpha -788   X   
Sp1 -788     X 
E1 -786     X 
MyoD -786     X 
Sp1 -779     X 
NF-1 -778     X 
Pax-5 -778   X   
p53 -778   X   
Sp1 -772     X 
AP-2alpha -769   X   
Sp1 -766     X 
GCF -759   X   
AR -754   X   
FOXP3 -753   X   
C/EBPbet
a -752   X 
  
Sp1 -728     X 
AP-2alpha -725   X   
GR-alpha -725   X   
Sp1 -719     X 
RXR-
alpHA -705   X 
  
Sp1 -701     X 
YY1 -698   X   
GATA-1 -694 X     
Egr-1 -690 X     
Sp1 -689     X 
WT1 -688     X 
GCF -688   X   
Sp1 -678     X 
AP-2alpha -677     X 
Pax-5 -677   X   
p53 -677   X   
NF-1 -675     X 
Pax-5 -671   X   
GR-alpha -667   X   
E2F-1 -665   X   
GATA-1 -656 X     
Sp1 -656     X 
AP-2alpha -653     X 
Sp1 -650     X 
Sp1 -642     X 
AP-2alpha -640   X   
STAT4 -636   x   
Sp1 -627     X 
Ik-2 -615 X     
IRF-1 -613   X   
GR-alpha -613   X   
STAT4 -609   x   
C/EBPbet
a -604   X   
Sp1 -600     X 
AP-2alpha -599     X 
GR-alpha -597   X   
AP-2alpha -597   X   
Sp1 -593     X 
Adf-1 -588     X 
Sp1 -585     X 
AP-2alpha -584     X 
RXR-
alpHA -566   X   
Sp1 -562     X 
D1 -548     X 
SRF -543     X 
YY1 -541   X   
GATA-1 -536   x   
GATA-1 -536     X 
Sp1 -532     X 
Sp1 -532 X     
Sp1 -531   X   
Egr-1 -531     X 
NF-1 -531     X 
Pax-5 -530   X   
ETF -530     X 
p53 -530   X   
RXR-
alpHA -521   X   
Sp1 -520     X 
AP-2alpha -513   X   
GR-alpha -512   X   
TFII-I -509   X   
TFIID -510   X   
C/EBPbet
a -508   X   
Sp1 -505     X 
p53 -503   X   
GR-beta -497   x   
CdxA -495 X     
SRY -491 X     
NF-Y -491   X   
CP1 -490     X 
CTF -489     X 
Pbx-1 -489 X     
C/EBPbet
a -488   X   
GR-beta -486   x   
Ik-2 -485 X     
IRF-1 -485   X   
TFII-I -481   X   
STAT4 -481   X   
C/EBPbet
a -479   X   
Sp1 -472     X 
C/EBPbet
a -471   X   
AP-2 -471     X 
GR-alpha -469   X   
AP2 -469   X   
C/EBPbet
a -468   X   
Sp1 -463     X 
Sp1 -463   X   
Adf-1 -460     X 
NF-Y -459   X   
RXR-
alpha -458   X   
Sp1 -457     X 
AP-2 -456     X 
C/EBPbet
a -456   X   
GR-beta -455   x   
NF-Y -453   X   
C/EBPbet
a -452   X   
STAT4 -450   X   
GR-beta -448   x   
Sp1 -444     X 
GR-beta -440   x   
AP-2alpha -433   X   
Sp1 -430     X 
STAT4 -427   x   
D1 -420     X 
YY1 -418   X   
AP-1 -415     X 
SRF -415     X 
YY1 -413   X   
Sp1 -411     X 
GATA-1 -408     X 
NF-Y -406   X   
Sp1 -404     X 
Egr-1 -403     X 
NF-1 -403     X 
Sp1 -403 X X   
EFI -403     X 
C/EBPbet
a -403   X   
Pax-5 -402   X   
p53 -402   X   
ETF -402     X 
GR-beta -401   x   
YY1 -400   X   
TFII-I -397   X   
RXR- -393   X   
alpha 
YY1 -390   X   
GR-alpha -384   X   
TFII-D -382   X   
C/EBPbet
a -380   X   
Sp1 -377     X 
p53 -375   X   
YY1 -372   X   
GR-beta -369   X   
TFII-I -369   X   
CdxA -366 X     
C/EBPbet
a -363   X   
NF-Y -363   X   
SRY -362 X     
CP1 -362     X 
CTF -361     X 
TFII-I -361   X   
C/EBPalp
ha -361   X   
C/EBPbet
a -360   X   
Pbx-1 -360 X     
GR-beta -358   X   
YY1 -355   X   
C/EBPbet
a -351   X   
GR -350   X   
C/EBPbet
a -340   X   
Sp1 -335   X X 
NF-Y -331   X   
C/EBPalp
ha -329   X   
C/EBPbet
a -328   X   
GR-beta -327   X   
GR-beta -326   X   
NF-Y -325   X   
C/EBPbet
a -324   X   
STAT4 -322   X   
GR-beta -320   X   
TEC1 -315     X 
GR-beta -312   X   
AP2 -305   X   
Sp1 -302     X 
STAT4 -299   X   
AP-1 -287     X 
Sp1 -283     X 
NF-Y -278   X   
EFI -275     X 
C/EBPbet
a -275   X   
C/EBPalp
ha -273   X   
Sp1 -269     X 
MZF1 -269 X     
GR-alpha -267   X   
YY1 -264   X   
YY1 -262   X   
NF-AT1 -262   X   
C/EBPalp
ha -262     X 
NFKB -261 X   X 
NFKB -261     X 
NF-Y -261   X   
STAT4 -261   X   
HSF2 -261 X     
c-Rel -260 X     
NF-AT1 -260   X   
TFII-I -257   X   
HSTF -257     X 
C/EBPalp
ha -240     X 
CTF -239     X 
EFI -238     X 
STAT4 -257   X   
HSF2 -251 X     
HSF1 -251 X     
C/EBPbet
a -238   X   
Pax-5 -233   X   
p53 -233   X   
GCF -231   X   
Sp1 -230     X 
GCF -227   X X 
NF-1 -221     X 
NFI/CTF -214   X X 
GR-beta -213   X   
C/EBPalp
ha -212   X   
NF-Y -211   X   
C/EBPbet
a -210   X   
NF-1 -210     X 
C/EBPalp
ha -206     X 
TFII-D -203   X X 
Sp1 -200 X     
NF-Y -197   X   
C/EBPalp
ha -195   X   
C/EBPbet
a -194   X X 
TFII-I -193   X   
Sp1 -173       
SRF -162     X 
GR-beta -162   X X 
Sp1 -158       
AP-2 -156     X 
AP2 -151   X X 
GATA-1 -147 X     
GATA-2 -147 X     
Sp1 -143 X     
RAP1 -143     X 
RXR-
alpha -138   X X 
TBP -135   X   
CdxA -135 X     
Sp1 -132 X     
GR-alpha -130   X X 
Sp1 -123     X 
NF-Y -123   X X 
C/EBPalp
ha -121   X   
C/EBPbet
a -120   X   
TFII-I -119   X   
AML-1a -112 X     
Egr-1 -110 X     
Sp1 -110     X 
MZF1 -107 X     
WT1 -107     X 
Sp1 -106     X 
AP2 -102   X X 
RXR-
alpha -95   X   
FOX-P3 -93   X   
C/EBPbet
a -92   X   
STAT4 -87   X   
GR-beta -86   X   
GR-beta -85   X   
Sp1 -82     X 
TFII-I -73   X X 
NF-Y -72   X   
C/EBPbet
a -69   X   
OCT -67 X     
GR-beta -67   X X 
YY1 -66   X   
Ets-2 -64   X   
Sp1 -64     X 
Elk-1 -63   X X 
C-Ets-1 -62     X 
MAF -62     X 
Ets-1 -61   X X 
STAT4 -59   X   
GATA-1 -52 X     
GATA-2 -52 X     
Sp1 -45   X   
Pax-5 -44   X X 
p53 -44   X   
T3R -40 X     
TER-beat -40     X 
CP2 -36 X     
C/EBPbet
a -34   X X 
CT-1 -33 X     
NF-Y -32   X   
C/EBPbet
a -29   X X 
GR-beta -27   X X 
RelA -10   X   
GR-beta -8   X   
TFII-I -8   X   
STAT4 -8   X   
AP2 21   X   
C/EBPbet
a 24   X   
Ets-2 24   X   
Elk-1 25   X   
Ets-1 27   X   
Sp1 33   X   
Pax-5 34   X X 
p53 34   X   
AP-2 38 X     
Sp1 39     X 
RXR-
alpha 46   X X 
STAT4 67   X   
Sp1 70 X     
AP2 74   X X 
Sp1 76 X     
AML-1a 86 X     
NFI/CTF 87   X X 
Ik-2 90 X     
C/EBPbet
a 91   X   
STAT4 94 X     
Appendix B:  Fluorescence and Confocal Images. 
 
 
Figure E19B: Phosphorylation of FAK and ERK1/2 is down-regulated by RAF Inhibition. 
The subcellular localisation of pFAK and pERK1/2 in Hs578T cells was determined using indirect 
immunofluorescence staining and fluorescence microscopy. Hs578T cells were seeded overnight onto glass 
coverslips and treated with 3.6 µM  Sorafenib or dimethyl sulfoxide (DMSO) for 12 or 24 hours. Cells were 
incubated with pFAK or pERK1/2 primary antibodies (1:50 dilution) followed by donkey anti-rabbit-488 
secondary antibody (green). The nuclei were stained with Hoechst-33342 (blue). Images captured using the 
Zeiss AxioVert AI FL-LED inverted fluorescence microscope with a 100x objective and were analysed by Zen 
Lite 2012. The scale bars indicate a length of 10 µm. Images shown are representative of triplicate images 
captured from randomly selected fields, with the dominant morphology shown. 
 
 Figure E20: The subcellular localisation of C/EBPβ and ETS-1 in Hs578T cells upon Sorafenib treatment. 
The subcellular localisation of (A) C/EBPβ and (B) ETS-1 in Hs578T cells was determined using indirect 
immunofluorescence staining and confocal microscopy. Hs578T cells were seeded overnight onto glass 
coverslips and treated with 3.6 µM  Sorafenib or dimethyl sulfoxide (DMSO) for 24 hours. Cells were 
incubated with C/EBPβ or ETS-1 primary antibodies (1:50 dilution) followed by donkey anti-rabbit-488 
secondary antibody (green). The nuclei were stained with Hoechst-33342 (blue). Images captured using the 
Zeiss LSM 780 Confocal Microscope with 60x and 100x objectives and were analysed by Zen Lite 2012. The 
scale bars represent a length of 10 µm or 20 µm as indicated. White arrows indicate C/EBPβ staining in 
peripheral clusters within the Hs578T cells. Images shown are representative of triplicate images captured from 
randomly selected fields, with the dominant morphology shown. 
 
 
Figure E21A: The subcellular localisation of ETS-1 in Hs578T cells upon ERK2i treatment. 
The subcellular localisation of ETS-1 in Hs578T cells was determined using indirect immunofluorescence 
staining and confocal microscopy (A). Hs578T cells were seeded overnight onto glass coverslips and treated 
with 60 µM  ERK2i or dimethyl sulfoxide (DMSO) for 24 hours. Cells were incubated with ETS-1 primary 
antibodies (1:50 dilution) followed by donkey anti-rabbit-488 secondary antibody (green). The nuclei were 
stained with Hoechst-33342 (blue). Images captured using the Zeiss LSM 780 Confocal Microscope with a 
100x objective and were analysed by Zen Lite 2012. The scale bars indicate a length of 20 µm. Images shown 
are representative of triplicate images captured from randomly selected fields, with the dominant morphology 
shown. 
 
  
Appendix C: HOP Promoter Truncations 
 
Figure E23: Cloning of the truncated HOP promoter. 
A) Illustration of the design of the HOP promoter (STIP1-x) and the HOP promoter truncation (STIP1-T743). 
The triangles represent ETS-1 cis-elements along the promoter. Numbering of the promoter sequence is in 
relation to the transcription start site (TSS) of the HOP gene. B) Blunt end cloning of the STIP1-T743 into a 
pGL4 vector was unsuccessful. The only clone to contain the STIP1-T743 insert is highlighted in red, lane 3. 
However the direction of the insert is incorrect. 
